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Abstract 
 
Resistance to apoptosis is a key hallmark of most cancers. The BCL-2 family of 
proteins are the major arbiters of the cell death program and the interactions between 
pro- and anti-apoptotic members of this family are believed to shift the fate of a cell 
towards life or death. The anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, 
MCL-1, BCL-w and BCL-2A1) are often overexpressed in cancer, thereby promoting 
abnormal cell survival. As a result, these proteins are highly attractive targets for novel 
chemotherapeutic approaches. The recent clinical success of inhibitors against BCL-2 
(Navitoclax and Venetoclax) has launched the compounds known as BH3 mimetics 
into the chemotherapeutic spotlight and has led to the successful development of 
several highly potent MCL-1 inhibitors. The targeting of MCL-1 in cancer is critical 
to restoring sensitivity to other chemotherapeutic approaches, as MCL-1 is strongly 
associated with abnormal cell survival and chemoresistance in many cancers. 
The aims of this study were to (1) assess the specificity and potency of the novel MCL-
1 inhibitor, S63845, as a single agent and in conjunction with other BH3 mimetics, to 
induce apoptosis in a range of cancer cell lines (2) characterise the dependence on 
BH3-only members for apoptosis induced by BH3 mimetics and (3) identify novel 
MCL-1 interacting partners which could explain BH3-only protein-independent 
apoptosis. 
Using a panel of cancer cell lines with various dependencies on BCL-2 family 
members, it was shown that S63845 is an extremely potent MCL-1 inhibitor which 
can induce extensive apoptosis alone or in combination with other BH3 mimetics. 
Immunoprecipitation studies of the BCL-2 family during BH3 mimetic-induced 
apoptosis revealed that the interactions of a pro-survival protein with certain BH3-
only proteins might not exclusively dictate sensitivity to certain BH3 mimetics. 
Moreover, extensive study of cells lacking the 8 key BH3-only proteins showed that 
BH3 mimetics can induce a BAX-dependent but BH3-only protein-independent 
apoptosis, going against the accepted dogma of BH3 mimetic action. 
With the possibility of other BH3-only-like proteins existing to mediate the apoptosis 
seen in the absence of the 8 major BH3-only proteins, novel interacting partners of 
MCL-1 were explored by mass spectrometry. DRP-1, a mitochondrial fission 
regulator, was thus identified as an MCL-1-interacting protein. While knockdown of 
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DRP-1 could abrogate BH3 mimetic-induced apoptosis in H1299 cells, it did not 
interact with MCL-1 via a BH3 motif and exacerbated apoptosis in the cells lacking 
the BH3-only proteins. Thus, DRP-1, while confirmed as a regulator of apoptosis, was 
not proposed to function like a novel BH3-only protein which can activate BAX/BAK 
in the absence of the BH3-only proteins.  
Overall this study reveals that S63845 is an important and highly effective MCL-1 
inhibitor with strong potential for use in the clinic both as a monotherapy and in 
combination with other approaches. Moreover, the mechanism underlying BH3 
mimetic-induced apoptosis and BAX activation has been revealed to be much more 
complicated than currently known, as it appears that the BH3-only proteins are 
dispensable for apoptosis following pro-survival protein neutralisation. Future studies 
should clarify how BAX can initiate MOMP without the BH3-only proteins, be it 
through activation of BAX by the outer mitochondrial membrane directly or, perhaps, 
the existence of novel BH3-only-like proteins which can activate BAX independently 
of the 8 key BH3-only proteins. 
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1.1 Overview of apoptosis 
Apoptosis is one of the major forms of cell death and is a highly orchestrated, 
genetically programmed process which continuously occurs from early development 
in many multicellular organisms. In one day, in a single human being, it is estimated 
that around 10 billion cells are made to replace those that have undergone apoptosis1, 
indicative of the widespread and essential nature of the process to homeostasis. The 
term apoptosis comes from the Ancient Greek term ‘ἀπόπτωσις’ – which translates to 
‘separation’ and ‘falling off’2 and was used because characteristics of an apoptotic cell 
resembled leaves falling away from a tree. While the concept of a programmed cell 
death was first remarked in a study of amphibian metamorphosis in 1842 by Carl 
Vogt3, the term ‘apoptosis’ was not coined until 1972, when John Kerr distinguished 
apoptotic death from accidental cellular death and subsequently published a study with 
Alastair R. Currie and Andrew Wyllie, describing the key morphological stages of 
‘cell deletion’, including neat condensation of the nucleus and cytoplasm and uptake 
of dying cells by other cells4. Almost 50 years later, the apoptotic process is 
considerably better understood and many new categories of programmed cell death 
have been described, however extensive research must still be done to fully 
comprehend the intricacies of apoptosis. 
1.2 Apoptosis induced by a variety of stimuli is central to both physiological 
and pathological processes. 
Apoptosis occurs at many developmental stages of an organism and continues in the 
adult, where it is central to homeostasis. The sculpting of organs is one of the best 
examples of the fundamental importance of apoptosis in development – demonstrated 
especially elegantly by digit formation, where cells undergo programmed cell death to 
allow distinct digits to form5. In adult organisms, apoptosis continues to play essential 
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roles throughout the body by maintaining cell numbers and removing aging, unwanted 
or dangerous cells. One well-studied example of apoptosis in the adult organism 
occurs in regulation of immune cell development. Lymphocytes undergo multiple 
differentiation steps and generate unique antigen receptors - integral units of the 
immune arsenal - in a stochastic manner. Consequently, some of the generated antigen 
receptors will recognise host antigens and the clones expressing these receptors must 
be removed by apoptosis to prevent autoimmunity6. With apoptosis being so pivotal 
to many processes, it comes as no surprise that signals to induce apoptosis exist in vast 
numbers and in many forms, including external signals such as death ligand-receptor 
binding7 and internal signals, such as excessive DNA damage8, aberrations in the cell 
cycle9 and endoplasmic reticulum (ER) stress10. Apoptosis can also occur as a result 
of a lack of signalling, such as deprivation of growth factors11–13. Minute changes in 
any one of these environmental or internal factors can be enough to alter the life-death 
balance, therefore it is essential that there are intricate mechanisms in place to regulate 
apoptosis and its activation. 
1.3  Apoptosis and disease 
As previously mentioned, a programmed cell death system allows for a precise balance 
of cells within an organism. If the balance of apoptosis is altered within a tissue, 
disease is likely to ensue. In the case of excessive apoptosis, neurodegenerative 
disorders (such as Alzheimer’s disease) can occur as a result of massive death of 
neuronal cells14. Excess apoptosis (in combination with necrosis) has also been 
described in cardiomyocytes during ischemia/reperfusion injury following myocardial 
infarction15 as well as in pancreatic β-islets in diabetes16. In contrast, failure of cells to 
undergo apoptosis is also believed to be the driving factor of multiple diseases, 
including autoimmune diseases where the body generates antibodies against its own 
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tissues, leading to their destruction. The generation of auto-antibodies is linked to 
failure of their associated lymphocytes to undergo apoptosis during their development, 
leading to dissemination of auto-reactive antigen receptor lymphocytes throughout the 
body and subsequent auto-immune response17. Perhaps one of the most striking 
diseases where the lack of apoptosis plays a central role is cancer. Abnormal cell 
survival is, in fact, one of the original hallmarks of cancer as defined by Hanahan and 
Weinberg18. Cancers arise when cells accumulate mutations in their DNA which 
permit them to grow and divide uncontrollably. In most circumstances, following 
detection of cellular abnormalities (especially DNA damage), various signalling 
pathways are initiated, often converging on the key tumour suppressor p53, to 
determine cell fate19,20. In a simple model, if the damaged DNA can be repaired, p53 
arrests the cell cycle until everything is repaired and the cell no longer poses a threat. 
However, when a cell accumulates too much DNA damage and may harbour 
potentially dangerous mutations, p53 no longer tries to instigate repair of the cell and 
instead, promotes transcription of proteins which will promote cell death (reviewed in 
21). The pivotal role of p53 in restraining abnormal growth and sending potentially 
cancerous cells to their death means that p53 is one of the most commonly mutated 
genes across all cancers (reviewed in 22). In the case of cancer cells, the loss of tumour 
suppressors like p53 results therefore results in excessive proliferation. However, 
simply having the capacity to wildly grow is not enough to allow a tumour to form, 
therefore the apoptotic machinery must somehow be altered to resist cell death. As the 
programmed cell death field has grown, it has become evident that resistance to 
apoptosis is essential to oncogenesis. In the case of the cancer cells which grow out to 
become tumours, these cells resist death, often by acquiring mutations which can 
either increase the levels of proteins which promote cell survival or decrease those 
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which promote apoptosis18. It is interesting to note that, despite cancer cells often 
being described as being more resistant to apoptosis than other cells, they are relatively 
‘primed’ for apoptosis induction, as remarked following the development of the BH3 
profiling technique. BH3 profiling uses synthetic peptides resembling the BH3 
domains of pro-apoptotic proteins to determine how ‘ready’ or ‘primed’ a cell is to 
undergo apoptosis23. This technique can be used to predict the response of cancer cells 
to chemotherapeutic responses24. Surprisingly, in addition to upregulating pro-
survival proteins, cancer cells are so genetically unstable that they often also 
upregulate pro-apoptotic proteins, leaving them ‘primed’ on a knife-edge of life or 
death. Moreover, cells of many healthy tissues are relatively un-primed as they tend 
to express low levels of pro-apoptotic proteins and could thus be considered 
resistant24. Thus, while cancer cells do indeed evade apoptosis, their inherent 
genetically instability places them in a precarious position which can be targeted using 
therapies which target arms of the apoptotic machinery, as discussed later.  
Overall, it is evident that alterations to apoptosis induction are central to multiple 
diseases, therefore understanding the process and developing potential therapeutics to 
target the arms of the apoptotic pathway is essential. 
1.4 Hallmarks of apoptosis 
The process of apoptosis is well-organised and causes minimal interruption of 
surrounding cells or tissue by limiting any inflammatory response. This well-
structured process means that apoptotic cells have a very defined morphology which 
was originally outlined in the first paper describing apoptosis4. It was shown that 
during the onset of apoptosis, a cell will shrink and round-up as the cytoplasm and 
chromatin condense. Furthermore, the nuclear envelope disintegrates and chromatin 
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bodies form from the condensed chromatin. Towards the later stages of apoptosis, the 
cell becomes fragmented, leaving apoptotic bodies for immune cells to recognise, 
engulf and safely dispose of to prevent inflammation4,25. These morphological changes 
are a result of distinct biochemical changes within the cell4. These major biochemical 
changes are facilitated by the activation/inactivation of numerous signalling proteins 
which result in activation of a specific family of enzymes called the caspases. The 
caspase family of proteins are the executioners of apoptosis which cleave specific 
targets within the cell to ultimately lead to its demise. Apoptotic caspases exist as 
inactive zymogens under non-apoptotic conditions and are typically split into two 
major groups – apical (or initiator) caspases and effector caspases. Apical caspases 
involved in apoptosis include caspases-2, -8, 9 and 10 while effector caspases are -3, 
-6 and -7. Caspases -1, -4 and -5, while associated with cell death, are often designated 
as non-apoptotic caspases as they are linked to the inflammatory response and 
subsequent pyroptosis, a form of cell death which is typical following intracellular 
infection (reviewed in 26 and 27). The distinct morphology of an apoptotic cell is a 
result of the caspases targeting specific proteins and structures within the cell. 
Examples include focal adhesion kinase (FAK), which regulates interactions of a cell 
to the extracellular matrix via integrins. FAK is cleaved by caspases, leading to loss 
of its activity, detachment of cells from the extracellular matrix and the rounded-up 
morphology of apoptotic cells28. Other proteins that are targeted during apoptotic 
signalling include core members of the cytoskeleton, such as actin, which is cleaved 
at the cell surface - this likely contributes to the shrinking and rounded up morphology 
of the apoptotic cell29, as well as proteins which maintain nuclear structure, such as 
lamins30, leading to the organised breakdown of the nucleus. Poly ADP ribose 
polymerase (PARP), a DNA repair enzyme31, is another key target of caspases. 
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Cleavage of PARP abrogates its ability to detect and label sites of DNA damage, 
meaning DNA can no longer be repaired effectively, thereby further committing the 
cell to apoptosis32,33. Cleavage of PARP has also been proposed to maintain cellular 
ATP levels during apoptosis, as PARP activity requires extensive use of ATP. 
Blocking PARP activity therefore aids the energy-dependent apoptotic process and 
allows a cell to avoid necrosis as a result of ATP depletion34.  In addition to cleaving 
targets to downregulate their activity, caspases can also cleave proteins to activate 
them. This includes other caspases within the family as well as enzymes such as 
scramblase, which induces the irreversible exposure of the phospholipid 
phosphatidylserine on the outer leaflet of the plasma membrane, which serves as an 
‘eat me’ signal for immune cells35. 
These targets of the apoptotic signalling pathway are just a few of the many proteins 
which are altered or degraded to induce a programmed cell death, allowing for an 
inflammation-free and consistent cell death. 
1.5 Major pathways of apoptosis. 
Programmed cell death can occur via two major pathways, namely the intrinsic and 
extrinsic pathways, with the pathway taken depending upon the apoptotic stimulus. 
The major steps of each pathway are summarised in Figure 1.1. While the extrinsic 
pathway occurs at the level of the cell surface, is activated by external factors and 
typically involves engagement of transmembrane ‘death receptors’ by their respective 
ligands, the intrinsic pathway of apoptosis detects issues within the cell and delivers a 
response as a result of changes to mitochondrial integrity. Typically, when we think 
of the mitochondria, we consider them as the powerhouse of the cell, providing vast 
amounts of energy through oxidative phosphorylation in order to maintain normal 
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cellular metabolism. However, they are also critical to cell death, particularly in the 
case of apoptosis, and could even be considered as the gatekeepers of life or death 
within the cell36. 
The intrinsic apoptotic pathway 
In order to understand how the mitochondria plays a role in apoptosis and therefore 
understand the intrinsic apoptotic pathway, it is first necessary to understand 
mitochondrial structure. Mitochondria are double membraned organelles, with the 
outer mitochondrial membrane (OMM), the intermembrane space (IMS), the inner 
mitochondrial membrane (IMM), the matrix and the cristae being the major features37. 
Each of these features play their own important roles in cell death regulation, 
withholding multiple apoptotic promoters from the rest of the cell until it is forced to 
undergo apoptosis. The key protein of the mitochondria which activates the cell death 
pathway is cytochrome c38. Cytochrome c normally functions as part of the electron 
transport chain, acting to transfer electrons at the junction of complexes III and IV39. 
However, it is also a life or death switch. Cytochrome c exists in the intermembrane 
space (between the OMM and IMM) and is believed to be sequestered by the folds of 
the IMM, known as the cristae (as shown in Figure 1.1), by proteins such as OPA1 
(optic atrophy 1). OPA1 is believed to act like the drawstring of a bag, withholding 
cytochrome c within the cristae folds to prevent it from escaping the mitochondria. 
During apoptosis, mitochondrial membrane integrity is disrupted and OPA1 is 
proteolysed, leading to re-modelling of the cristae and cytochrome c release from the 
IMM folds40. Subsequently, for the newly released cytochrome c to escape the 
mitochondria, members of the BCL-2 family (as discussed in detail later) form pores 
in the outer mitochondrial membrane41. Cytochrome c thus escapes through the 
BAX/BAK pores in the outer mitochondrial membrane42,43 into the cytosol, where it 
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performs the apical steps of the post-mitochondrial apoptotic signalling pathway. This 
process is thought to be the terminal step in the life or death decision process, as it is 
believed that release of cytochrome c is an irreversible process, although some studies 
have suggested otherwise, if caspase activity is blocked44. Once cytochrome c enters 
the cytosol, it binds to and activates apoptotic protease activating factor 1 (APAF1), 
inducing oligomerisation of APAF1 and subsequent recruitment and activation of the 
apical pro-caspase-9. This complex of proteins is often referred to as the apoptosome 
and activated caspase-9, at the peak of the caspase signalling network, can initiate 
downstream apoptotic signalling via activation of other caspases, such as caspase-3 
and caspase-745–47. Once activated, these enzymes begin to target structures and 
proteins within the cell to lead to its death in an organised manner as previously 
described26,48,49. In addition to cytochrome c, the mitochondria also sequester other 
pro-apoptotic factors, including SMAC (secondary mitochondrial activator of 
caspases), also known as DIABLO. SMAC is localised to the IMS and, like 
cytochrome c, is released to the cytosol during apoptosis. Once released, SMAC binds 
to inhibitors of apoptosis (IAPS), which are believed to bind to and prevent the activity 
of caspases. Release of SMAC inhibits IAP activity, thereby relieving the restrain on 
the caspases and bolstering the apoptotic signalling pathway50,51. Though both 
cytochrome c and SMAC are released from the mitochondria during apoptosis, they 
are very distinct in function and activation - knockout studies suggest that SMAC 
release occurs downstream of cytochrome c and requires caspase activity52,53. Thus, 
cytochrome c is the major apoptotic promoter withheld by the mitochondria that 
activates caspases, with SMAC existing to further fine-tune apoptotic signalling and 
caspases are the major effectors of the apoptotic program. 
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The extrinsic apoptotic pathway 
The intrinsic pathway of apoptosis can convert a wide variety of internal stress stimuli 
into an appropriate apoptotic response. The extrinsic pathway, meanwhile, can do the 
same and shares of a number of elements with the intrinsic pathway, but the initial 
processes of the extrinsic pathway take place at the plasma membrane and involves an 
array of distinct proteins. Following engagement of a death ligand and its receptor, a 
death-inducing signalling complex (DISC) is recruited to the receptor. The DISC is 
made of up multiple proteins including FADD (FAS-associated death domain), an 
adaptor protein which forms the link between cell surface death receptors and 
downstream signalling elements, such as caspases54,55. Caspases-8 and -10 are 
required for the extrinsic pathway and are activated by the DISC complex following 
their homodimerisation54,56. Once activated, caspase-8 and caspase-10 can initiate 
extrinsic apoptotic signalling via two distinct pathways. The first involves caspase-8/-
10-mediated activation of the executioner caspases (namely caspase-3) which go on 
to execute the demolition of the cell. In some cases, however, cells require the extrinsic 
pathway to converge on the intrinsic mitochondrial pathway. This occurs via cleavage 
of the pro-apoptotic BCL-2 family protein, BID, which is cleaved to truncated BID 
(tBID) by caspases-857 and -1058. The highly promiscuous tBID can then translocate 
to the mitochondrial membrane and disrupt interactions of the BCL-2 protein family, 
namely by binding to and activating BAK59 and BAX60, leading to MOMP, 
apoptosome formation and, eventually, activation of the executioner caspases57. Thus, 
the extrinsic pathway of apoptosis can function independently of the mitochondria by 
directly activating caspases or may converge on the intrinsic apoptotic when a more 
robust apoptotic signalling is required. 
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Figure 1.1 Both major pathways of apoptosis converge on activation of the 
caspases. The intrinsic apoptotic pathway functions via the mitochondria and 
apoptosome, while the extrinsic pathway can activate caspases independently of the 
mitochondria. The two pathways can converge via tBID, which translocates to the 
mitochondria to facilitate BAX/BAK translocation and activation. Ultimately, 
activation of either pathway will lead to cleavage of effector caspases, driving the 
organised breakdown of the cellular structure and death. 
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1.6 The BCL-2 family proteins are the master regulators of apoptosis 
Mitochondria withhold several proteins which promote apoptosis from the rest of the 
cell, thereby preventing cell death under normal circumstances. However, the 
complexity of the life-death balance begins much earlier in the hierarchy of the 
apoptotic signalling pathway and involves members of the BCL-2 protein family. This 
family, consisting of over 25 proposed members, can be grouped into either pro- or 
anti-apoptotic proteins, based on their functions. The anti-apoptotic members prevent 
a cell from dying, while the pro-apoptotic members, which are further split into 
activator, sensitiser and effector subgroups, promote activation of the apoptotic 
signalling pathway, with some capable of directly disrupting mitochondrial integrity. 
The balance and interactions of these different pro- and anti-apoptotic BCL-2 proteins 
within a cell is thought to be what determines its fate61. 
The BCL-2 protein family shares a strong degree of structural homology in the form 
of BCL-2 homology (BH) domains (Fig. 1.2). Phylogenetic analysis has revealed that 
these short (~20 amino acid) sequences62, first identified in BCL-263 and subsequently 
BAK64, typically contain distinct, conserved residues that dictate the binding of the 
pro- and anti-apoptotic proteins. While initially named BH domains, the literature is 
moving towards calling these sequences ‘motifs’, as they are short amino acid 
sequences with only small number of conserved residues rather than distinct conserved 
domains65. Traditionally, it is proposed that anti-apoptotic BCL-2 family proteins 
contain BH1, BH2, BH3 and BH4 motifs in addition to a transmembrane domain, 
allowing membrane insertion. Some of the well-characterised anti-apoptotic BCL-2 
family members are BCL-2, BCL-XL and MCL-1, and these are generally found to be 
highly expressed in several cancers, conferring resistance to apoptosis. Meanwhile, 
pro-apoptotic BCL-2 family members contain distinct groups of BH motifs which set 
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the basis for the different subgroups – effectors and BH3-only proteins. The effector 
proteins BAX and BAK, that form pores in the outer mitochondrial membrane to 
facilitate the release of cytochrome c, have BH1, BH2 and BH3 motifs, plus a BH4-
like region, which shares some homology with the anti-apoptotic BH4 motif. In 
contrast, the other pro-apoptotic BCL-2 family members, categorised as activators and 
sensitisers, contain only BH3 motifs and are thus termed BH3-only proteins 
(extensively reviewed in 66). BH3-only proteins are highly promiscuous in binding as 
described below and this is partly attributed to the fact that most of them are 
intrinsically disordered proteins, meaning that their three-dimensional structure can 
vary greatly, permitting diverse binding67–70. 
Current evidence suggests that the BH3 motif is the minimum requirement for a 
protein to be classed as a member of the BCL-2 family. Thus, the BH3 motif is often 
considered as the most important motif of the BCL-2 protein family and is arguably 
the best understood. Sequence analysis of several BCL-2 family members revealed 
that a signature LXXXGDE sequence is the standard format for a BH3 motif, with 
only the aspartate residue being completely conserved across all BH3-only proteins71. 
This sequence has since been re-defined multiple times to a 13-residue motif, which 
represents the more general structures of the BH3 motifs of different BCL-2 family 
proteins, with distinct types of residues (though not necessarily distinct amino acids) 
present at certain points72. This highlights the massive potential variation within the 
BH3-only proteins and supports the notion of diverse interactions. Remarkably, 
despite the high sequence variability, BH3-only proteins largely adopt the same 
structure - a helical BH3 motif with its hydrophobic features typically buried in the 
groove of the anti-apoptotic protein that it is in complex with73. Moreover, the BH3 
domain has a dual function within the BCL-2 family – it functions as a ligand in the 
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BH3-only proteins while functioning like a receptor within the pocket of multi-motif 
BCL-2 family members. This interaction is believed to be central to the two-way 
inhibitory effects that pro- and anti-apoptotic BCL-2 family members exert on each 
other. 
 
 
Figure 1.2 The BCL-2 protein family shares a high degree of homology in the 
form of BH motifs. All members of the BCL-2 protein family contain at least one 
BCL-2 homology domain, with the BH3 motif being common to all members. Some 
BCL-2 family members also contain transmembrane (TM) domains which allow 
membrane localisation. MCL-1 has a unique structure among the major anti-apoptotic 
BCL-2 proteins, with no evident BH4 motif and an elongated N-terminal tail 
containing regulatory PEST (proline, glutamic acid, serine, threonine) sequences 
which are associated with its rapid turnover74–76. ‘N’ and ‘C’ represent the amino and 
carboxy terminals of the proteins respectively. 
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1.7 The pore-forming, effector BCL-2 proteins, BAX and BAK. 
BAX and BAK are the keys to unlocking the mitochondrial death gates – they are the 
two proteins proposed to form the pores in the mitochondria, thereby disrupting 
mitochondrial integrity and releasing cytochrome c into the cytosol. 
Initially, BAX was identified as a BCL-2-associated protein (and thus termed BCL-2 
associated X) which, when overexpressed, can dramatically increase apoptosis 
induced by loss of interleukin-3 signalling, even in the presence the pro-survival BCL-
2. Thus, it was initially proposed that the balance of BCL-2 versus BAX was what 
determined cell fate77, though how this could actually lead to the destruction of the 
cell was unclear. Subsequent studies showed that BAX can form high order oligomers 
and translocate from the cytosol to the mitochondria under stress conditions78,79 which 
could cause the release of cytochrome c from the mitochondria to the cytosol and 
induce apoptosis80,81. Based on the structural similarity of BCL-2 family members to 
pore-forming bacterial toxins, it was hypothesised that BAX could potentially form 
pores in the mitochondrial membrane once oligomerised to initiate cytochrome c 
release82. This was confirmed in later studies and the pore-forming activity of BAX 
was shown to be antagonised by BCL-283. Since then, there have been extensive 
studies of the intricacies of the formation of BAX pores in the mitochondria (reviewed 
in 41).  Following identification of BAX, a second pro-apoptotic BCL-2 family 
member, BAK (BCL-2-homologous antagonist killer), was found simultaneously by 
two groups84,85 and was proposed to function in the same manner as BAX – able to 
induce apoptosis when overexpressed alone. BAK was shown to be able to release 
cytochrome c following cleavage of BID in the extrinsic apoptotic pathway59, 
affirming it as a protein with some degree of functional redundancy to BAX. 
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Though some aspects of how both BAK and BAX end up as pores in the mitochondrial 
membrane remain controversial, it is known that both must undergo multiple stages of 
conformational changes to become activated. BAX must transform from its cytosolic, 
inactive, globular structure within which its pro-apoptotic regions (the hydrophobic 
BH3 binding groove and the transmembrane domain) are internalised86. Upon 
activation by BH3-only proteins, reportedly at the ‘rear’ activation site of BAX, these 
internalised domains are exposed, permitting insertion at the mitochondrial membrane 
and its oligomerisation with other BAX molecules. This has been suggested to allow 
for transient interactions between the BCL-2 family members and BAX, therefore 
permitting a two-step activation process – with BAX translocating to the 
mitochondrial membrane first before exposure of the hydrophobic BH3-binding 
groove which is critical for pore-formation60,87,88. This allows for a finer control of 
apoptotic signalling and allows for cycling of BAX back to the cytosol when apoptosis 
is not required. Activation of BAK may involve a little less fine control as it is believed 
that the major activation site is the BH3-binding groove. However recent work 
supports the idea of separate activation sites on BAK, suggesting that, like BAX, it 
may also have fine layers of regulation89–91. Notably, while BAX has a cytosolic 
localisation under basal conditions and moves to the OMM during apoptosis, BAK 
has been proposed to be predominantly mitochondrially localised under basal 
conditions92, further differentiating these proteins and suggesting that their regulation 
mechanisms may be a little different. 
It is worth noting that, as the major effectors of the apoptotic pathway, both BAK and 
BAX can be considered as tumour suppressors and in turn, have been identified as 
proteins which are likely to be mutated in cancers to drive abnormal cell survival. 
Indeed, it has been shown that DNA repair defects in colon and gastric cancers can 
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leads to mutations in both the BAX and BAK genes and this can promote abnormal 
cell survival93–95.  
In addition to BAX and BAK, there is a third proposed pore-forming BCL-2 family 
protein, BOK (BCL-2-related ovarian killer), whose roles in classical apoptosis are 
controversial. BOK can form pores in the OMM, however it is believed to do so 
independently of the known BCL-2 family proteins and is strongly associated with 
endoplasmic reticulum stress. Instead of modulation by BCL-2 family proteins, it has 
been suggested that the constant degradation of BOK inhibits its activity96, 
highlighting the idea that not all BCL-2 family proteins may function in the same way. 
1.8 The activator BH3-only proteins 
As previously mentioned, the pro-apoptotic BCL-2 proteins can be categorised into 
effector (BAX/BAK) and activator and/or sensitiser proteins. Three of the BH3-only 
proteins, namely BIM, BID and PUMA, are proposed to be capable of interacting with 
and altering the activity of multiple pro- and anti-apoptotic BCL-2 family members, 
which means that they are designated as both ‘activator’ and ‘sensitiser’ proteins. 
While this could suggest that these proteins are functionally redundant, studies have 
shown that each of these BH3-only proteins has its own unique regulation and activity. 
BIM 
BIM, first identified in a screen to search for BCL-2 -interacting proteins97 is 
considered to be especially promiscuous in its ability to bind multiple members of the 
BCL-2 family (Fig. 1.3.). BIM exists as multiple isoforms - extra-long (BIMEL), long 
(BIML) short (BIMS)), all of which can induce apoptosis but with different 
potencies98,99. BIM is highly regulated at transcriptional, epigenetic, post-
transcriptional and post-translational levels, with many phosphorylation sites 
20 
 
identified (reviewed in 100). Of note, it has been proposed that BIM is normally 
sequestered by components of the cytoskeleton (namely LC8 of the motor protein 
dynein) and, upon apoptotic signalling, is released from the cytoskeleton and 
translocates to the anti-apoptotic proteins, where it may quench their activity and 
initiate apoptosis101. These types of regulation, along with many others, allow intricate 
control of the highly promiscuous BIM under healthy and cellular stress conditions 
and maintains a precise ratio between BIM and its anti-apoptotic counterparts, thereby 
regulating apoptosis. It is therefore not surprising that, as one of the major pro-
apoptotic proteins, BIM is often altered in some cancers, conferring protection from 
apoptosis. For example, multiple reports suggest that BIM expression is reduced in 
lung cancers and that the presence of deleterious BIM polymorphisms negatively 
impacts patient survival102–104. BIM has also found been found to undergo 
homozygous deletion in various lymphomas105, suggesting it is likely an important 
tumour suppressor in multiple types of cancer. 
PUMA 
PUMA (p53 upregulated modulator of apoptosis) was originally identified as one of 
the BCL-2 family proteins upregulated by p53 following cellular stress, such as DNA 
damage106,107. PUMA is also highly responsive to many other forms of cellular stress 
in both p53-dependent and -independent scenarios, including cytokine deprivation and 
both glucocorticoid and staurosporine exposure108,109. Like BIM, PUMA is thought to 
be promiscuous in binding multiple members of the anti-apoptotic BCL-2 family 
(summarised in Figure 1.3). With the high incidence of p53 mutations in many cancer 
types, PUMA expression can be vastly altered in cancer cells as p53 can no longer 
upregulate its expression following DNA damage, thereby allowing cancer cells to 
resist apoptosis110. 
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BID 
Meanwhile, BID (BH3 interacting-domain death agonist) was identified in a search 
for proteins that could heterodimerise with other BCL-2 family proteins, including 
both effector proteins (BAX) and pro-survival proteins (BCL-2)111. Subsequent 
studies demonstrated that BID could regulate release of cytochrome c from the 
mitochondria to the cytosol following activation of the various death receptors112. This 
highlighted BID as the mediator of cross-talk between the intrinsic and extrinsic 
apoptotic pathways. As described earlier, BID can be cleaved by caspase 8/10 to tBID. 
tBID is proposed to translocate to the mitochondrial membrane where it is believed to 
facilitate the translocation, insertion and activation of the BCL-2 effector proteins, 
BAX60/BAK59, at the mitochondrial membrane, leading to apoptosis57,112,113. While 
tBID is a remarkably potent activator of apoptosis, its full-length, non-truncated form 
is also believed to be associated with apoptosis111, as mutation of the caspase-cleavage 
site does not fully attenuate its pro-apoptotic activity114. 
1.9 The ‘sensitiser’ BH3-only proteins 
Sensitiser BH3-only proteins are distinct from the activators as they generally have 
more specific subsets of pro-survival binding partners and are not believed to be 
capable of binding to and activating the effector proteins directly. Instead, it is 
proposed that they add a finer layer of control over apoptosis and each protein has its 
own distinct regulation mechanisms. 
BAD 
The BH3-only protein BAD (BCL-2-associated agonist of cell death) was identified 
in a screen for BCL-2-interacting proteins and has been shown to be capable of 
heterodimerising with both BCL-2 and BCL-XL (but not MCL-1) to antagonise their 
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cell survival activity115. Like other BH3-only proteins, BAD can undergo post-
translational modifications to alter its activity. For instance, phosphorylation of two 
serine residues in BAD prevents its interaction with BCL-XL but instead facilitates its 
interaction with another protein, 14-3-3, following exposure of a cell to certain 
survival factors, such as interleukin-3. This in turn sequesters BAD in the cytosol, 
where it cannot promote apoptosis, allowing BCL-XL signalling to promote 
survival116–118.  
BMF 
BMF (BCL-2-modifying factor), identified as a BH3-only protein in a yeast-two-
hybrid screen using MCL-1 as bait, is a pro-apoptotic protein which, like BIM, might 
have its activity sequestered by components of the cytoskeleton. Thus, when the cell 
undergoes stress (for example detachment from the extracellular matrix), the 
cytoskeleton undergoes changes and BMF is released and can activate apoptosis119. 
Further studies have also showed that BMF expression can be upregulated following 
inhibition of CAP-dependent protein synthesis as a result of various factors, including 
loss of growth factor signalling and hypoxia120. Elevated or free BMF can therefore 
promote apoptosis under multiple stress conditions by binding to and altering the 
activity of its BCL-2 family partners. 
NOXA 
In addition to PUMA, p53 also upregulates another BH3-only protein called NOXA 
(also known as Phorbol-12-myristate-13-acetate-induced protein 1 or PMAIP) which 
was identified as a BCL-2 family member following a screen for elevated proteins in 
mRNA expression profiles in wild-type versus IRF-1 (interferon regulatory factor 
1)/p53-deficient (both tumour suppressors), irradiated cells121. Later studies showed 
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that NOXA mediates apoptosis via regulation of the BCL-2 protein family, thereby 
activating MOMP122. NOXA has been suggested to perform the partner function of 
BAD, binding to the two major anti-apoptotic proteins that BAD does not – MCL-1 
and BCL-2A1, as outlined in Figure 1.3. NOXA is highly labile therefore it is not 
surprising that several studies have highlighted tight post-translational regulation of 
NOXA – notably NOXA is a key target of the proteasome123–125. It was presumed that 
the targeting of NOXA to the proteasome was a result of the ubiquitination system, 
however data seems to indicate that proteasome-dependent degradation of NOXA is 
ubiquitination-independent126 and may in fact rely on its unstable C-terminal 
structure127. 
BIK 
Meanwhile BIK (BCL-2-interacting killer), originally identified as an interacting 
partner of both BCL-2 and BCL-XL, was one of the first BH3-only proteins identified. 
While BIK was shown to be important to apoptosis, its interaction with anti-apoptotic 
proteins alone is not enough to induce apoptosis, allowing for categorisation of BIK 
as a sensitiser BH3-only protein128. Interestingly, BIK has been shown to have a very 
strong endoplasmic reticulum localisation and is thought to even function from the ER 
to modulate mitochondrial integrity during apoptosis129. 
HRK 
Similar to BIK, Harakiri (HRK) was identified in a yeast two-hybrid screen as a 
protein that could interact with BCL-2 and BCL-XL but not the effector pro-apoptotic 
proteins and was therefore proposed to be another member of the sensitiser BH3-only 
protein group, with the BH3 motif being found to be required for its pro-apoptotic 
capacity130. HRK, like the other BH3-only proteins, can be induced by various stimuli, 
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including lack of growth factor signalling131. Interestingly, HRK has been identified 
as a key tumour suppressor that is altered in gastric cancers, with possible epigenetic 
silencing of HRK contributing to a malignant phenotype132. This further highlights the 
importance of assessing the levels of pro-apoptotic BCL-2 proteins in cancer. 
1.10 The pro-survival BCL-2 family members 
Pro-survival members of the BCL-2 family are the endogenous antagonists of the pro-
apoptotic subgroups, existing in dual functions to prevent activity of both BH3-only 
and effector BCL-2 family proteins and thereby preventing apoptosis. As such, the 
pro-survival proteins are overexpressed or altered in a vast number of cancers, 
allowing tumour cells to survive abnormally. 
BCL-2 
The first and founding member of the BCL-2 family identified, as the name might 
suggest, was BCL-2 (B-cell lymphoma 2). BCL-2 was identified and named following 
the seminal article describing the study of an acute B-cell leukaemia cell line 
established from a patient with follicular lymphoma133. In this cell line, it was 
remarked that a chromosomal translocation (14;18) between a highly active 
immunoglobulin heavy chain enhancer and a putative oncogene was one of the driving 
factors of the malignancy developed in a multi-step process of oncogenesis. The 
chromosomal translocation permitted hyperexpression of the putative oncogene, BCL-
2, and this hyperexpression augmented B-cell survival, thereby promoting 
oncogenesis133. Despite extensive further study into the BCL-2 chromosomal 
translocation in leukaemia, it was not until four years later that the pro-survival 
function of BCL-2 was suggested, following the observation that forced expression of 
BCL-2 could mediate resistance to cell death induced by growth factor withdrawal in 
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multiple cell lines12. Subsequent generation of knockout mice revealed that BCL-2 is 
a pro-survival protein which is essential to the survival of multiple types of cells, 
including various haematopoietic lineages and cells of the kidneys134. Later, 
identification of a number of proteins with structural homology to BCL-2 revealed the 
true nature of this protein family, which are able to hetero- and homodimerize with 
each other to mediate apoptosis. Indeed, BCL-2 has been suggested to interact with a 
number of other BCL-2 family proteins (as summarised in Figure 1.3) to regulate 
apoptosis. Moreover, since its identification, many studies have demonstrated that 
overexpression of BCL-2 was not limited to specific subsets of lymphoid malignancies 
and in fact, multiple cancers could be driven by BCL-2, including chronic lymphocytic 
leukaemia135, non-Hodgkin’s lymphoma136 and acute myeloid leukaemia137. BCL-2 
overexpression has also been detected in many non-haematological tumours including 
breast138, prostate139, lung140, bladder141, colorectal142 and brain malignanices143.  
BCL-XL 
B-cell lymphoma extra-large (BCL-XL) was identified in an effort to identify BCL-2- 
related genes and was first described as a ‘BCL-2-independent regulator of 
programmed cell death’144. BCL-XL is expressed in various tissues including the 
central nervous system while also being highly expressed in cells undergoing 
development as part of the immune system144 and was later shown to be functionally 
and structurally similar, though not functionally redundant to, BCL-2145. BCL-XL has 
very similar binding preferences for BH3-only proteins as BCL-2, though does indeed 
have some unique interaction partners (Fig. 1.3), further exemplifying it as a pro-
survival protein distinct from BCL-2.  Like BCL-2, BCL-XL has been identified as 
overexpressed or possessing aberrant activity in various types of cancer, including 
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colorectal146, prostate147,148, chronic myeloid leukaemia (CML)149,150 and head and 
neck malignancies151.  
BCL-2A1  
There are also several pro-survival proteins which are less well understood than those 
originally identified. This includes BCL-2A1, also known as BCL-2 related gene 
expressed in foetal liver (BFL-1), an anti-apoptotic protein which has been shown to 
interact with many of the pro-apoptotic BCL-2 family members, as summarised in 
Figure 1.3 BCL-2A1 is associated with multiple types of cancers, including acute 
lymphoblastic leukaemia152, CLL153, stomach154 and  breast cancers154,155. BCL2-A1 
may also play a central role in resistance to chemotherapy, particularly therapy 
targeting other arms of the BCL-2 family156,157. 
BCL-w  
BCL-w is another pro-survival protein which is relatively unexplored but with vast 
potential implications for disease, especially cancer158. While it was demonstrated that 
induced expression of BCL-w can promote survival of various haemapoietic cell lines 
under stress conditions, knockout of BCL-w in mice did not significantly impact 
development of the organism and was shown to only be essential to spermatogenesis159 
However other studies have claimed important roles for BCL-w in the epithelium of 
the small intestine160 as well as in the survival of B cells during their development161, 
supported by the notion that BCL-w is overexpressed in various B cell 
malignancies162.  Furthermore, BCL-w has been found to be overexpressed or 
important to various other types of cancers, including in melanoma163, colorectal164 
and breast cancer cell malignancies165. 
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MCL-1 
Myeloid cell leukaemia 1 (MCL-1), named after the cell in which it was first identified 
(ML-1 human myeloid leukaemia) is quite a distinct member of the BCL-2 family for 
multiple reasons. While it does contain the standard BH1-3 motifs, it is unusual in that 
it lacks an identifiable BH4 motif76 (Figure 1.3). Moreover, MCL-1 has a long, 
unstructured N-terminus with two regulatory PEST (proline, glutamic acid, serine, 
threonine) sequences which regulate the rapid turnover of short-lived proteins, such 
as MCL-1. The rapid turnover of MCL-1 is also attributed to its intricate regulation by 
various post-translation modifications including ubiquitination. It has been shown that 
MCL-1 is ubiquitinated by multiple E3 ligases, including MULE – a BH3 motif- 
containing E3 ligase which targets MCL-1 for degradation by the proteasome166,167. 
Thus, MCL-1 has a vast number of potential sites for modification and unsurprisingly, 
multiple signalling pathways (including the STAT3168 and MEK/MAPK and PI-
3K/AKT169 pathways) can therefore regulate MCL-1 expression at the level of 
transcription, with further post-transcriptional, post-translational and epigenetic 
control mechanisms over MCL-1 existing to finely regulate its activity.  
Another distinct feature of MCL-1 and its regulation comes in the form of the distinct 
MCL-1 isoforms. When analysed by immunoblotting, MCL-1 appears to exist as 
multiple isoforms, that can be detected by the presence of multiple bands between the 
28 and 40 kDa range, depending on the antibody used. There has been much debate 
about what these isoforms are and how they come to be, however, as no single study 
has suggested what the distinct isoforms are and how they arise. Alternative splicing 
has been attributed to the presence of two major MCL-1 isoforms, MCL-1L and MCL-
1S which have mitochondrial and cytosolic localisation respectively. MCL-1L is 
proposed to be a mitochondrial-localised, anti-apoptotic protein76,170 whose expression 
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is associated with poor clinical outcome in a number of cancers171,172 while it has been 
proposed that the short MCL-1 protein, containing only the BH3 domain, is pro-
apoptotic173,174.  
To further complicate matters, the shortest isoform of MCL-1 (proposed to be 
detectable in immunoblotting at 36 kDa) has been shown to localise to the inner 
mitochondrial membrane to perform non-apoptotic mitochondrial roles, including but 
not limited to regulation of mitochondrial bioenergetics175. Furthermore, some reports 
also claim other forms of MCL-1 exist, including MCL-1 extra short (MCL-1ES) and 
MCL-1 short nuclear (MCL-1SN) which are claimed to have pro-apoptotic
176 and cell 
cycle regulatory functions respectively177. It remains unclear if all these variants are 
directly represented by the bands seen in immunoblotting and some of these isoforms 
of MCL-1 may arise under very distinct circumstances, however these studies clearly 
highlight the complex biology of MCL-1. 
At the subcellular level, MCL-1 can, unsurprisingly, be found at high levels at the 
mitochondrial membrane76 due to the anchoring of its N-terminal region on the 
OMM75. Its localisation is, in fact, much more widespread than just the OMM 
however, indicative of its multi-faceted behaviour. Studies have reported MCL-1 
expression in the nuclear envelope178, nucleus177–180, the cytosol180, the inner 
mitochondrial membrane175,181,182 and the endoplasmic reticulum76. Some of these 
localisations have also been linked to unique and unexpected functions of MCL-1, 
including regulation of oxidative phosphorylation175, lipid metabolism183, the cell 
cycle177,180 and the DNA damage response179,184. 
Meanwhile, at the tissue level, MCL-1 is also widely expressed. While first identified 
as an immediate-early gene induced by PMA in ML-1 cells76, MCL-1 is now known 
29 
 
to be essential to the survival of many cell types in a non-functionally redundant 
manner. Tissues and cell types which MCL-1 is essential to include B and T cells185,186, 
granulocytes187, neutrophils188, haematopoietic stem cells (HSCs)189, neuronal cells190 
and fibroblasts191. The exact number of cell types that MCL-1 is essential to remains 
unclear as MCL-1 is also important at the developmental stage, as knockout of MCL-
1 in mice is embryonic lethal before E3.5192. While this has made identifying tissue-
specific requirements for MCL-1 difficult, it further highlights the non-redundant 
functions of the BCL-2 family members, particularly as BCL-XL knockout only 
induces embryonic death by E13.5193. In further support of the non-redundant nature 
of pro-survival proteins, MCL-1 has a unique set of BCL-2 family interaction partners, 
as shown in Figure 1.3. While MCL-1 can bind to the three main ‘activator’ BH3-only 
proteins, it also has very strong affinity for NOXA194 while the major other BCL-2 
family members do not bind to NOXA (Fig 1.3). 
Like the other pro-survival BCL-2 family members, MCL-1 has been described as an 
oncogene which, when aberrantly overexpressed, promotes the key cancer hallmark 
of resistance to apoptosis. MCL-1 is one of the most highly amplified genes in most 
cancers195 and is often overexpressed or mutated in both solid and haematological 
cancers195, including multiple myeloma196, acute myeloid leukaemia (AML)197, 
lung198,199 breast200–202, oral171 and oesophageal cancers203, hepatocellular204, 
thyroid205, ovarian206, prostate207 and pancreatic cancers208. The wide expression of 
MCL-1 in many cancers has highlighted it as both as an important therapeutic 
candidate to target in tumours and also a chemoresistance factor for other therapies. 
Indeed, many studies have shown that targeting MCL-1 is imperative to sensitising 
cells to various types of chemotherapy, as tumour cells can upregulate MCL-1 (or 
already have high levels of MCL-1) that mediates resistance to death even in high 
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stress conditions. High MCL-1 expression levels have also been linked to resistance 
of cancers to various conventional chemotherapeutic approaches, including 
cisplatin171,203 and radiotherapy172,208 as well as targeted therapies like BRAF 
inhibitors209.  
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Figure 1.3 The complex interaction network of the major BCL-2 protein family 
members. Pro-survival BCL-2 family proteins (red) are proposed to interact with both 
activator/sensitiser and effector BCL-2 family members (green/blue) to regulate 
induction of apoptosis within a cell. The promiscuous activator BH3-only proteins can 
bind to the major pro-survival and effector proteins, while the sensitiser BH3-only 
proteins have more specific binding patterns for each pro-survival protein. For 
example, BCL-2, BCL-w and BCL-XL can bind to and inhibit BAD, while MCL-1 
and A1 cannot. Instead, MCL-1 and BCL-2A1 can uniquely bind to NOXA. Thus, the 
network of interactions is highly intricate. While some of these interactions have been 
shown in vivo, some have only been inferred by studies in in vitro binding models and 
therefore remain to be clarified23,60,185,210–216. 
 
1.11 The BCL-2 family and apoptosis induction 
While it has been established that it is the interactions between the pro- and anti-
apoptotic BCL-2 family members that dictate the apoptotic status of a cell, the precise 
molecular mechanisms underlying these events have proven to be both complicated 
and controversial. Early models first proposed that anti-apoptotic BCL-2 proteins 
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functioned simply by directly binding to and inhibiting BAX216. However, this kind 
of model was not compatible with the distinct localisations of the BCL-2 family 
proteins or the ever-expanding BCL-2 protein family. Further studies led to the 
proposal of direct and indirect activation models. 
The direct model proposes that, that upon receipt of signals for death upstream in the 
cell, ‘activator’ BH3-only proteins bind to and directly activate BAX/BAK, leading to 
apoptosis. In this model, it is proposed that the pro-survival proteins function to inhibit 
the activator BH3-only proteins (and vice-versa), while the sensitiser BH3-only 
proteins relieve this inhibition23,210–212. Meanwhile, the indirect model proposes that 
anti-apoptotic proteins directly sequester the effector proteins (BAX/BAK) thereby 
stopping their insertion into the mitochondrial membrane and ensuing apoptosis. In 
this case, on receipt of death stimuli, the BH3-only proteins interact with and displace 
the anti-apoptotic proteins from BAX/BAK, freeing them to disrupt mitochondrial 
integrity213,215,217. These two models highlight the nature of the pro- and anti-apoptotic 
protein interactions during apoptosis but do not capture the more complex interaction 
network of the BCL-2 family. For example, the direct activation model does not 
explain why MCL-1 binds to and potently inhibits the activity of BAK215,218. 
Thus, a more refined and complex model - the ‘unified’ model - of activation was 
proposed, which integrates both the direct and indirect activation models by 
classifying different ‘modes’ of apoptosis which depend on cellular stress levels. In 
mode 1 (the direct model), anti-apoptotic proteins, such as MCL-1, bind to and inhibit 
the activity of pro-apoptotic BH3-only proteins, such as BIM, while in mode 2 (the 
indirect model), MCL-1 would bind to and directly sequester BAX and/or BAK to 
limit their activity. Mode 2 is suggested to be a more efficient mechanism of inhibition 
of apoptosis since it involves direct activity against that of the effector proteins and 
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would require upregulation of BH3-only proteins (and hence high stress conditions) 
to displace effector proteins from pro-survival proteins219. Furthermore, it has also 
been suggested that retrotranslocation of BAX/BAK, from the mitochondria to the 
cytosol, by BCL-2 family members might be considered a ‘mode 0’ of apoptosis 
regulation41.  
Further complicating the activation models of apoptosis, recent work has shown that 
the proposed subgroups of BH3-only proteins (i.e. sensitisers versus activators) are 
also not as simple as previously thought, as some BH3-only proteins which were 
thought to function exclusively as sensitiser BH3-only proteins (NOXA) have been 
shown to be capable of functioning like activators of BAX/BAK. Thus, an 
‘interconnected hierarchical model’ of apoptosis was suggested220.  
There is no doubt that future work to unravel this hierarchy will reveal even more 
complex behaviour of the BCL-2 protein family. Altogether, studies seem to point 
towards a bi-modal, complex activation of apoptosis, where both major subsets of pro-
apoptotic proteins (effectors and BH3-only proteins) are inhibited by the pro-survival 
proteins and this inhibition must be un-done in a step-wise manner. Activator BH3-
only proteins may convert BAX/BAK to their active forms (direct activation) and 
subsequently, block the activity of anti-apoptotic proteins, thus relieving their 
inhibition of BAX/BAK insertion in the mitochondrial membrane. This suggests that 
the majority of the BCL-2 family interactions are highly dynamic and intricate, with 
multiple levels of control in place to regulate MOMP.  
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Figure 1.4 The proposed activation models of apoptosis. Multiple models of 
activation of the effector BCL-2 family proteins have been proposed. The direct 
activation model (A) suggests that ‘activator’ BH3-only proteins, like BIM, bind to 
and directly activate BAX/BAK following relief of their inhibition by pro-survival 
proteins thanks to ‘sensitiser’ BH3-only proteins. The indirect model (B) suggests pro-
survival proteins, like BCL-2, bind to and inhibit effector proteins. Effector proteins 
are then indirectly activated by ‘activator’ BH3-only proteins, which block the activity 
of pro-survival proteins. Extensive studies support the notion of both of these types of 
activation occurring in the unified model (C) (with mode 1 being direct and mode 2 
being indirect activation) to allow extremely precise control of effector protein 
activation. Even further complexities exist in the form of retrotranslocation of 
BAX/BAK from the mitochondria to the cytosol by pro-survival proteins (mode 0) 
and the hierarchical model of apoptosis, where some ‘sensitiser’ BH3-only protein can 
function like activator BH3-only proteins. 
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1.12 Targeting the BCL-2 family – a key therapeutic approach in cancer 
Until recently, most chemotherapeutic approaches exploited the fact that cancer cells 
are genetically unstable and divide very quickly. Agents such as cisplatin are able to 
rapidly incorporate into the DNA of cells that are highly proliferative, leading to 
massive DNA damage as the cells try to replicate. Excessive DNA damage and 
inability to repair it subsequently triggers cell death221. While these approaches are 
often some of the first-line approaches to cancer therapy and are consistently used in 
the clinic, the focus of translational cancer medicine has shifted towards targeted 
approaches which exploit more specific aspects of individual cancers.  
Key targets in many cancers include hyperactive proteins such as kinases and many 
compounds have recently been developed against such proteins, such as the landmark 
compound vemurafenib – a inhibitor that targets the BRAF V600E mutation in 
melanoma222. This mutation of a valine residue to a glutamic acid residue leads to 
hyperactivation of BRAF kinase and its downstream targets in the MEK/ERK 
signalling pathway, promoting oncogenicity and this is a key oncogenic driver in more 
than 50% of melanomas223–225. Vemurafenib initially demonstrated remarkable results 
following use in late-stage melanoma, with complete regression of tumours at a 
remarkable rate in some patients. However, unfortunately, in most cases, some tumour 
cells remained and acquired mutations which made them resistant to further 
vemurafenib treatment, as other signalling pathways were co-opted in order to 
promote oncogenic signalling (reviewed in 226). While targeted therapy of proteins like 
kinases can be initially very effective, they are also highly susceptible to resistance 
mechanisms, especially when the targeted proteins exist at a nexus of signalling 
pathways that might allow tumour cells to circumvent the inhibition of the protein they 
are addicted to. 
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Recent therapeutic strategies that target the BCL-2 family of proteins have 
demonstrated much promise in overcoming the issue of acquired resistance. The 
proteins that are targeted act downstream of most major signalling pathways therefore 
acquired resistance is much more difficult to achieve, as there are many fewer 
pathways to be exploited by cancer cells. Thus, much emphasis has been placed on 
ways to induce apoptosis by altering the behaviour of the BCL-2 protein family. 
Designing compounds to directly inhibit the BCL-2 family has proven challenging 
however, as to inhibit their activity requires disruption of protein-protein interactions.  
Successful targeting of the BCL-2 family members has now been achieved by several 
strategies, including by stabilising the pro-apoptotic BCL-2 family members to 
promote apoptosis, by reducing the expression levels of the anti-apoptotic members at 
the level of transcription or by directly disrupting the BCL-2 family interactions. Early 
compounds in this field include flavopiridol, a cyclin-dependent kinase (CDK) 
inhibitor which was described as potent inducer of apoptosis in CLL cells227 and was 
later shown to be able to induce cell death in both CLL and multiple myeloma, thanks 
to indirect transcriptional downregulation of MCL-1 and IAPs228,229. Although initial 
Phase I/II studies suggested that continuous flavopiridol infusion had no effect on 
relapsed CLL patients230, adjusting the dose and timings of administration in Phase II 
showed extremely promising results, with high response rates in CLL231. However, 
the non-specific nature and potential toxicity of the compound limited its use in the 
clinic. 
The pro-apoptotic BCL-2 family can also be targeted indirectly – although to induce 
apoptosis, their expression must be elevated rather than downregulated. One 
mechanism to do this is by using histone deacetylase inhibitors (HDACis), which can 
relieve the epigenetic silencing of BH3-only proteins such as NOXA and BIM. Such 
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an indirect approach can also potentially increase the expression of pro-survival 
proteins (namely MCL-1) in CLL, however. While HDAC inhibitors could induce 
some apoptosis despite the increase in both pro- and anti-apoptotic proteins, inhibition 
of MCL-1 using CDK inhibitors could potentiate the HDACi-induced apoptosis232,233. 
Some studies have also shown that inhibition of the proteasome can also induce 
apoptosis by stabilising BH3-only proteins. One example of an effective proteasome 
inhibitor is Bortezomib, which has been shown to stabilise NOXA levels, thereby 
abrogating MCL-1 pro-survival activity123. Bortezomib has been used with success in 
treatment of multiple myeloma234 and mantle cell lymphoma235,236 but has struggled 
to perform in other malignancies. One issue of using such broad action inhibitors such 
as HDACis or proteasome inhibitors is their inherent non-specificity in modulating 
expression levels of numerous short-lived proteins that may impinge on the apoptotic 
pathways. This means that it is possible that levels of tumour-promoting or pro-
survival proteins can be elevated using such approaches, thus negating the effect of 
the increase of pro-apoptotic BH3-only proteins. Nonetheless, these types of inhibitors 
have proven useful in some cancers and may be of use in combination therapy in the 
future. It is clear, however, that directly targeting the anti-apoptotic proteins 
themselves is of great importance. 
1.13 Inhibitors of the BCL-2 protein family - BH3 mimetics 
Early BH3 mimetics functioned as pan-BCL-2 antagonists 
Designing compounds to directly inhibit the BCL-2 family has proven challenging as 
to inhibit their activity requires disruption of protein-protein interactions between the 
anti- and pro-apoptotic BCL-2 family members. However, such compounds have 
recently been developed in the form of BH3 mimetics - small molecule inhibitors that 
mimic the pro-apoptotic BH3-only members in an attempt to compete with the pro-
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apoptotic members to bind and inhibit their anti-apoptotic counterparts. To be defined 
as a BH3 mimetic, a compound must satisfy two minimum requirements: it should be 
able to (1) induce apoptosis in a BAK/BAX-dependent manner (2) bind to the pro-
survival BCL-2 family members with nanomolar affinity237. 
Early work described the activity of several putative BH3 mimetics – natural or 
synthetic compounds which seemed to have BH3 mimetic-like behaviour, able to 
inhibit the activity of one or more of the pro-survival BCL-2 family members in vitro. 
Key examples include obatoclax238 and derivatives of gossypol (apogossypol, 
sabutoclax239,240) – which exhibited pan-BH3 mimetic-like properties in binding to the 
key pro-survival proteins and displacing effector proteins to induce apoptosis, albeit 
at micromolar concentrations. Obatoclax, however, could induce apoptosis in 
BAX/BAK null cells, suggesting it was not a true BH3 mimetic. Meanwhile, gossypol 
(and its derivatives), natural compounds derived from cottonseeds, had been known to 
have anti-neoplastic activity for more than 50 years241, although were only designated 
as a putative BH3 mimetic 40 years later242. Despite the multiple steps of re-
engineering of gossypol to other compounds like apogossypol, TW37 and sabutoclax, 
these compounds represented poor therapeutic potential, as they had weak binding 
affinities for the anti-apoptotic proteins243,244. Moreover, many of these compounds 
could also induce BAX/BAK-independent apoptosis, indicating likely off-target 
toxicities245–247. 
While many of these compounds were BH3 mimetic-like, none could be considered 
true BH3 mimetics and most demonstrated both off-target effects in addition to a lack 
of specificity within the BCL-2 family itself. With the knowledge that different 
cancers can rely on different BCL-2 family proteins for survival, specific targeting of 
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one or more members of the anti-apoptotic BCL-2 with true BH3 mimetics was 
pursued. 
Development of synthetic, BH3-like peptides 
Since it was remarked that native BH3-only proteins are direct antagonists of the pro-
survival proteins, Walensky et al. set about designing synthetic peptides based off the 
structure of the endogenous BH3-only proteins248. Stable, stapled peptides based on 
the BH3 motifs of multiple BH3-only proteins, including BIM, BAD and BID were 
generated by stabilising peptides with hydrocarbon groups and were named SAHBs – 
stabilised alpha-helix of BCL-2 domains. The ability of these peptides to induce 
apoptosis was assessed by measuring in vitro cytochrome c release or 
phosphatidylserine (PS) externalisation in cancer cells, with the peptides 
demonstrating a BAK-dependent increase in both measurements211,248. These studies 
provided the basis for the development and identification of compounds with similar 
properties, able to bind to the hydrophobic groove of anti-apoptotic proteins and 
induce BAX/BAK-dependent apoptosis. 
1.14 The advent of bonafide BH3 mimetics  
Development of ABT-737 
ABT-737 was developed following an NMR-based screen searching for small 
molecules that could specifically bind to the BH3 binding groove of BCL-XL. 
Promising hits from the screen were subjected to extensive structural modifications to 
yield the BAD-like BH3 mimetic, ABT-737. It was designed based on how BAD 
bound to BCL-XL, and hence called a BAD-mimetic. True to its name, ABT-737 could 
bind to and inhibit BCL-2, BCL-XL and BCL-w but not MCL-1, just like BAD. The 
binding affinity of ABT-737 to the aforementioned anti-apoptotic proteins is 
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extremely low at ≤1 nM and it was shown to be able to induce apoptosis as a single 
agent in both haematological and solid cancer cell lines and could induce significant 
cytochrome c release in isolated mitochondria at concentrations as low as 10 nM. 
ABT-737 also showed low nanomolar activity in follicular lymphoma and CLL patient 
samples as well as xenograft models of small cell lung cancer, where it reduced tumour 
volume and greatly improved survival of mice249.  
Development of ABT-263 
Despite its remarkable ability to induce apoptosis in cell lines and mouse models, the 
therapeutic potential of ABT-737 was limited by its poor oral bioavailability246. To 
first overcome this, a second-generation inhibitor, ABT-263 (Navitoclax) was 
developed through re-engineering of ABT-737. ABT-263 displayed similar binding 
affinities for BCL-2, BCL-XL and BCL-w but did not bind the other pro-survival 
proteins as expected. The bioavailability of ABT-263 was assessed by oral gavage in 
several species and was shown to be ~20%, which increased to ~50% by incorporation 
into a lipid formula246. Like ABT-737, ABT-263 was also able to induce cytochrome 
c release as well as apoptosis in solid and haematological cancer cell lines and 
regression of tumours in xenograft mouse models, all at clinically relevant doses246. 
This suggested that ABT-263 could have great therapeutic potential for treating 
various tumours in the clinic. The specificity of ABT-263 was also demonstrated by 
the fact that it could not induce apoptosis in BAX/BAK null cells, indicating that ABT-
263 functions through the apoptotic pathway and can be considered a bonafide BH3 
mimetic246. 
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ABT-199 – the first BCL-2 specific and highly effective BH3 mimetic 
Due to extremely promising pre-clinical outcomes, ABT-263 was taken forward to 
multiple Phase I and II clinical trials in both lymphoid and solid (small cell lung 
cancer) malignancies. While ABT-263 resulted in extensive apoptosis and increased 
survival of patients, this was marred by its dose-limiting thrombocytopenia250–253. 
Studies confirmed that the thrombocytopenia observed was, in fact, an on-target 
toxicity, as ABT-263 inhibited multiple members of the pro-survival BCL-2 family, 
including BCL-XL, which is required for survival of platelet cells
254.  
To circumvent the unwanted toxicity of ABT-263, ABT-199 (Venetoclax), a BCL-2-
specific inhibitor, was developed for use in CLL, where BCL-2 is a major contributing 
factor to disease progression255,256. ABT-199 showed a remarkable sub-nanomolar 
affinity for BCL-2 and induced significant apoptosis in several BCL-2-dependent 
malignancies including non-Hodgkin’s lymphoma cell lines. In vivo xenograft studies 
also demonstrated that ABT-199 can work as a monotherapy or in combination with 
other chemotherapeutic agents to promote tumour regression and increase survival, all 
without causing thrombocytopenia256. Furthermore, an initial study of ABT-199 in 
patients suffering from refractory CLL demonstrated that ABT-199 can induce a rapid 
reduction (within 24 h of administration) in tumour burden in patients while sparing 
platelets135,256. ABT-199 has since been FDA-approved to treat refractory CLL with 
the 17p deletion257 and is being explored for the treatment of other BCL-2-driven 
malignancies, both as a single agent and in combination with other therapies, including 
non-Hodgkin's lymphoma258, acute myeloid leukaemia259 and multiple myeloma260,261. 
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Development of BCL-XL specific inhibitors  
With the successful development of a specific and highly potent BCL-2 inhibitor 
complete, it set the basis for development of specific inhibitors of the other pro-
survival BCL-2 family members, including BCL-XL and MCL-1. Several inhibitors 
have been developed that specifically target BCL-XL, the first being WEHI-539, 
identified in a high-throughput screen of ~100,000 compounds. The compound was 
shown to have sub-nanomolar affinity for BCL-XL and was able to induce apoptosis 
in MCL-1-null fibroblasts but not BAK-null MEFs, suggesting it acts through the 
apoptotic pathway as expected. As another marker of on-target activity, the effect of 
WEHI-539 was assessed on platelets derived from mice which should require BCL-
XL for survival. WEHI-539 was able to induce apoptosis in these cells, suggesting that 
it does indeed hit BCL-XL
262
. 
While WEHI-539 was an extremely important leap in the development of BH3 
mimetics, its chemical structure (with potentially toxic hydrazone groups) limited its 
use in the clinic262–264. Thus, further work was carried out in search of more BCL-XL 
inhibitors, such as A-1155463263 and A-1331852265. Both of these compounds were 
able to induce a BCL-XL specific apoptosis in the nanomolar range, with A-1331852 
being up to 50-fold more potent than A-1155463 while also being orally bioavailable. 
These inhibitors are extremely important steps forward in targeting the BCL-2 family 
but also useful tools for dissecting the functional interplay between the pro- and anti-
apoptotic proteins and have provided a basis for the development of further therapeutic 
tools. 
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In search of a potent, MCL-1-specific BH3 mimetic 
The development of BH3 mimetics targeting BCL-2, BCL-XL and BCL-w proved to 
be relatively successful, however development of a specific MCL-1 inhibitor has 
proven much more difficult. This is thought to be linked to the fact that the MCL-1 
hydrophobic binding groove possesses a very rigid conformation compared to the 
other anti-apoptotic BCL-2 family members. Furthermore, MCL-1 has a very high 
affinity for its endogenous BH3-only protein binding partners266. However, the MCL-
1-specific BH3 mimetic field has developed at a very rapid pace in the past few years, 
beginning with the development of A-1210477267. This compound was developed as 
the lead MCL-1 inhibitor in a series of compounds derived from an indole-2-
carboxylyic acid core following a structure-guided inhibitor design. The inhibitor 
displaced the endogenous ligands from the hydrophobic binding groove of MCL-1 and 
also induced the typical hallmarks of apoptosis in MCL-1-dependent cell lines267. 
While A-1210477 was shown to have a high binding affinity for MCL-1 (0.45 nM), 
the in vivo working concentration was in the micromolar range267 which restricted its 
use to preclinical studies. However, A-1210477 demonstrated the classic features of a 
bona fide MCL-1 inhibitor and was an important step in the development of MCL-1 
inhibitors267. 
Since the development of A-1210477, multiple other compounds which are 
purportedly better inhibitors of MCL-1 have been demonstrated. AMG-176 is a novel 
MCL-1 inhibitor which has been shown to have picomolar binding ability in vitro and 
was able to rapidly induce apoptosis in various haematological cancer cell lines as well 
as tumour xenograft models and patient samples. Furthermore, AMG-176 could 
synergise with other BH3 mimetics to induce apoptosis in AML models, suggesting 
that it may have great therapeutic potential268. Indeed, a clinical trial is currently 
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recruiting patients to test AMG-176 as an MCL-1 inhibitor in relapsed or refractory 
multiple myeloma and acute myeloid leukaemia (ClinicalTrials.gov Identifier: 
NCT02675452), further highlighting its potential. 
Likewise, S63845 is another promising MCL-1 inhibitor, developed following an 
NMR-based fragment screen and structure-guided discovery. S63845 binds the BH3 
binding groove of MCL-1, partly due to its carboxylate moiety strongly binding a well-
known anchor point for anti-apoptotic BCL-2 family inhibitors at Arg263 (also seen 
in multiple other MCL-1 inhibitors267). S63845 could induce rapid apoptosis at 
nanomolar concentrations in several cell lines and also demonstrated potential for in 
vivo use with no apparent toxicity in mice269. Subsequent studies have confirmed the 
potency of S63845 and further explored its potential use in synergy with other 
chemotherapeutic agents in various cancers including AML270, T-cell acute 
leukaemia271 and breast cancer202. 
Thus, despite the challenges facing development of a specific MCL-1 inhibitor, recent 
advances have been greatly successful and multiple highly potent and specific MCL-
1 inhibitors are now in the process of being developed for therapeutic use, while also 
providing excellent tools for the study of the biology of MCL-1. 
1.15 Challenges facing BH3 mimetic therapy 
Immense progress has been made in the BH3 mimetic field recently, however the use 
of these compounds in a clinical setting still faces a wide array of challenges. BCL-2 
can now be effectively targeted using ABT-199 in a clinical setting, often achieving 
excellent results in specific subsets of cancers. Meanwhile, the targeting of BCL-XL, 
while achievable, faces its own challenges in the form of on-target toxicity, as 
previously described. Moreover, now that effective inhibitors of these proteins have 
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been developed, possible resistance mechanisms are being highlighted in the literature. 
Indeed, it has been demonstrated that tumours may acquire resistance to ABT-199 
through expression of MCL-1 or BCL-XL
272,273, while other studies have shown that 
ABT-199 resistance may arise through downregulation of BCL-2 and/or BIM274 or 
even acquired mutations in BCL-2 itself275. 
Inhibition of MCL-1, either as a first-line therapy or to overcome resistance to other 
BH3 mimetics, provides unique challenges too. The multi-faceted nature of MCL-1 
along with its extensive healthy tissue expression means that targeting MCL-1 in 
human cancer may have undesirable side-effects and therefore must be carefully 
explored and controlled prior to potential MCL-1 inhibitors entering the clinic. Indeed, 
recent animal studies show that loss of MCL-1 (via genetic knockout) results in 
cardiotoxicity as a result of altered mitochondrial function – indicating the importance 
of MCL-1 in regulation of mitochondrial dynamics and bioenergetics276,277. Hence, 
further knowledge regarding how MCL-1 functions in both normal and cancerous cells 
is required in order to efficiently target MCL-1 in tumour cells while causing minimal 
harm to healthy cells. Until recently, the possibility of specifically targeting MCL-1 
in cancer remained difficult, however following the development of inhibitors specific 
to individual BCL-2 family members, several novel MCL-1 inhibitors which work at 
clinically acceptable concentrations have now been established. While these inhibitors 
must be trialled extensively before use in patients, the advent of highly specific and 
highly potent BH3 mimetics which have enormous potential therapeutic value is a 
great step forward for the programmed cell death field.  
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1.16 Aims  
Following the recent development of purportedly highly potent and specific MCL-1 
inhibitors, this thesis aims to explore these novel compounds in order to confirm their 
ability to induce apoptosis alone and in combination with other BH3 mimetics, which 
could potentially represent highly effective chemotherapeutic approaches in the future. 
The first specific MCL-1 inhibitor, A-1210477, works in the micromolar range to 
induce apoptosis, however our group has multiple MCL-1 inhibitors, both published 
and unpublished, which are proposed to work in the nanomolar range, representing a 
huge potential improvement in MCL-1-targeting. Since MCL-1 is one of the most 
overexpressed genes in cancer and represents a key therapeutic target, validating the 
efficacy of these new inhibitors and exploring their mechanism is of great importance 
as it improves the scope of targeting MCL-1 in cancer. 
The mechanism of action of MCL-1 and other BCL-2 family inhibitors will also be 
explored in order to identify the role of BH3-only proteins in apoptosis induction, 
which has recently been identified as a controversial point in the field. It is now known 
that the BH3-only proteins may be dispensable for apoptosis induction when both 
MCL-1 and BCL-XL are neutralised, however it is not known if highly specific BH3 
mimetics, which are now available for all major pro-survival proteins, can induce 
apoptosis in the absence of the BH3-only proteins. This is important to explore as this 
goes against the proposed mechanism of action of BH3 mimetics and raises important 
questions as to how they function. 
Furthermore, this thesis will explore novel MCL-1-interacting proteins in order to 
attempt to explain BH3-only protein-independent apoptosis. The notion that 
undiscovered, BH3-only-like proteins exist, which could be binding to MCL-1 and 
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mediating apoptosis in the absence of the known BH3-only proteins is one critical 
hypothesis to explain the previously observed BH3-only protein-independent 
apoptosis.  MCL-1 is known to be an unusually complicated member of the BCL-2 
family, with multiple binding partners and functions lying outside of apoptosis, thus, 
this work will not only address the possibility of novel BH3-only-like proteins, but 
may also identify new functions or pathways that MCL-1 is involved in. This is a key 
angle of MCL-1 biology research as it is a complex protein whose diverse functions 
remain to be fully understood. This could mean that there may be on-target but 
unexpected effects of targeting MCL-1 in cancer. 
With all of this taken into account, the main aims of this study are (1) to assess the 
specificity and potency of novel MCL-1 inhibitors as well as their mechanism of 
action, (2) to determine the requirements of the known BH3-only proteins in BH3 
mimetic-induced apoptosis and (3) to identify novel MCL-1-interacting proteins 
which could mediate apoptosis in the absence of the 8 major BH3-only proteins. 
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2.1 Cell culture  
Cells were purchased from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ, Braunschweig, Germany) or American Type Culture Collection 
(ATCC, Manassas, VA, USA) unless otherwise specified in Table 2.1, and were 
cultured in appropriate cell culture media, as indicated in Table 2.1. Cell culture media 
was purchased from Life Technologies Inc (Paisley, UK) and supplemented with 10% 
foetal bovine serum (FBS) and 2 mM L-glutamine (Life Technologies). Cells were 
grown at 37°C, 5% CO2 and were passaged every 48 h or according to their growth 
rate in order to maintain approximately 80% confluence. For passaging of adherent 
cell lines, media was aspirated from cell culture dishes, cells washed once with 
warmed PBS (ThermoFisher Scientific, MA, USA) and then incubated with 0.05% 
trypsin-EDTA (Gibco, ThermoFisher Scientific) at 37°C for 5 min. Fresh media was 
then added to the cells to inhibit the activity of trypsin and cell suspension divided into 
plates with new media accordingly. Suspension cell lines had media replaced every 48 
h.  
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2.2 Cell lines  
Table 2.1 – Cell lines used in this study, their specified media, BCL-2 family 
protein survival dependencies and additional notes including sources. 
 
Media   
Cell line and tumour 
origin 
Reported 
survival 
dependency 
Notes 
Roswell 
Park 
Memorial 
Institute 
(RPMI) 
1640 
 
H1299, H23 (non-small 
cell lung carcinoma, 
adherent) 
BCL-XL 
and MCL-1, 
MCL-1 
Purchased from ATCC. 
 PC-3 (prostate cancer, 
adherent) 
BCL-XL 
and MCL-1 
Gift from Y. Ke 
(University of Liverpool). 
 
MV-4-11, OCI-AML3, 
HL-60, U937, THP-1, 
MOLM-13 (acute 
myeloid leukaemia, 
suspension) 
BCL-2 and 
MCL-1 
Purchased from ATCC. 
 
U-2946 (diffuse large B-
cell lymphoma, 
suspension) 
MCL-1  Purchased from DSMZ. 
 Jurkat (acute T-cell 
leukaemia, suspension) 
MCL-1 
Wild-type, caspase-9 null, 
caspase-8 null and FADD 
null Jurkat cells were gifts 
from J. Blenis (Weill 
Cornell Medicine, USA). 
 
K562, KCL-22 (chronic 
myeloid leukaemia, 
suspension) 
BCL-XL  
Gift from R. Clark 
(University of Liverpool). 
 MAVER-1 (mantle cell 
lymphoma, suspension) 
BCL-2 
Gift from J. Slupsky 
(University of Liverpool). 
 H929 (multiple 
myeloma., suspension) 
MCL-1 
Purchased from ATCC. 
Additionally supplemented 
with 0.02% 2-
mercaptoethanol.  
  
Chronic lymphocytic 
leukaemia (CLL) patient 
cells, suspension 
BCL-2 
Freshly isolated from CLL 
patient blood samples after 
patient consent and ethical 
approval.  
Dulbecco’s 
modified 
Eagle 
Medium 
(DMEM) 
 HELA (cervical 
carcinoma, adherent) 
BCL-XL 
and MCL-1 
Purchased from ATCC. 
 SUIT-2 (pancreatic 
cancer, adherent) 
BCL-XL 
and MCL-1 
Gift from A. Mielgo 
(University of Liverpool). 
 
MDA-MB-231 (triple 
negative breast cancer, 
adherent) 
BCL-XL 
and MCL-1 
Gift from P. Meier 
(Institute of Cancer 
Research, UK).  
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McCoy’s 
5A 
Modified 
  
HCT116, HT-29 (colon 
carcinoma, adherent) 
 
 
 
BCL-XL 
and MCL-1 
HCT116 WT, DKO and 
8KO cells were from our 
collaborator X. Luo 
(University of Nebraska). 
HCT116 BAX/BAK KO 
cells were from R. J. Youle 
(National Institute of 
Health, USA).  
    
HT-29 cells were a gift 
from J. Parsons (University 
of Liverpool). 
DMEM/F-12 
A549 (non-small cell 
lung carcinoma, 
adherent) 
BCL-XL 
and MCL-1 
Purchased from ATCC. 
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2.3 Cell line authentication  
Genomic DNA from all cell lines was isolated using the DNeasy kit (Qiagen, 
Cambridge, UK) and the samples were subjected to short tandem repeat (STR) 
profiling to ensure authenticity using GenePrint® 10 (Promega, Madison, WI, USA) 
at the University of Liverpool Cell Line Authentication Facility. Percentage matches 
of cell lines to multiple cell databases are indicated in Table 2.2. 
 
Table 2.2 – Cell lines were authenticated using STR profiling and matched 
against multiple databases. Cells were required to have at least an 80% match to 
online databases. *MDA-MB-231 cells were originally thought to be HCC-1187 cells, 
however STR profiling revealed that they matched 83% to MDA-MB-231 versus 34% 
to HCC-1187. 
 
Cell line % Match Databases 
OCI-AML3 100% DSMZ and ExPASy 
HL-60 100% DSMZ, PHEngland and ExPASy 
MOLM-13 100% DSMZ, ExPASy 
MV-4-11 100% DSMZ, ATCC 
THP-1 100% DSMZ, ATCC, PHEngland 
U-937 100% DSMZ, ATCC, PHEngland 
K562 83% DSMZ 
U-2946 100% DSMZ 
H929 79% DSMZ, ATCC 
MAVER-1 94% DSMZ 
KCL-22 100% DSMZ 
H1299 100% DSMZ/ATCC 
A549 86% DSMZ, ATCC, ExPASy 
PC-3 92% ATCC 
SUIT-2 100% DSMZ 
HCT116 WT 89% DSMZ, ATCC 
HCT116 8KO 89% DSMZ, ATCC 
HT-29 100% DSMZ, ATCC 
HELA 100% PHEngland, ExPASy 
MDA-MB-231 34%* DSMZ 
H1299 100% DSMZ, ATCC 
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2.4 Reagents and inhibitors  
All reagents, chemicals and buffers, unless otherwise specified, were from Sigma-
Aldrich (now Merck) Darmstadt, Germany)). Inhibitors used throughout the study are 
indicated in Table 2.3. Large-scale pre-prepared subcellular fractions (extranuclear, 
nuclear, ‘S100’, mitochondria) for immunoprecipitation and mass spectrometry 
analysis were purchased from Ipracell (Ipratech, Belgium) and lysed according to the 
immunoprecipitation protocol outlined. 
 
Table 2.3 – Inhibitors used, their targets and sources. Selleck represents Selleck 
Chemicals Co (Houston, TX, USA), Abbvie represents Abbvie (Chicago, IL, USA), 
Active Biochem represents Active Biochem (New Jersey, USA). 
Inhibitor Target Source 
ABT-199 BCL-2 Selleck 
A-1331852 BCL-XL Abbvie 
A-1210477 MCL-1 Abbvie 
S-30 MCL-1 Collaborator gift 
AMG-176 MCL-1 Amgen 
S63845 MCL-1 Selleck 
MG-132 Proteasome Active Biochem 
Z-VAD-FMK Caspases Selleck 
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2.5 Antibodies 
 
Table  2.4  –  Antibodies  used  in  different  protocols,  divided  into  functional  
subsets. Clone numbers and epitopes are indicated where available. The applications 
where each antibody was used is also indicated. ‘AA’ represents amino acids. ‘SC’ 
represents  Santa  Cruz  Biotechnology  (CA,  USA),  ‘CST’  represents  Cell  
Signalling  Technologies  (MA,  USA),  ‘Abcam’  represents  Abcam  (Cambridge,  
UK),  ‘BD’  represents  BD  BioSciences  (CA,  USA),  ‘Milli’.  represents  
Millipore/Merck  (Darmstadt,  Germany), ‘Enzo’ represents Enzo Biochem Inc (NY, 
USA), ‘Calbio’. represents Calbiochem Research Biochemicals (now Merck) and 
‘Upstate’ represents Upstate USA Inc (NY, USA).  
   Antibody Epitope Application(s) Source Catalogue # 
BCL-2 
family 
        
BCL-2 (100) AA 41-54 Immunoblotting SC sc-509 
BCL-2 
(6C8) 
Recombina
nt protein 
Immunoprecipitation BD 51-1513GR 
BCL-XL Around 
Asp61 
Immunoblotting CST 2762 
BCL-XL (E-
18] 
AA 1-100 Immunoprecipitation Abcam ab32370 
MCL-1 (S-
19) 
AA 89-139 Immunoblotting SC sc-819 
MCL-1 (Y-
37) 
AA 100-
200 
Immunoprecipitation Abcam ab32087 
PUMA C terminal Immunoblotting CST 4976 
BIM 
(C34C35) 
Around 
Pro25 
Immunoblotting CST 2933 
BIK N-terminal Immunoblotting SC sc-1710 
BAD Around 
Ser112 
Immunoblotting CST 9292 
BMF Around 
Gly81 
Immunoblotting CST 5889 
HRK AA 30-50 Immunoblotting SC sc-6971 
NOXA 
(114C307) 
Recombina
nt protein 
Immunoblotting Milli. OP180 
BID Cleavage 
site 
Immunoblotting CST 2002 
BAK (AB-1) Active Site Activation assay Calbio. AM-03 
BAK Internal Immunoblotting SC sc-832  
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BAX (C3) AA 55-178 Immunoblotting & 
Immunocytochemistry 
BD 610983 
BAX (6A7) Active site Activation assay Enzo ALX-804-
224-C100 
BAX (N-
terminal) 
N-terminal Immunoprecipitation Upstate 06-499 
Apoptosis         
Cytochrome 
c 
Around 
residue 62 
Immunocytochemistry BD 556432 
Caspase-8 
(1C12) 
C-terminal Immunoblotting CST 9746 
Caspase-9 Asp315 Immunoblotting CST 9502 
FADD Ser194 Immunoblotting CST 2782 
Misc.         
Tubulin (6-
11B-1) 
Around 
Lys40 
Immunoblotting Abcam ab24610 
GAPDH 
(FL-335) 
AA 1-335  Immunoblotting SC sc-25778 
HSP60 
(C24) 
Recombina
nt protein 
Immunocytochemistry BD 611562 
BAP31 C-terminal Immunoblotting Abcam ab37120 
DRP-1 AA 601-
722 
Immunoblotting BD 611113 
GM130 AA 869-
982 
Immunoblotting BD 610822 
Vimentin 
(V9) 
Whole 
vimentin 
(porcine 
eye lens)  
Immunoblotting SC 6260 
ATPB (3D5) Whole 
mitochondri
a (human 
heart)  
Immunoblotting Abcam ab14730 
NDUFA9 
(20C11) 
 Whole 
purified 
complex I 
(bovine) 
Immunoblotting SC sc-58392 
PARP-1 (F-
2) 
AA 764-
1014 
Immunoblotting SC sc-8007 
 
  
57 
 
2.6 RNA interference 
All siRNAs (small interfering RNA oligoduplexes) were purchased from Qiagen 
(Cambridge, UK). Knockdowns were performed in Opti-MEM Reduced Serum Media 
(Life Technologies), using Interferin transfection reagent (Polyplus, Illkirch, France). 
Cells were seeded at their required densities to be confluent following a 72 h 
incubation with a 10 nM final concentration of siRNAs.  
 
Table 2.5 – siRNA catalogue numbers and their target regions of the indicated 
proteins. The targeted region of the proteins is indicated by the highlighted region, 
with the grey bar below the transcript indicating the coding sequence of the gene. The 
BCL-XL siRNA targets the 5’ untranslated region (UTR) while the MCL-1 and HRK 
siRNAs target the 3’ UTR. The DRP-1 siRNA targets the coding region. 
 
Protein 
targeted 
siRNA 
catalogue 
number 
Sequence Targeted 
BCL-XL SI03025141 TTGGCTTTGGATCTTAGAAGA 
MCL-1 SI02781205 CCCGCCGAATTCATTAATTTA 
DRP-1 S104274235 CACGGTGGGCGCCGACATCAT 
Non-
targeting 
control 
1027310   
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2.7 SDS-PAGE (Immunoblotting) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using in-house gels made with lower gel buffer (1.5 M Tris-HCL, 0.4% 
SDS, pH 8.8), upper gel buffer (Tris-HCL 0.5 M, 0.4% SDS, pH 6.8) Protogel 
acrylamide (30%) (National Diagnostics, Atlanta GA, USA), 10% APS and TEMED. 
Cells intended for immunoblotting were collected, pelleted by centrifugation and lysed 
in radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-Cl (pH 8.0), 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 
mM NaCl) containing 20 µM MG-132 and a protease inhibitor tablet (Roche, Basel, 
Switzerland). Cells were incubated on ice for 15 min in RIPA lysis buffer then 
subjected to sonication using a Bandelin SONOPULS ultrasonic homogeniser 
(Bandelin, Berlin, Germany). Protein concentration was then determined in a 
colorimetric (Bradford) assay using the BioRad Protein Assay Dye Reagent (BioRad, 
CA, USA). Optical density at 600 nm (OD600) of samples was measured in a 
spectrophotometer (Eppendorf, Hamburg, Germany) and compared to a known 
standard of bovine serum albumin (BSA) to establish protein concentrations. 
10-50 µg of protein lysate was then combined with 4x NuPAGE LDS sample buffer 
(Life Technologies) and heated for 5 min at 70°C (ThermoFisher Scientific). Samples, 
alongside the SeeBlue™ Plus2 Pre-stained Protein Standard (ThermoFisher 
Scientific) were then subjected to SDS-PAGE in electrode buffer (25 mM Tris-HCL, 
192 mM glycine, 10% SDS) at 130 V for 90 min then transferred to Amersham 
ProTran nitrocellulose membranes (VWR, Radnor, PA, USA) in transfer buffer (25 
mM Tris-HCL, 192 mM glycine, 20% methanol) at 100 V for 90 min. Membranes 
were subsequently blocked in non-fat 5% milk in TBS-T (Tris-buffered saline with 
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0.1% Tween, 20 mM Tris-HCL, 150 mM NaCl, 0.1% Tween-20) for 30 min then 
incubated with the indicated primary antibodies, diluted 1:1000 in TBS-T, overnight 
at 4°C. Membranes were then rinsed with TBS-T and incubated with either anti-mouse 
or anti-rabbit IgG, HRP-linked secondary antibodies (Cell Signalling Technology) for 
1 h, then washed three times in TBS-T before visualisation of protein bands with ECL 
reagents (GE Healthcare, IL, USA) either using X-ray film (GE Healthcare) or the 
ChemiDoc Imaging system (BioRad). 
2.8 Immunoprecipitation 
For immunoprecipitation (IP) experiments, Protein G Dynabeads (30 µl/sample) 
(ThermoFisher Scientific) were washed three times with PBS-T (PBS with 0.05% 
Tween-20) before being resuspended in PBS-T with 5 µg of antibodies against the 
protein of interest. The antibody-protein mix was rotated for 4 h at 4°C and beads 
subsequently washed with 0.2 M triethanolamine (TEA). The antibody-bead 
conjugates were then cross-linked using 5.4 mg/ml dimethylpimelidate (DMP) at 
room temperature for 30 min. The cross-linking reaction was then neutralised with 50 
mM Tris-HCL pH 7.5 at room temperature for 15 min, with agitation. Bead-antibody 
complexes were then washed three times in PBS-T and resuspended in 500 µg of cell 
lysate.  
Cell lysates for immunoprecipitation were prepared using 1% CHAPS lysis buffer 
(150 mM KCl, 50 mM HEPES (pH 7.4) 1% CHAPS) containing 20 µM MG-132 and 
a protease inhibitor tablet. Cells were incubated with 1% CHAPS lysis buffer for 45 
minutes on ice and centrifuged at 14,000 RPM for 10 min at 4°C to remove cell debris. 
Bead-antibody complexes were incubated with the lysates overnight at 4°C with 
rotation and then flow-through (immunodepleted lysates collected post-
immunoprecipitation) collected and the beads washed three times with PBS-T. Protein 
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was eluted from beads using 2x NuPAGE LDS sample buffer (Life Technologies) by 
incubation at 55°C for 10 min with shaking and samples subsequently loaded onto gels 
alongside an input (whole cell lysate from the same lysates used for the 
immunoprecipitation) and in some cases, a bead control (beads with no antibody 
bound, incubated with lysates) and a flow-through. Immunoblotting for 
immunoprecipitation experiments was carried out according to the immunoblotting 
protocol described. Immunoprecipitation for mass spectrometry analysis was 
performed in the same way but with minor changes. Lysates were incubated for 30 
min at 4°C with 30 µl protein G Dynabeads to pre-clear and reduce non-specific 
binding of protein to beads. Furthermore, pre-elution, the beads were washed with 
low-salt PBS and water and protein was eluted using 1% Rapigest (Waters, UK) into 
lo-bind tubes (Eppendorf).  
2.9 Coomassie staining of protein gels 
Gels for Coomassie staining were subjected to electrophoresis in the same way as done 
for standard SDS-PAGE. Upon completion of electrophoresis, the gels were fixed 
using a mix of 45% methanol and 10% glacial acetic acid for 1 h at room temperature. 
Gels were then washed and incubated with EZBlue Gel Staining Reagent overnight at 
room temperature, washed 3 times with water for 5 min and images acquired using the 
BioRad ChemiDoc imaging system. 
2.10 Fast protein liquid chromatography  
Fast protein liquid chromatography (FPLC), used to fractionate cell lysates to analyse 
BCL-2 family protein complexes, was performed using an FPLC ÄKTA system with 
Superose 6 and Superdex 200 columns (GE Healthcare). Columns were washed prior 
to use with water then equilibrated with running buffer (50 mM Tris, 150 mM KCL, 
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1 mM EDTA, 5% glycerol, 1 mM DTT, 1 mM PMSF, pH 8). Columns were also 
subjected regular runs with protein standards to determine fraction sizes. Cells 
intended for gel filtration were lysed in 1% CHAPS on ice for 45 min and then 
centrifuged at 14,000 RPM at 4°C for 10 min and the supernatant collected as protein 
lysate. Lysates were filtered to remove any remaining debris and subjected to Bradford 
assays as described previously to determine protein concentration. 500 µl protein 
lysate (minimum 20 mg/ml) was then loaded on to the columns using a 500 µl loop 
and collected in 50 x 500 µl fractions. Collected fractions were either mixed directly 
with 4x LDS sample buffer or saved as pure lysate for further experiments. The 
UNICORN Control System software (GE Healthcare) was used to control the 
columns. Column peaks were used to determine which fractions would be loaded on 
gels, typically beginning with fraction 16 of Superose 6 and ending with fraction 35 
of Superdex 200. 
2.11 Flow cytometry – apoptosis  
Cells were seeded at a density of 0.1 million cells/well and exposed to the required 
drug treatment for the indicated time. Following incubation at 37°C, cells were 
collected – cells from haematological malignancies were directly transferred to tubes 
while adherent cells were washed once with PBS, trypsinised and collected in their 
media before being centrifuged to pellet the cells. For Annexin-V-FITC and propidium 
iodide (PI) labelling, cells were resuspended in 500 µl of 1x Annexin Binding Buffer 
(10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4 with Annexin-V (1:20,000, 
made in-house) and 5 µl PI added just before analysis. To assess the extent of labelling, 
cells were passed through the Attune NxT flow cytometer (ThermoFisher) using red 
and blue lasers for PI and Annexin V staining respectively. 10,000 events were 
captured per sample and at least three replicates were analysed for each experiment. 
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2.12 Flow cytometry – BAX/BAK activation 
To measure BAX and BAK activation, cells were exposed to the indicated treatments, 
collected and fixed with 2% paraformaldehyde (PFA) at room temperature for 10 min. 
Fixed cells were then washed with PBS and re-suspended in permeabilisation buffer 
(0.1% saponin, 0.5% BSA in PBS) for 10 min. Primary antibodies (mouse anti-BAX 
6A7 or mouse anti-BAK AB-1) were then added to the cells at a volume of 1:100 in 
permeabilisation buffer and cells incubated for 1 h at 4°C. Goat-anti-mouse IgG-
AlexaFluor-488 conjugated secondary antibody was then mixed with the cells and 
incubated for 1 h at 4°C. Activated BAX or BAK was then detected using flow 
cytometry using a blue (BL1) laser (530/30 nm emission filter) as the excitation source 
for the AlexaFluor-488 tag of the secondary antibodies. 
2.13 Flow cytometry – BH3 profiling 
Cells were collected in TEB buffer (Derived from Trehalose Experimental Buffer, 135 
mM trehalose, 50 mM KCl, 20 µM EDTA, 20 mM EGTA, 0.1% BSA, 5 mM 
succinate, 10 mM HEPES-KOH pH 7.5) and permeabilised with digitonin (0.002%) 
and incubated at room temperature with the indicated peptides for 90 min. 
Tetramethylrhodamine ethyl ester (TMRE), a positively charged dye that accumulates 
in active mitochondria as a result of membrane potential278 was then added (200 nM 
final) to each tube and the cells then incubated a further 30 min at room temperature 
and loss of mitochondrial membrane potential (ψm) assessed using flow cytometry 
(blue (BL2) laser, 574/26 emission filter). FCCP (Carbonyl cyanide-4-
phenylhydrazone), a mitochondrial un-coupler was used as a positive control for 
depolarisation279. 
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Peptides used in BH3-profiling were MS-1 (RPEIWMTQGLRRLGDEINAYYAR) 
and BAD (LWAAQRYGRELRRMSDEFEGSFKGL) from New England Peptide 
(Gardner, MA, USA). 
2.14 Immunocytochemistry 
Cells were seeded at 0.1 million cells/well on sterile coverslips and left to grow for the 
required time, up to 70% confluence. Coverslips were removed from media and cells 
fixed in 4% (w/v) paraformaldehyde for 10 min then permeabilised in 0.5% (v/v) 
Triton X-100 in PBS for 10 min, both at room temperature. Coverslips were then 
incubated with primary antibody diluted 1:300 in 3% BSA for 1 h followed by a 1 h 
incubation with an AlexaFluor fluorescently-conjugated secondary antibody (Life 
Technologies) diluted in 1:2000 in 3% BSA.  Coverslips were then washed briefly 
three times in water and mounted on glass slides using Polymount (Polysciences, PA, 
USA) and imaged using a 3i Marianas spinning disk confocal microscope, fitted with 
a Plan-Apochromat × 63/1.4 NA Oil Objective, M27 and a Hamamatsu ORCA-
Flash4.0 v2 sCMOS Camera (Intelligent Imaging Innovations, GmbH, Gottingen, 
Germany). 
2.15 Molecular biology 
mRNA extraction 
To assess mRNA levels of BCL-2 family members in HCT116 cells, the three cell 
lines used (WT, DKO and 8KO) were subjected to RNA extraction using the Qiagen 
RNeasy Kit (Qiagen, Hilden, Germany) according to the kit protocol. Briefly, 1 x 107 
cells were harvested per cell line and lysed in RLT buffer. 1 volume of 70% ethanol 
was then added to the lysate and mixed before being transferred to a RNeasy Mini spin 
column in a collection tube and the tubes centrifuged together for 15 sec at 8000 x g. 
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The flow-through was discarded and Buffer RW1 was added to the spin column and 
centrifuged again. The flow-through was discarded and RPE buffer was added and the 
tubes spun again. This step was then repeated before the column was placed in a 1.5 
ml collection tube and 30 µl RNase-free water added to the column. The tubes were 
spun at 8000 x g for 1 min and the RNA yield quantified using a NanoDrop 
spectrophotometer (ThermoFisher Scientific).  
Generation of cDNA 
The mRNA from the RNA extraction above was then used to generate cDNA from the 
three cell lines using reverse transcription. To generate cDNA, 2 µg RNA was mixed 
with 1 µl 10 mM dNTPs, 50 µg Oligo dT and nuclease-free water and incubated at 
65°C for 5 min then the mixture combined with 2 µl 10x reverse transcriptase buffer, 
50 mM 2 µl MgCl2, 1 µl DTT, 1 µl RNase out (recombinant RNase inhibitor), 1 µl 
SuperScript II RT polymerase (200 units/µl) and nuclease-free water. The mix was 
then subjected to PCR with the following conditions: 50 oC for 100 min, 85 oC for 5 
min. All reverse transcription materials were purchased from Invitrogen (CA, USA). 
qPCR 
qPCR was performed using gene-specific QuantiTect Primer Assay primers (Qiagen) 
for BCL-2 (QT00025011), BIK (QT00070777) and HRK (QT00203588) (Qiagen) 
using 5x HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis Biodyne, Estonia). The 
qPCR reaction was run on Stratagene Mx3005P (Thermo Fisher) under the following 
cycling conditions: 1 cycle: 95 oC for 15 min. 45 cycles: 95 oC for 15 sec, 60 oC for 
20 sec, 72 oC for 30 sec, 78 oC for 11 sec. 1 cycle: 95 oC for 1 min, 55 oC for 30 sec 
and 97 oC continuously. Relative mRNA expression levels of proteins of interest were 
calculated using the following formula280: 
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= 2 – (ΔCTgene of interest ΔCTgapdh). 
2.16 Mass spectrometry and analysis 
Three individual replicates of eluates from immunoprecipitation of MCL-1 in each 
Ipracell subcellular fraction, plus bead controls (beads and lysates with no antibody) 
were submitted for mass spectrometry analysis. Mass spectrometry and statistical 
analysis was performed by The Centre for Proteome Research at The University of 
Liverpool by Deb Simpson. 
Protein lists were returned for each subcellular fraction with peptide counts, calculated 
p values based on the three replicates, q values to adjust for false discovery rate (FDR), 
maximum fold change in the bead control versus immunoprecipitation and confidence 
scores. Proteins were selected for pathway analysis if they were detected > 2-fold 
higher in the immunoprecipitation versus bead control, > 2 spectral counts (i.e. more 
than 2 peptides of an individual protein detected) and < 10% frequency in a database 
of 400+ mass spectrometry experiments (the CRAPome). Subsequently, only proteins 
with fold change of > 5 in the immunoprecipitation versus bead control and a q value 
of < 0.02 were selected to further remove non-significant proteins. Where protein lists 
were still high in number following this triage, pathway analysis was performed using 
the Reactome and proteins associated with apoptosis highlighted. 
2.17 Statistics 
For time-course studies, a two-way ANOVA was performed. All other studies were 
analysed for statistical significance with one-way ANOVA and the asterisks depicted 
correspond to the following p values:  * for p ≤ 0.05, ** for p ≤ 0.005 and *** for p ≤ 
0.001. 
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Chapter 3  
 
MCL-1 inhibitors and the BCL-2 
protein family 
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3.1  Background 
BH3 mimetics, the novel group of pharmacological compounds, were designed to 
function like BH3-only proteins - binding to the hydrophobic groove of the pro-
survival proteins and displacing them from their pro-apoptotic BH3-only protein 
partners. Subsequently, the native pro-apoptotic BCL-2 family members are proposed 
to be free to induce apoptosis. In order to be classified as a bona fide BH3 mimetic, a 
compound must comply with two key criteria: bind to target anti-apoptotic proteins 
with a high affinity and induce a BAX- and/or BAK-dependent apoptosis245. As 
described earlier, the first clinically viable BH3 mimetic was ABT-263 (Navitoclax), 
an orally available form of ABT-737, which inhibits BCL-2, BCL-XL and BCL-w and 
potently induces apoptosis in several solid and haematological cancers246. Navitoclax 
was identified as a very strong chemotherapeutic candidate for chronic lymphocytic 
leukaemia (CLL) as many of these malignancies demonstrate dependence on BCL-2 
for survival12,281,282. Although initial results of trials of ABT-263 in CLL were 
encouraging, studies were halted by a dose-limiting thrombocytopenia – a result of 
ABT-263’s ability to target BCL-XL in addition to BCL-2. The inhibition of BCL-XL 
resulted in the death of platelets as they are extremely dependent on the anti-apoptotic 
BCL-XL for survival
254. While this was an on-target effect of ABT-263, it meant that 
the use of Navitoclax in patients was limited. Thus, ABT-263 was re-engineered and 
was soon followed by ABT-199 (Venetoclax), a BCL-2-specific inhibitor, which 
could induce cytotoxicity at a nanomolar range while sparing platelets256. ABT-199 
has proven to be greatly successful in the clinic and is now FDA-approved for use in 
patients with CLL refractory to at least one prior treatment. However, potential 
resistance mechanisms to ABT-199 have already been reported in some diseases273–
275. One of the major resistance factors is likely upregulation of MCL-1 – an anti-
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apoptotic protein which has remained largely untargeted by specific BH3 mimetics, 
until recently. MCL-1 is a key survival protein in many cancers and is associated with 
resistance to various chemotherapeutic approaches. As a result, there has been an 
intense effort to identify specific MCL-1 inhibitors that have a high potency. 
While indirect methods for inhibiting MCL-1 have been established, only recently has 
a bona fide MCL-1-specific inhibitor which works at a clinically relevant 
concentration been demonstrated, in the form of S63845269. Efforts to develop MCL-
1 specific inhibitors which work at low nanomolar concentrations have proven 
difficult and it is thought that this, in part, is due to the properties of the BH3 binding 
groove of MCL-1 which has been shown to be very rigid and furthermore, tightly 
binds the native BH3 only proteins, making them hard to displace266. In addition to 
S63845, multiple other MCL-1 specific compounds have been or are in development 
and many groups and pharmaceutical companies are all vying to develop the best 
MCL-1 inhibitors for future use in large number of cancers. 
Here, a panel of four of the most recently described MCL-1 inhibitors (A-1210477, 
AMG-162, S-30 and S63845) were assessed to determine whether novel MCL-1 
inhibitors have improved the potential of targeting MCL-1 in cancer. While A-
1210477 is known to work in the micromolar range, it has not been compared to newer 
inhibitors such as S-30 and AMG-162. The ability of these inhibitors to induce the 
intrinsic pathway of apoptosis was assessed using cancer cell lines that lack distinct 
members of the apoptotic pathway, while the specificity of the inhibitors to exclusively 
target MCL-1 was assessed using a panel of cell lines that depend on BCL-2, BCL-XL 
or MCL-1 for survival. The initial report on S63845 suggested high specifity to MCL-
1, however, observations made here could imply otherwise. Choosing S63845 as the 
major focus of the subsequent studies, the potential for combining S63845 with other 
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BH3 mimetics was explored in a range of cancer types, while its ability to displace 
BH3-only members from MCL-1 was correlated with its ability to induce apoptosis in 
order to further characterise the mechanisms underlying MCL-1 inhibition and 
apoptosis induction in cancer. 
 
 
 
Figure 3.1. The chemical structures of four key MCL-1 inhibitors. The chemical 
structures of the four MCl-1 inhibitors A-1210477, AMG-162, S-30 and S63845, 
demonstrating their structural differences and similarities. *The chemical structure of 
AMG-162 is unavailable therefore a close analogue (AMG-176) has been utilised. 
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3.2 MCL-1 inhibitors induce rapid apoptosis in MCL-1-dependent cell lines. 
In order to test the potential of the selected MCL-1 inhibitors to induce apoptosis in a 
MCL-1-specific manner, two cell lines known to be dependent on MCL-1 for survival, 
H929267 and U-2946283, were exposed to a concentration range of A-1210477, S63845, 
AMG-162 or S-30 for 4 h. Apoptosis was assessed using FITC-labelled Annexin V 
(which binds to externalised phosphatidylserine during apoptosis284) labelling in flow 
cytometry (Fig. 3.2). A-1210477 only induced significant apoptosis in both cell lines 
at 10 µM, in line with previous findings that it is effective in the micromolar range267. 
AMG-162 started to induce apoptosis at lower concentrations than A-1210477, 
however significant apoptosis could only be observed at ~1 µM, suggesting AMG-
162 has an IC50 of ~500 nM. Meanwhile, both S63845 and S-30 had an IC50 of ~100 
nM in both cell lines, suggesting that they are both equally potent and very effective 
MCL-1 inhibitors. While all four inhibitors were able to induce apoptosis in both 
MCL-1 dependent cell lines, it was evident that S63845 and S-30 are significantly 
better inhibitors than A-1210477 and AMG-162, both able to induce apoptosis at 
nanomolar concentrations (Fig 3.2). 
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Figure 3.2. MCL-1 inhibitors can induce rapid apoptosis in MCL-1-addicted cell 
lines. H929 and U-2946 cells were exposed to a concentration range of either (A) A-
1210477, (B) S-30, (C) AMG-162 or (D) S63845 for 4 h and apoptosis was assessed 
by phosphatidylserine (PS) externalisation using Annexin V labelling in flow 
cytometry. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
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3.3 MCL-1 inhibitors bind to and stabilise MCL-1. 
It is known that the binding of MCL-1 inhibitors to MCL-1 causes its stabilisation – 
an unexpected effect of compounds designed to ablate the activity of MCL-1267,269. 
While it is not entirely understood how MCL-1 is stabilised by its own inhibitors, it is 
possibly linked to the MCL-1-NOXA interaction, which is disrupted following BH3 
mimetic exposure. NOXA is thought to continually promote the translocation, 
phosphorylation and degradation of MCL-1, thus it has been proposed that when BH3 
mimetics disrupt the MCL-1-NOXA interaction, MCL-1 starts to stabilise126,285. In 
order to verify that the four drugs tested here were indeed binding to and stabilising 
MCL-1, HELA cells were exposed to the indicated compounds at their approximate 
IC50 measures at various timepoints up to 24 h and MCL-1 protein levels observed 
using immunoblotting (Fig. 3.3). At early timepoints in all conditions, of the three 
known bands of MCL-1 (a ~40 kDa isoform associated with anti-apoptotic activity175, 
a ~38 kDa middle band and a ~36 kDa lower band, which has been associated with 
the inner mitochondrial membrane functions of MCL-1175 and perhaps, its nuclear 
functions177) only the 40kDa isoform could be clearly seen (Fig 3.3). However, 
following exposure to the MCL-1 inhibitors, stabilisation of MCL-1 started to become 
obvious as early as 2 h and MCL-1 continued to stabilise from this point, with much 
higher levels of the long isoform of MCL-1 being detectable at 24 h in all treatments. 
Surprisingly, despite being one of the less potent MCL-1 inhibitors at inducing 
apoptosis, AMG-162 seemed to stabilise MCL-1 better than S-30 and S63845, as 
stabilisation occurred at earlier timepoints in the AMG-162-treated cells. This could 
be a result of 10-fold difference in concentration used, however. Regardless of this, 
all four BH3 mimetics clearly stabilised MCL-1, indicating that they all bind to MCL-
1 and therefore this is likely the mechanism by which they induce apoptosis. 
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Figure 3.3. MCL-1 inhibitors continually stabilise MCL-1 over a 24 h period. 
HELA cells were exposed to either (A) A-1210477, (B) AMG-162, (C) S-30 or (D) 
S63845 at their respective approximate IC50 values (as determined in Fig. 3.2) at the 
indicated time points. Cells were collected and lysed in RIPA buffer for 
immunoblotting for MCL-1 and GAPDH as a loading control. Approximate molecular 
weights of bands are indicated. 
 
3.4 S63845 does not inhibit BCL-XL 
Of the four MCL-1 inhibitors tested, S63845 and S-30 were clearly the most potent, 
able to induce significant apoptosis within 4 h at low nanomolar concentrations. Since 
these two inhibitors displayed similar activity, further experiments were focused on 
S63845 (along with A-1210477 as a control in some cases), as these inhibitors have 
been published267,269 and were readily available.  
S63845 was designed to specifically target MCL-1 and, as expected, it can induce 
apoptosis in MCL-1-dependent cell lines. However, given its therapeutic potential, it 
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was important to confirm that S63845 exclusively targets MCL-1 and not the other 
anti-apoptotic BCL-2 family members which share a high degree of homology with 
each other. It must be noted that previous BH3 mimetics, such as Navitoclax, targeted 
multiple members of the BCL-2 family, thus resulting in on-target thrombocytopenia, 
therefore new BH3 mimetics should be specific to individual proteins to avoid effects 
like this in the future. To assess the specificity of S63845 to induce apoptosis in a 
MCL-1- but not BCL-XL- dependent manner, K562 and KCL-22 cells (two BCL-XL-
dependent chronic myeloid leukaemia cell lines149,286,287) were exposed to increasing 
concentrations of S63845, alongside A-1210477 and the BCL-XL inhibitor A-1331852 
(as a positive control) and apoptosis assessed by PS externalisation in flow cytometry 
(Fig. 3.4). As expected, S63845 (as well as A-1210477) failed to induce apoptosis in 
both K562 and KCL-22 cells, with only a small increase (~20%) in cell death observed 
for S63845 at high concentrations (10 µM). However, extensive apoptosis was 
observed in both cell lines following exposure to A-1331852, with an IC50 of ~100 nM 
but apoptosis becoming evident at concentrations as low as 10 nM. This data suggested 
that S63845 does not target BCL-XL to induce apoptosis, supporting MCL-1 specific 
activity. 
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Figure 3.4. S63845 does not have any inhibitory activity against BCL-XL. The 
BCL-XL-addicted cell lines K562 and KCL-22 were exposed to A-1331852, A-
1210477 or S63845 for 24 h and apoptosis was assessed by PS externalisation using 
Annexin V labelling in flow cytometry. S63845 and A-1210477 failed to induce 
apoptosis in these cells, while A-1331852 induced significant apoptosis at 100 nM. 
Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001.  
 
3.5 S63845 induces apoptosis in BCL-2 dependent cells 
Further to the previous experiment, to ensure that S63845 also did not have inhibitory 
activity against BCL-2, S63845 was tested in MAVER-1, a BCL-2-dependent cell line 
derived from a mantle cell lymphoma malignancy288. As expected, exposure of 
MAVER-1 cells to the BCL-2 inhibitor ABT-199 resulted in extensive apoptosis, with 
an IC50 of ~100 nM but apoptosis being detectable at as low as 10 nM (Fig. 3.5A). 
Surprisingly however, S63845 appeared to induce apoptosis in the MAVER-1 cell 
line, albeit at higher concentrations than ABT-199. At 100 nM S63845, ~20% cell 
death was detected, increasing to 30% and 40% at 1 µM and 10 µM respectively. 
While it was clear that S63845 could not induce apoptosis to the same extent at 100 
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nM as ABT-199, S63845 appeared to have some unexpected inhibitory activity against 
BCL-2. A-1210477 could also induce low levels of apoptosis in MAVER-1 cells, 
although this was limited to ~20% and was only detectable at 10 µM. To confirm this 
observation, the same experiment was performed in chronic lymphocytic leukaemia 
(CLL) patient cells, which are known to be highly BCL-2 dependent251,255,256. In line 
with the previous data, exposure of these cells to even 1 nM ABT-199 induced 60% 
cell death, rapidly rising to 100% cell death with increasing concentrations (Fig. 3.5B). 
A-1210477 did not induce significant apoptosis in the CLL patient cells until 10 µM, 
where ~70% of cells were apoptotic. Remarkably however, S63845 could induce more 
than 60% apoptosis in the CLL patient cells at 100 nM, reaching a complete cell death 
like ABT-199 at higher concentrations. This data suggests that S63845 can potentially 
inhibit BCL-2 in an unexpected, off-target manner. The original report on S63845 
demonstrating its capacity as an MCL-1 inhibitor did explore the in vitro binding of 
S63845 to other BCL-2 family members in addition to assessing cell death in various 
cell lines with different dependencies, but they did not report any binding or inhibitory 
capacity of S63845 against BCL-2269. While higher concentrations of S63845 were 
required to inhibit BCL-2 in MAVER-1 cell lines, only 100 nM was required to induce 
> 60% death in CLL patient cells, which are known to be exquisitely BCL-2 
dependent. This suggests that the use of S63845 in the clinic must be carefully 
explored, since off-target effects can be observed even at the nanomolar range in 
patient cells and hitting BCL-2 could have adverse effects on healthy cells which 
require it for survival134. 
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Figure 3.5. BCL-2-dependent cells undergo apoptosis following exposure to 
S63845. (A) The BCL-2-addicted cell line MAVER-1 and (B) CLL patient cells were 
exposed to a concentration range of either ABT-199, A-1210477 or S63845 for 8 h 
and apoptosis was assessed by PS externalisation using Annexin V labelling in flow 
cytometry. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
 
3.6 S63845 induces the intrinsic and not extrinsic apoptotic pathway. 
The remarkable result of S63845 inducing apoptosis in BCL-2 addicted cell lines was 
very surprising and warranted exploration of whether S63845 was only inducing the 
intrinsic apoptotic pathway and not other cell death pathways, as expected. In order to 
test this, Jurkat cell lines deficient in key components of the intrinsic or extrinsic 
pathway were used: wild-type (WT), caspase-9 deficient (the apical initiator caspase 
of the intrinsic pathway which acts as part of the apoptosome47), FADD deficient (the 
adaptor protein which links the extrinsic pathway TNF receptor superfamily to the 
caspases to form the DISC54,55) and caspase-8 deficient (one of the key caspases in the 
DISC54,289). These cells were exposed to a concentration range of S63845 for 24 h and 
cell death assessed by PS externalisation in flow cytometry (Fig. 3.6). The WT cells 
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started to undergo apoptosis at low concentrations of S63845, as low as 100 nM, 
reaching 80% death at 10 µM. Both the caspase-8- and FADD-deficient cells also 
underwent similar levels of apoptosis at the same concentrations, while the caspase-9-
deficient cells did not undergo any apoptosis, even at 10 µM S63845. This data 
confirmed that S63845 induces the intrinsic apoptotic pathway, as cells can still 
undergo apoptosis even when key components of the extrinsic pathway are missing 
while no apoptosis occurs when caspase-9, the apical caspase of the intrinsic pathway, 
is missing. 
 
 
 
Figure 3.6. S63845 induces cell death via the intrinsic and not extrinsic apoptotic 
pathway. Wild-type (WT) Jurkat T cell leukaemia cells and cells deficient in key arms 
of the intrinsic and extrinsic apoptotic pathways were exposed to a concentration range 
of S63845 for 24 h and apoptosis was assessed by PS externalisation using Annexin 
V labelling in flow cytometry. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and 
***p ≤ 0.001.  
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3.7 S63845 is more potent than ABT-199 in inducing apoptosis in AML cell 
lines 
Since S63845 appeared to induce the intrinsic apoptotic pathway in both an MCL-1- 
and BCL-2 dependent manner, it is possible that it might be of use in certain cell lines 
which have a BCL-2 and MCL-1 dependence. Recent reports indicate that cells 
derived from acute myeloid leukaemia (AML) patients can be effectively targeted with 
a BCL-2 and/or MCL-1 inhibitor, although other studies suggest that these cells 
depend primarily on BCL-2 for survival272,290,291. Despite this, MCL-1 inhibitors are 
currently entering clinical trials to treat AML and multiple myeloma patients (Clinical 
trials - NCT02979366; NCT02675452; NCT02992483). Since S63845 inhibits MCL-
1, and (perhaps) to a lesser extent BCL-2, we investigated whether S63845 could 
induce apoptosis alone or in combination with other BH3 mimetics in a panel of AML 
cell lines. Six AML cell lines were exposed to a concentration range of either S63845 
or ABT-199 alone or, a combination of the two, with a fixed concentration of ABT-
199 at 100 nM and a concentration range of S63845 and then assessed for apoptosis 
by PS externalisation in flow cytometry (Fig. 3.7). Of the six cell lines tested, MV-4-
11 cells (Fig. 3.7A) exhibited the highest sensitivity to both S63845 and ABT-199 
individually, with IC50s of ~20 nM and ~50-100 nM) respectively. The combination 
of S63845 and ABT-199 induced almost complete death at just 10 nM S63845, 
demonstrating the exquisite sensitivity of these cells to BH3 mimetics. THP-1 cells 
were much more resistant to ABT-199 (Fig. 3.7B), requiring ~1 µM to induce even 
20% death, however they were considerably more sensitive to S63845, which induced 
~75% apoptosis at 100 nM. The combination of S63845 and ABT-199 however, like 
in MV-4-11 cells, induced high levels of apoptosis (~90%) even at 10 nM. Meanwhile, 
OCI-AML3 cells were completely resistant to ABT-199 at all concentrations and only 
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underwent apoptosis following S63845 exposure at higher concentrations (Fig. 3.7C), 
with an IC50 of ~500 nM and extensive death induced by 1 µM S63845. S63845 and 
ABT-199 combination treatment was considerably more effective than the single 
inhibitors at inducing apoptosis however, with ~20% apoptosis occurring at 10 nM of 
the combination therapies and ~70% at 30 nM.  Some of the AML cell lines tested 
were considerably more resistant to all treatments. U937 cells were completely 
resistant to ABT-199 and only underwent ~40% apoptosis at 1 µM S63845 (Fig. 
3.7D), while the combination treatment of ABT-199 and S63845 did not vastly 
increase cell death compared to S63845 alone. Similarly, MOLM-13 cells were 
resistant to ABT-199 and relatively insensitive to S63845 (Fig. 3.7E) – 1 µM S63845 
only induced ~30% apoptosis, while the combination treatment could induce 
significant apoptosis with 1 µM S63845 and 100 nM ABT-199. Finally, HL-60 cells 
were largely resistant to both BH3 mimetics individually but 1 µM S63845 could 
induce ~30% apoptosis (Fig. 3.7F). While the HL-60 cells were somewhat sensitive 
to the combination treatment, they were clearly less sensitive than many of the other 
cell lines tested as even at ~500 nM S63845, only 40% cell death could be seen in 
combination with ABT-199.  
Overall, it would therefore seem that, while AML cells can differ quite drastically in 
their sensitivity to BH3 mimetics (which could perhaps be a result of their dependency 
on other pro-survival BCL-2 family proteins) S63845 is a better inducer of apoptosis 
alone than ABT-199 alone in these cells. Whether this can be attributed to the fact that 
S63845 might have some off-target BCL-2 inhibitory activity in combination with 
MCL-1 remains unclear, as the AML cells tested might tend to rely on MCL-1 over 
BCL-2 for survival. It is clear however that S63845 might be of therapeutic use in 
some cases of AML. 
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Figure 3.7. S63845 can be combined with ABT-199 to induce apoptosis in AML 
cell lines. AML cell lines were exposed to a concentration range of either S63845 or 
ABT-199 alone or concentration range of S63845 with ABT-199 at a constant 
concentration of 100 nM for 24 h and assessed for PS externalisation using Annexin 
V labelling in flow cytometry. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and 
***p ≤ 0.001. 
 
 
3.8 Resistance to ABT-199 and/or S63845 in some AML cell lines could be 
attributed to BCL-XL. 
 As previously mentioned, some of the AML cell lines were considerably more 
resistant to inhibition of BCL-2 and MCL-1 than others. In order to test whether any 
of the resistant AML cell lines had some dependency on BCL-XL and hence explain 
why they were not susceptible to the combination of S63845 and ABT-199, U-937, 
MOLM-13 and HL-60 cells were exposed to A-1331852 (a BCL-XL inhibitor) alone 
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or in combination with the other previously tested BH3 mimetics and apoptosis 
detected by PS externalisation in flow cytometry (Fig. 3.8). In both U-937 (Fig. 3.8A) 
and HL-60 cells (Fig. 3.8C), where the combination of S63845 and ABT-199 could 
only induce ~50% apoptosis even at higher concentrations, A-1331852 failed to 
induce significantly more apoptosis in combination with ABT-199 and S63845, 
suggesting these cells do not depend on BCL-XL for survival and instead, one of the 
more obscure anti-apoptotic BCL-2 family members could be promoting survival. 
Meanwhile, in the MOLM-13 cells, 100 nM of A-1331852 alone, unlike S63845 and 
ABT-199, could induce significant apoptosis (~60% at 100 nM) and in combination 
with either ABT-199 or S63845 could induce up to 80% apoptosis, suggesting a key 
role for BCL-XL in survival in this cell line (Fig. 3.8B). 
 
Overall, it was evident from this data that many AML cell lines are indeed dependent 
on MCL-1 and/or BCL-2 and that S63845 is better at inducing apoptosis in these cell 
lines than ABT-199, perhaps in part because S63845 can potentially inhibit BCL-2 in 
addition to MCL-1. It is also possible that many of these cells are more dependent 
upon MCL-1 than BCL-2 for survival and thus, hitting them with an MCL-1 inhibitor 
can induce more apoptosis than a BCL-2 inhibitor. With this in mind, further studies 
were undertaken on the AML cell lines to explore the dynamics of the BCL-2 family 
interactions with and without BH3 mimetics, in order to determine if the sensitivity to 
certain BH3 mimetics is a result of disruption of certain interactions between BH3-
only proteins and their anti-apoptotic partners, as would be expected in the proposed 
mechanism of BH3 mimetic action. 
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Figure 3.8 AML cell lines resistant to BCL-2/MCL-1 inhibition exhibit varying 
sensitivity to inhibition of BCL-XL. The indicated cell lines were exposed to the 
different BH3 mimetics (all at 100 nM) for 24 h and apoptosis assessed by PS 
externalisation. Error bars = Mean ± SEM. 
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3.9 BCL-2 appears to be the major anti-apoptotic protein in MV-4-11 cells 
despite a marked sensitivity to S63845.  
Mechanistically, BH3 mimetic-induced apoptosis is usually attributed to the 
displacement of BH3-only proteins from their anti-apoptotic partners, leading to 
BAX/BAK activation. Since the different AML cell lines tested exhibited varied 
responses to BH3 mimetic-induced apoptosis, it could be suggested that there is varied 
binding and/or displacement of the different BH3-only proteins to their known 
survival counterparts which determines the sensitivity of a cell to a certain BH3 
mimetic. For example, a cell which is largely dependent upon MCL-1 would be 
expected to have large amounts of BIM, NOXA and PUMA bound to MCL-1, which 
would get displaced to initiate apoptosis upon addition of S63845 or another 
appropriate BH3 mimetic. To explore the BCL-2 family interactions in AML cells 
during apoptosis, one extremely sensitive (MV-4-11) (Fig. 3.9) one moderately 
sensitive (OCI-AML-3) (Fig. 3.10) and one resistant (HL-60) (Fig. 3.11) cell line were 
chosen as representative cells of each level of sensitivity and subjected to BCL-2 
family immunoprecipitation experiments to detect the interactions of the key survival 
proteins with the major BH3-only proteins. Drug treatments were performed at 
different concentrations and time-points between cell lines to better represent the IC50 
measures of the sensitive versus resistant cells. Cells were collected for lysis after 
~50% apoptosis was achieved (measured by PS externalisation, data not shown). 
In MV-4-11 cells, which are highly sensitive to both ABT-199 and S63845, the 
promiscuous activator BH3-only protein BIM was bound preferentially to BCL-2, 
with traces also bound to MCL-1 (Fig. 3.9). The activator BH3-only protein BID could 
not be seen bound to either MCL-1 or BCL-2, while PUMA, another activator BH3-
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only protein which has promiscuous binding activity, was found bound to BCL-2 
exclusively. NOXA, a sensitiser BH3-only protein, could be seen bound to MCL-1 in 
traces and not BCL-2 (as would be expected), while BAD, another sensitiser BH3-
only protein, could not be seen bound to BCL-2 despite being present in the input at 
reasonable levels. Following exposure of the MV-4-11 cells to ABT-199, only a very 
small amount of the BIM bound to BCL-2 was displaced, with most appearing to 
remain bound. PUMA was also not significantly displaced from BCL-2 following 
ABT-199 treatment. The small amount of BIM bound to MCL-1 was readily displaced 
from MCL-1 following exposure to S63845 and, similarly, the traces of NOXA bound 
to MCL-1 underwent dissociation from MCL-1 too. Taken together, the results of this 
experiment were surprising – MV-4-11 cells were very sensitive to both ABT-199 and 
S63845 yet, significant levels of the BH3-only proteins, particularly BIM and PUMA, 
were preferentially bound to BCL-2 over MCL-1. Moreover, neither BIM nor PUMA 
were displaced from BCL-2 following ABT-199 treatment. How ABT-199 can induce 
such significant death at low concentrations in these cells is therefore somewhat of a 
mystery, as BIM, the only BH3-only protein bound to BCL-2, was not significantly 
displaced from BCL-2 following ABT-199 treatment. Further adding to this, S63845 
could induce extensive apoptosis even when most BIM was sequestered by BCL-2 
and only a very low level was released from MCL-1 following S63845 exposure. Thus, 
there appear to be discrepancies in the binding/release of BH3-only proteins to their 
pro-survival partners and apoptosis induction following BH3 mimetic treatment. It 
was therefore of great interest to explore whether this observation was specific to MV-
4-11 cells or if it was perhaps a more general feature of AML and possibly other cell 
lines. 
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Figure 3.9. BCL-2 family protein interactions and displacements following BH3 
mimetic exposure in MV-4-11 cells. Immunoprecipitation of MCL-1 and BCL-2 was 
carried out in MV-4-11 cells following exposure to S63845 (30 nM) or ABT-199 (50 
nM) for 6 h. Collected cells were lysed and incubated with bead-antibody conjugates 
with antibodies against MCL-1 and BCL-2. The eluted complexes were 
immunoblotted for the indicated proteins. The input represents total cell lysate, IP 
indicates immunoprecipitation and BC indicates bead control. Approximate molecular 
weights of proteins are indicated alongside the blots. 
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3.10 BCL-2 appears to be the major anti-apoptotic protein in OCI-AML3 cells 
despite a marked sensitivity to S63845.  
To further examine the notion of BCL-2 family interactions not reflecting sensitivity 
to BH3 mimetics, the same experiment was performed in the moderately sensitive 
OCI-AML3 cell line (Fig 3.10). In this cell line, binding patterns of BH3-only proteins 
to pro-survival proteins were similar to those seen for MV-4-11. BIM was largely 
bound to BCL-2 and a smaller amount bound to MCL-1, while PUMA was 
preferentially bound to BCL-2 and traces of NOXA were bound to MCL-1. Neither 
BAD nor BID appeared to bind either anti-apoptotic protein. In contrast to the MV-4-
11 cells, exposure to ABT-199 resulted in a slightly more obvious displacement of 
BIM and PUMA from BCL-2, despite the cells being largely resistant to ABT-199 
treatment. Furthermore, BIM and NOXA bound to MCL-1 were readily displaced with 
S63845, supporting the fact that these cells are sensitive to S63845. The observation 
that MV-4-11 and OCI-AML3 cells share a very similar binding pattern of BCL-2 
family interactions yet displayed significantly different sensitivities to S63845 and 
ABT-199 is quite remarkable and unexpected. Strikingly, ABT-199 was capable of 
inducing displacement of BIM and PUMA from their major binding partner (BCL-2) 
in OCI-AML3 cells which are markedly less sensitive than MV-4-11 cells, where BIM 
is displaced less from BCL-2. This further suggested that the interactions between the 
pro- and anti-apoptotic BCL-2 protein family members may be more complicated than 
thought in terms of dictating sensitivity to BH3 mimetics. 
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Figure 3.10. BCL-2 family protein interactions and displacements following BH3 
mimetic exposure in OCI-AML3 cells. Immunoprecipitation of MCL-1 and BCL-2 
was carried out in OCI-AML3 cells following exposure to S63845 (30 nM) or ABT-
199 (50 nM) for 8 h. Collected cells were lysed and incubated with bead-antibody 
conjugates with antibodies against MCL-1 and BCL-2. The eluted complexes were 
immunoblotted for the indicated proteins. The input represents total cell lysate, IP 
indicates immunoprecipitation and BC indicates bead control. Approximate molecular 
weights of proteins are indicated alongside the blots. 
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3.11 BCL-2 appears to be the major anti-apoptotic protein in HL-60 cells despite 
a marked resistance to both ABT-199 and S63845 treatment. 
Both cell lines tested previously for BCL-2 family interaction profiles were very or 
somewhat sensitive to at least one or a combination of BH3 mimetics. The resistant 
HL-60 cell line, however, did not undergo extensive apoptosis with S63845 or ABT-
199 alone, while the combination could only achieve ~40% apoptosis. Furthermore, 
these cells did not depend on BCL-XL, the other major anti-apoptotic protein, for 
survival, as shown in Figure 3.8C. It was therefore of interest to detect where BH3-
only proteins were being sequestered and what could cause displacement in these cells, 
in order to better understand the concept of BCL-2 family interacting proteins 
reflecting sensitivity to BH3 mimetics. In the HL-60 cells, binding patterns were 
remarkably similar to those seen for MV-4-11 and OCI-AML3 cells. BIM and PUMA 
bound almost exclusively to BCL-2, while BID and BAD were not bound to either 
MCL-1 or BCL-2 (Fig 3.11). Moreover, of all the BH3-only members, only traces of 
NOXA appeared to interact with MCL-1. The lack of BH3-only proteins, apart from 
traces of NOXA, being bound to MCL-1 is compatible with HL-60 cells being very 
resistant to S63845 treatment. The large amounts of BIM bound to BCL-2 were only 
slightly displaced following ABT-199 treatment which is, again, compatible with the 
cells being resistant to ABT-199. Meanwhile, PUMA was partially displaced by 
treatment of HL-60 cells with ABT-199, which could suggest that ABT-199 could 
therefore induce apoptosis through PUMA alone, but with the cells being very 
resistant to BH3 mimetics, this is evidently not the case. This was a remarkable 
observation as the HL-60 and MV-4-11 cells, despite looking very similar in BH3-
only protein binding preferences, demonstrated vastly different sensitivities to BH3 
mimetics. Taken together, these results suggest that interactions between the pro- and 
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anti-apoptotic BCL-2 family members may not necessarily reflect the relative 
sensitivities of different AML cell lines to undergo BH3 mimetic-mediated apoptosis 
and may suggest involvement of other survival factors, including perhaps other anti-
apoptotic proteins but also a more complex level of control of the cell fate decision-
making process. 
 
 
Figure 3.11. BCL-2 family protein interactions and displacements following BH3 
mimetic exposure in HL-60 cells. Immunoprecipitation of MCL-1 and BCL-2 was 
carried out in HL-60 cells following exposure to S63845 (30 nM) or ABT-199 (50 
nM) for 8 h. Collected cells were lysed and incubated with bead-antibody conjugates 
with antibodies against MCL-1 and BCL-2. The eluted complexes were 
immunoblotted for the indicated proteins. The input represents total cell lysates, IP 
indicates immunoprecipitation and BC indicates bead control. Approximate molecular 
weights of proteins are indicated alongside the blots. 
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3.12 S63845 can combine with A-1331852 to induce apoptosis in solid tumour 
cell lines. 
To further explore the phenomenon of BCL-2 family interactions not reflecting BH3 
mimetic sensitivity (while also examining  the possibility of using S63845 in 
combination with other BH3 mimetics), several solid tumour cell lines, which 
typically depend on both BCL-XL and MCL-1 for survival
199,245,292–295, were exposed 
to S63845 and A-1331852 (at a fixed concentration of 100 nM) for 4 h and apoptosis 
assessed by PS externalisation in flow cytometry. Six cell lines derived from various 
kinds of solid tumour malignancies including H1299 and A549 (non-small cell lung 
carcinoma (NSCLC)), HCT116 and HT-29 (colorectal cancer), SUIT-2 (pancreatic 
cancer) and PC-3 (prostate cancer) were used.  
H1299 cells did not undergo apoptosis following exposure to either S63845 or A-
1331852 alone at any concentration but with the combination treatment, began to 
undergo apoptosis at 100 nM, with an IC50 of ~100 nM. H1299 cells were completely 
apoptotic following exposure to 10 µM S63845 and 100 nM A-1331852 (Fig. 3.12A). 
Meanwhile, the second NSCLC cell line, A549, was somewhat more sensitive to the 
single compounds. S63845 began to induce apoptosis alone at higher concentrations 
of 10 µM, while A-1331852 induced just less than 20% apoptosis at 1 µM and ~30% 
at 10 µM (Fig. 3.12B). These cells were significantly more sensitive to the 
combination treatment – just 10 nM S63845 combined with 100 nM A-1331852 could 
induce ~30% apoptosis, while 100 nM of both S63845 and A-1331852 induced almost 
90% cell death. 
Like A549 cells, HCT116 cells were somewhat sensitive to the single BH3 mimetics 
– S63845 induced ~30% apoptosis at 10 µM while A-1331852 could induce ~20% 
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death at 100 nM and ~30% death at 1 µM (Fig. 3.12C). Again, however, the 
combination of the two inhibitors was the most effective at inducing death - 100 nM 
of each inhibitor induced ~60% cell death and almost 100% of cells were apoptotic 
following exposure to 10 µM S63845 and 100 nM A-1331852 together. The second 
colon carcinoma cell line tested, HT-29, presented a very different death profile. Both 
single drugs could induce ~40% death but only at 10 µM, while 100 nM of the drugs 
combined also induced ~40% apoptosis (Fig. 3.12D). Even at higher concentrations 
of S63845 however, only 60% apoptosis could be achieved, suggesting there may be 
another factor promoting survival here – perhaps another pro-survival BCL-2 family 
protein such as BCL-w. Indeed, less well explored pro-survival proteins have been 
implicated in survival of colorectal cancer cells164, supporting this concept. 
The pancreatic cell line, SUIT-2, was similar to H1299 cells in that they were largely 
insensitive to single BH3 mimetics but very sensitive to the combination treatment. 
Only at 10 µM could either S63845 or A-1331852 alone induce apoptosis and even 
then, this was limited to ~20%. The combination of the two inhibitors, however, 
induced ~40% death at 100 nM and almost complete death at 1 µM S63845 combined 
with 100 nM A-1331852 (Fig. 3.12E). Finally, the prostate cancer cell line tested, PC-
3, demonstrated a similar apoptotic profile to SUIT-2 cells, although were overall less 
sensitive to BH3 mimetics. S63845 did not induce apoptosis until 10 µM, where it 
induced ~20% death, while A-1331852 induced 20% apoptosis at 1 µM and ~30% at 
10 µM alone (Fig 3.12F). Surprisingly, unlike the other cells, the combination of 100 
nM of each inhibitor did not induce significant apoptosis, while increasing the 
concentration of S63845 10-fold to 1 µM alongside 100 nM A-1331852, resulted in 
massive cell death, approaching 90%. These cells appeared to have an IC50 of ~500 
nM S63845 when combined with 100 nM A-1331852. 
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Figure 3.12. S63845 can be combined with A-1331852 to induce apoptosis in cell 
lines derived from various solid tumours. Solid tumour cell lines derived from 
different types of cancers were treated with a concentration range of S63845 and a 
constant concentration of 100 nM of A-1331852 for 4 h and assessed for PS 
externalisation using Annexin V labelling in flow cytometry. Error bars = Mean ± 
SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
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Overall, this data demonstrated that while some cells derived from solid tumour cells 
can be moderately sensitive to single BH3 mimetics, they mostly require inhibition of 
both MCL-1 and BCL-XL in order for significant death to be induced.  Since BCL-XL 
and MCL-1 have different BH3-only protein binding partners, the interactions and 
displacement events with each of the BH3 mimetics was next studied using 
immunoprecipitation, as done for the AML cell lines.  
3.13 H1299 cells demonstrate a proto-typical BCL-2 family protein interaction 
profile. 
To corroborate earlier findings in AML cell lines and assess interactions between the 
different BH3-only proteins with their key pro-survival counterparts, namely BCL-XL 
and MCL-1, immunoprecipitation studies were repeated in three of the solid tumour 
cell lines. All the cell lines tested demonstrated sensitivity to the combination of BCL-
XL and MCL-1 inhibition, while a couple of cell lines also showed low levels of 
sensitivity to the single BH3 mimetics. Thus, H1299 and SUIT-2 cells, which were 
sensitive to the combination BH3 mimetic treatment, and HCT116 cells, which were 
slightly sensitive to A-1331852 inhibition at 100 nM and combination treatment, were 
chosen as the model cell lines. Since these cells demonstrated very similar sensitivities 
to the combination treatment, it was thought that their BCL-2 family binding profiles 
would be similar, however this proved to not be the case.  
In H1299 cells, BIM appeared to preferentially bind MCL-1, while, BID could not be 
seen bound to MCL-1 or BCL-XL, suggesting it does not play a major role in the 
intrinsic apoptotic pathway in these cells (Fig. 3.13). Meanwhile PUMA, which can 
also bind both MCL-1 and BCL-XL, preferentially bound to BCL-XL, though a small 
amount of PUMA was also bound to MCL-1. NOXA exhibited the expected selective 
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binding to MCL-1, while BAD demonstrated specific binding to BCL-XL. Following 
exposure of H1299 cells to S63845, BIM was clearly displaced from MCL-1. 
Interestingly, while little BIM appeared to bind BCL-XL under control conditions, in 
the S63845 treatment, where BIM was displaced from MCL-1, small amounts of BIM 
could be seen bound to BCL-XL instead, suggesting that when displaced from its anti-
apoptotic protein of choice, BIM is capable of binding the other key anti-apoptotic 
protein, in this case BCL-XL. This could, in part, explain why no death was seen with 
the single BH3 mimetics, since BIM is not actually freed upon S63845 or A-1331852 
treatment and is instead sequestered by BCL-XL, which will prevent its pro-apoptotic 
activity. In the case of PUMA (which could bind both MCL-1 and BCL-XL), exposure 
of the cells to A-1331852 resulted in dramatic displacement of PUMA from BCL-XL, 
while S63845 also caused moderate displacement of PUMA from MCL-1. Unlike 
BIM however, the counter anti-apoptotic protein did not appear to sequester PUMA 
when displaced from the other. Both BAD and NOXA underwent displacement from 
their respective anti-apoptotic partners following A-1331852 and S63845 treatment 
respectively. H1299 cells therefore represent a very typical model of BCL-2 family 
interactions, particularly in terms of displacement with BH3 mimetics. In the H1299 
cells, displacement of BIM, PUMA and NOXA from MCL-1 can drive apoptosis but 
only when BCL-XL is also neutralised, as BCL-XL can sequester any free BIM 
released from MCL-1 with S63845 treatment, while also sequestering BAD. 
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Figure 3.13. BCL-2 family protein interactions and displacements following BH3 
mimetic exposure in H1299 cells. Immunoprecipitation of MCL-1 and BCL-XL was 
carried out in H1299 cells following exposure to S63845 (100 nM) or A-1331852 (100 
nM) for 2 h. Collected cells were lysed and incubated with bead-antibody conjugates 
with antibodies against MCL-1 and BCL-XL. The eluted complexes were 
immunoblotted for the indicated proteins. The input represents total cell lysates, IP 
indicates immunoprecipitation, and BC indicates bead control. Approximate 
molecular weights of proteins are indicated alongside the blots. 
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3.14 SUIT-2 cells do not display the exact same binding pattern as H1299 cells, 
despite having the same BH3 mimetic sensitivity. 
SUIT-2 cells were not particularly sensitive to single BH3 mimetics alone but 
underwent significant apoptosis with a combination of the BCL-XL and MCL-1 
inhibitors at nanomolar concentrations (Fig. 3.12E). In SUIT-2 cells, BIM was bound 
to both MCL-1 and BCL-XL almost equally while PUMA was surprisingly not bound 
to either MCL-1 or BCL-XL (Fig. 3.14). Furthermore, unlike in H1299 cells where no 
BID could be seen bound to either anti-apoptotic protein, a small amount of BID could 
be seen bound to BCL-XL in SUIT-2 cells. NOXA was bound exclusively to MCL-1 
and BAD was bound exclusively to BCL-XL, as would be expected.  Following 
exposure to BH3 mimetics, BIM was displaced to differing extents– a slight 
displacement from MCL-1 following S63845 treatment was observed, while a 
complete displacement from BCL-XL could be seen (Fig. 3.14) with A-1331852 
treatment. Moreover, the complete displacement of BIM from BCL-XL with A-
1331852 treatment was also followed by increased binding of BIM to MCL-1, similar 
to what was seen with BIM in H1299 cells but in reverse. There was also a possible 
slight increase in binding of BIM to BCL-XL following its displacement from MCL-1 
after exposure of the cells to S63845.  
Both BAD and NOXA were also significantly displaced from their binding partners 
following A-1331852 and S63845 treatment respectively. Overall, H1299 and SUIT-
2 cells exhibited significant differences in their BCL-2 family interaction profile, 
despite similar expression levels of the different proteins and responses to the 
combination of A-1331852 and S63845. This further re-enforced the idea of BCL-2 
family interactions not exclusively dictating sensitivity to BH3 mimetics. 
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Figure 3.14. BCL-2 family protein interactions and displacements following BH3 
mimetic exposure in SUIT-2 cells. Immunoprecipitation of MCL-1 and BCL-XL was 
carried out in SUIT-2 cells following exposure to S63845 (100 nM) or A-1331852 
(100 nM) for 2 h. Collected cells were lysed and incubated with bead-antibody 
conjugates with antibodies against MCL-1 and BCL-XL. The eluted complexes were 
immunoblotted for the indicated proteins. The input represents total cell lysates, IP 
indicates immunoprecipitation and BC indicates bead control. Approximate molecular 
weights of proteins are indicated alongside the blots. 
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3.15 Most BH3-only proteins bind to BCL-XL in HCT116 cells even though both 
MCL-1 and BCL-XL must be neutralised for extensive apoptosis. 
The inconsistencies in binding/displacement patterns versus sensitivity to BH3 
mimetics were even more evident in HCT116 cells, which were moderately sensitive 
to inhibition of BCL-XL but required dual inhibition of BCL-XL and MCL-1 for 
extensive apoptosis. In these cells, BIM was exclusively bound to BCL-XL, with very 
little binding to MCL-1 (Fig. 3.15). A band was present in the BIM blots in the MCL-
1 immunoprecipitation lane, however it is at a molecular weight which is not the same 
as any of the other bands in the input or BCL-XL immunoprecipitation, suggesting this 
band may not be BIM. Furthermore, BID, like SUIT-2 cells was bound to BCL-XL but 
in very small amounts compared to the expression in the input. For the BH3-only 
proteins which have specific binding partners, binding was very similar to the other 
cells as expected. NOXA was only bound to MCL-1, while BAD was bound to BCL-
XL. The effects of BH3 mimetics on these interactions were very interesting – both 
BIM and PUMA were almost completely displaced from BCL-XL following A-
1331852 treatment but were not in turn sequestered by MCL-1. This is in line with 
HCT116 cells being somewhat sensitive to A-1331852 treatment alone, however the 
lack of sequestration of free BIM/PUMA by MCL-1 (which is not bound to any other 
BH3-only protein apart from NOXA) is surprising, since MCL-1 must be neutralised 
alongside BCL-XL for full apoptosis. The traces of BID bound to BCL-XL were also 
displaced following exposure of cells to A-1331852, while both BAD and NOXA 
were displaced from their respective binding partners with the indicated treatments. 
Collectively the data in solid tumour cell lines shows that while the BH3-only proteins 
which are specific to certain anti-apoptotic proteins do not vary in binding and are 
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always displaced with the appropriate BH3 mimetics, the more promiscuous members 
of the BH3-only protein family, i.e. PUMA, BIM and BID vary greatly in binding to 
the different anti-apoptotic proteins, even in cells which demonstrate virtually the 
same sensitivity to BH3 mimetics. For example, BIM binds MCL-1 in the H1299s, 
both MCL-1 and BCL-XL in SUIT-2 cells and exclusively BCL-XL in in HCT-116 
cells, yet all three cell lines require both inhibitors to induce significant apoptosis. 
Moreover, PUMA also showed discrepancies between the cell lines – binding MCL-
1 and BCL-XL to differing extents in H1299s, neither anti-apoptotic protein in SUIT-
2 cells and only BCL-XL in HCT-116. It could be suggested that the similarities in 
binding/displacement of the specific BH3-only proteins (i.e. NOXA/BAD) is what is 
dictating the sensitivity of the three cell lines to BH3 mimetics, explaining why they 
share the same sensitivity. However, the many discrepancies identified suggest that 
something much more complex is happening. For example, BIM and PUMA and 
displaced to dramatically different extents in the different cell lines, despite them 
sharing the same sensitivity to BH3 mimetics, while MCL-1 can sequester freed BH3-
only proteins in some cell lines but not others. These results suggest that the 
preferential sequestration of different BH3-only proteins to distinct anti-apoptotic 
counterparts does not solely dictate dependency of a cell line on an individual anti-
apoptotic protein and therefore could suggest that there is more at play than just the 
BH3-only proteins in determining the sensitivity of a cell to BH3 mimetics.  
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Figure 3.15. BCL-2 family protein interactions and displacements following BH3 
mimetic exposure in HCT116 cells. Immunoprecipitation of MCL-1 and BCL-XL 
was carried out in HCT116 cells following exposure to S63845 (100 nM) or A-
1331852 (100 nM) for 2 h. Collected cells were lysed and incubated with bead-
antibody conjugates with antibodies against MCL-1 and BCL-XL. The eluted 
complexes were immunoblotted for the indicated proteins. The input represents total 
cell lysates, IP indicates immunoprecipitation and BC indicates bead control. 
Approximate molecular weights of proteins are indicated alongside the blots. 
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3.16 Discussion 
Targeting the BCL-2 family in cancer has shown promising results for therapy 
despite the fact that, up until recently, inhibition of MCL-1 has been difficult. Novel 
inhibitors are, however, showing great promise. Here, three novel MCL-1 inhibitors 
were explored alongside A-1210477, the best previous inhibitor, to assess their 
ability to induce MCL-1-specific apoptosis and combine with other BH3 mimetics 
in a variety of cell lines derived from both solid and haematological malignancies. 
All four of the inhibitors tested were able to stabilise MCL-1 continually up to 24 h 
and induce MCL-1-specific apoptosis in MCL-1-addicted cell lines, though with 
very different IC50 values. While A-1210477 could only induce apoptosis at 10 µM, 
the three novel MCL-1 inhibitors could induce apoptosis at lower concentrations, 
with S63845 and S-30 both having approximate IC50 values of an impressive 100 
nM. This corroborates previous findings that A-1210477 requires micromolar 
concentrations to induce apoptosis267 while S63845 is considerably better at 
inducing MCL-1-dependent apoptosis, though we show here that S63845 can 
induce apoptosis at a 100-fold less concentration than A-1210477 while the original 
report on S63845 suggests the difference is actually 1000-fold less269. This could 
perhaps be a result of the differences in approaches used to examine apoptosis – 
here cells were incubated for 4 h with S63845 and apoptosis assessed by PS 
externalisation, while in the original report, cells were incubated with the compound 
for 48 h and apoptosis assessed by MTT assays. Regardless of this, S63845 is 
clearly a very potent MCL-1 inhibitor with great promise for future use in targeting 
MCL-1 in a therapeutic context. Moreover, it will be greatly useful as a tool 
(alongside other highly specific BH3 mimetics) to dissect the BCL-2 family 
pathways, allowing a better understanding of apoptosis and its regulation.  
104 
 
With S63845 appearing to be a very potent inhibitor of MCL-1, it was chosen as the 
focus of the study. Remarkably, it was observed that S63845 could induce apoptosis 
in BCL-2-addicted cell lines, suggesting it had some activity against BCL-2. While 
Kotschy et al. reported no binding of S63845 to the other anti-apoptotic proteins269, 
it is clear from the data here that S63845 may possess some ability to induce 
apoptosis in BCL-2-addicted cell lines. It could be suggested that both MAVER-1 
and CLL patient cells have some MCL-1 dependence and therefore, when exposed 
to S63845, undergo apoptosis. In the case of CLL patient cells, this certainly could 
be the case, as patient cells are typically very sensitive to exposure to drugs and 
thus, a small amount of MCL-1 inhibition could release enough BH3-only proteins 
to activate BAX and/or BAK and commit the cells to apoptosis. It could also be 
suggested however that S63845 is inducing a non-specific, non-apoptotic cell death 
in these cells. This is unlikely to be the case however, as S63845 could not induce 
apoptosis in Jurkat cells lacking caspase-9, which is critical to the intrinsic apoptotic 
pathway. Clearly there is more to S63845 activity in BCL-2 addicted cells than 
meets the eye and further work is necessary to understand how S63845 causes 
apoptosis in these cells before it is used in therapy. With the possibility of S63845 
having inhibitory activity against MCL-1 and BCL-2, it was hypothesised that it 
might be of use in AML malignancies since they are thought to be largely BCL-2- 
and/or MCL-1-addicted272,290,291,296. To test this, a panel of AML cell lines was 
exposed to S63845 and/or ABT-199 to test whether S63845 alone could induce 
significantly more apoptosis than ABT-199 alone and whether the two drugs 
combined could induce complete apoptosis. The six cell lines tested demonstrated 
starkly different sensitivities to S63845 and/or ABT-199, with some being very 
sensitive to the single BH3 mimetics alone and some being completely resistant to 
105 
 
single BH3 mimetic exposure. S63845 largely demonstrated a better capacity to 
induce apoptosis in most of the cell lines tested and when combined with ABT-199, 
high levels of apoptosis could be induced in some of the more sensitive cell lines, 
although some of the AML cell lines demonstrated resistance to even a combination 
of S63845 and ABT-199, suggesting the involvement of other anti-apoptotic 
proteins in their survival. Previous reports demonstrate that MCL-1 is a key player 
in resistance to ABT-199 monotherapy in AML272,290,291 and that targeting MCL-1 
can overcome this resistance, which is in line with the data here showing that dual 
inhibition of both MCL-1 and BCL-2 can potently induce apoptosis in some AML 
cell lines. The resistance to both MCL-1 and ABT-199 inhibition seen here also 
suggested that BCL-XL might play a role in ABT-199 resistance which was shown 
here and which has also been described previously by Wood et al.272, where MCL-
1 and BCL-XL were shown to be upregulated following BCL-2 inhibition and 
furthermore, inhibition of BCL-XL or MCL-1 could overcome ABT-199 resistance 
in multiple AML cells272. Only one cell line, MOLM-13, was sensitive to BCL-XL 
inhibition however, suggesting that further additional factors are at play. Regardless 
of the difference is sensitivities, it is evident that BH3 mimetics will be a useful in 
treating AML malignancies, especially when tools such as BH3 profiling297 can be 
used on patient samples to determine tumour cell addictions to BCL-2 family 
proteins and potential resistance mechanisms. 
It was also demonstrated here that S63845 can synergise with a BCL-XL inhibitor, 
A-1331852, to induce apoptosis in a range of different cell lines derived from solid 
tumours which typically depend on both MCL-1 and BCL-XL for 
survival199,245,292,293,298. While this combination of BH3 mimetics is clearly very 
effective in inducing cancer cell death, the therapeutic potential of this drug 
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combination might be limited since inhibition of both MCL-1 and BCL-XL may 
have side-effects on normal cells. However, this work demonstrates that these cell 
lines depend exquisitely upon the two anti-apoptotic protein members which could 
be targeted alone or in combination with other chemotherapeutic agents to induce a 
cancer cell specific death. 
Having shown that S63845 could synergise with both ABT-199 and A-1331852 to 
induce apoptosis in a range of cell lines, the apoptosis induced by these inhibitors 
was assessed further, by means of immunoprecipitation, to observe the interactions 
and possible displacements of BH3-only proteins from their respective anti-
apoptotic partners. Remarkably, in both suspension and solid tumour cell lines, the 
sensitivity of a cell line to specific inhibitors of pro-survival BCL-2 family proteins 
did not always match the binding and displacement patterns of BCL-2 family 
members. For example, in the case of MV-4-11 which are extremely sensitive to 
both S63845 and ABT-199, BIM was bound to both MCL-1 and BCL-2 but only 
readily displaced from MCL-1 and not BCL-2 with the respective BH3 mimetics. 
Moreover, no other BH3-only protein was released from BCL-2 following exposure 
to ABT-199. It is therefore unclear, following the defined mechanisms of apoptosis 
initiation, how ABT-199 can induce apoptosis in these cell lines, if no native BH3-
only proteins are released from BCL-2 to activate the effectors of apoptosis, BAX 
and BAK. Similar observations could be made in solid tumour cell lines, with a 
particularly interesting case for HCT116, which require inhibition of MCL-1 and 
BCL-XL for extensive apoptosis induction, yet with the exception of NOXA, no 
BH3-only proteins are bound to MCL-1 and almost all BIM is sequestered by BCL-
XL. 
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It could be suggested that in these cell lines, minute amounts of BIM or another 
BH3-only protein could be released from BCL-2 following ABT-199 treatment, 
which is enough to induce apoptosis but is not detectable by immunoblotting. In 
support of this, in MV-4-11 cells, a small amount of BIM is seen bound to MCL-1 
and is readily displaced when the cells are exposed to S63845. However, it is 
striking that more BIM is not released from BCL-2, when it is completely displaced 
in other cases following ABT-199 exposure. Moreover, the striking dependence of 
HCT116 cells on both MCL-1 and BCL-XL goes against this. 
In order to better understand the BCL-2 family interactions during apoptosis, further 
techniques could be used, such as proximity ligation or dissociation assays in 
shorter, immunofluorescent live-cell imaging. This would allow for observation of 
the protein-protein interactions during the onset of apoptosis and would also 
eliminate any issue of detergent-induced changes in interactions which have been 
previously implied by other studies299,300. Moreover, this would allow for better 
observations of the whole BCL-2 family subcellular pools, as lysis of cells with 
CHAPS for immunoprecipitation may have resulted in loss of some degree of 
proteins present in the insoluble fraction, since CHAPS may not allow for full 
recovery of such proteins. A live-cell imaging approach would also require use of 
Z-VAD-FMK to inhibit caspases and thereby prevent downstream apoptotic 
signalling, which would remove the possibility of any artefacts seen in the 
immunoprecipitation experiments where cells might already be undergoing 
extensive apoptosis. Shorter time-points could also prevent this, as here, cells were 
collected for immunoprecipitation when ~50% of cells were apoptotic in order to 
ensure full displacement of BH3-only proteins from pro-survival proteins, however 
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it is possible that displacement occurs much earlier before apoptosis takes place, 
thus live-cell imaging at shorter time-points would improve any observations made. 
Taken together, this data seems to suggest that the interactions and dispensability 
of the BCL-2 family in BH3 mimetic-induced apoptosis is much more complicated 
than originally thought. Indeed, multiple recent reports has shown that some, if not 
all, of the BH3-only proteins may actually be dispensable for BAX/BAK activation 
and subsequent apoptosis following suppression of both MCL-1 and BCL-
XL
220,301,302. To further explore the role of the BH3-only proteins in BH3 mimetic-
induced apoptosis in cancer cell lines, a genetically modified cell line lacking the 8 
key BH3-only proteins, thought to be essential to apoptosis, was utilised and will 
be discussed in the next chapter. 
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Chapter 4  
 
The dispensability of the BH3-only 
proteins in apoptosis 
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4.1 Background 
In the previous chapter, it was shown that the interactions between the different BCL-
2 family proteins might not always necessarily reflect the sensitivity of cell lines to 
undergo apoptosis following exposure to specific BH3 mimetics. If this is the case, 
the importance of the BH3-only proteins in determining whether a cell will die 
following suppression of the pro-survival proteins is put in question. As described 
earlier, there are multiple competing theories which try to explain how the BCL-2 
protein family interactions regulate apoptosis. The most well-accepted model of 
effector protein activation is the unified model, where anti-apoptotic BCL-2 proteins 
restrain the activity of both pro-apoptotic BH3-only proteins and the effector proteins 
(BAX and BAK). Upon receipt of an apoptotic stimulus, two main ‘modes’ of 
apoptosis can ensue – ‘mode 1’ where increased levels of BH3-only proteins bind to 
and activate the effector proteins (direct activation) and ‘mode 2’ where effector 
proteins are released from anti-apoptotic proteins as increased levels of BH3-only 
proteins displace the pro-survival/effector protein interactions (indirect activation). In 
reality, both of these processes are likely to occur, resulting in a bi-modal activation 
of the effector proteins, allowing for finer control over BAX and BAK activation. It 
has been made evident from all of the proposed models that BH3-only proteins, in one 
way or another, are considered essential to the activation of BAX and BAK. Recent 
work by our collaborators, however, suggests otherwise, however303. The lab of 
Professor Xu Luo at The University of Nebraska Medical Centre developed a panel of 
BCL-2 family knockout HCT116 cell lines using CRISPR-Cas9 technology which 
revealed some very surprising results concerning the BCL-2 family and their 
dispensability in apoptosis. HCT116 cells, as confirmed in this study as well as in our 
findings (Fig 3.12C), depend on both MCL-1 and BCL-XL for survival.  Neutralisation 
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of these two proteins by RNA interference or other approaches in these cells resulted 
in rapid induction of apoptosis in a BAX/BAK-dependent manner. Surprisingly, the 
‘activator’ BH3-only proteins BIM, PUMA and BID were dispensable for activation 
of BAX/BAK and the ensuing apoptotic pathway304. This suggested that inhibition of 
MCL-1 and BCL-XL alone was sufficient to activate BAX/BAK and induce 
apoptosis304, perhaps with the help of the other sensitiser BH3-only proteins (for 
example NOXA, BIK, HRK). Indeed, some reports have suggested that the 
‘sensitisers’ do not exclusively function to sensitise a cell to apoptosis induction by 
altering the activity of anti-apoptotic proteins and instead, may be able to activate 
apoptosis themselves220. To follow up on this, the team, led by Professor Luo, further 
developed their HCT116 BH3-only protein KO cells to an octa-knockout (8KO) cell 
line, apparently not expressing any of the eight key BH3-only proteins: BIM, BID, 
PUMA, NOXA, HRK, BMF, BIK and BAD. While these cells were resistant to 
apoptosis induced by general apoptotic stimuli, such as serum starvation, thapsigargin 
(an ER stress inducer305) and the death ligand TRAIL, the 8KO cells underwent 
extensive BAX/BAK-dependent apoptosis following neutralisation of MCL-1 and 
BCL-XL, just like the wild-type parental cells, ruling out a requirement of all known 
BH3-only proteins in apoptosis induction. This is supported by previous studies which 
have also outlined the lack of an absolute requirement of certain BH3-only proteins, 
such as BIM, PUMA and BID, in activation of apoptosis217,220, while other reports 
suggest that even some sensitiser BH3-only proteins can weakly activate the effector 
proteins90,306.  
Collectively, these studies suggest that a simple model of activation of BAX and/or 
BAK by BH3-only proteins is unlikely to exist and instead, the interactions and 
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activity of the BCL-2 family are much more complicated, with the notion of activator 
versus sensitizer BH3-only proteins being largely irrelevant. 
Data from the previous chapter suggested that BH3-only protein interactions with the 
anti-apoptotic proteins do not exclusively determine sensitivity to BH3 mimetics, 
while previous studies imply that BH3-only proteins are not required for apoptosis 
when BCL-XL and MCL-1 are neutralised. Here, it was therefore asked whether the 
BH3-only proteins were required to mediate apoptosis following exposure to highly 
potent and specific BH3 mimetics, which has not previously been studied using any 
of the knockout cells. We demonstrate that in the absence of the eight key BH3-only 
proteins, inhibitors of MCL-1 and BCL-XL can still induce apoptosis, going against 
the central dogma of BH3 mimetic design and challenging the current understanding 
of how BCL-2 protein family interactions work. 
4.2 HCT116 8KO cells do not express the eight key BH3-only proteins. 
The HCT116 8KO cells, alongside parental wild-type (WT) and double knockout 
(DKO, lacking BAX and BAK, used as a negative control) were a gift from Professor 
Luo (University of Nebraska Medical Centre, Nebraska). In order to first verify the 
knockouts in each of the cell lines, the cells were subjected to immunoblotting using 
antibodies against each of the key BH3-only proteins. The cell lysates were also 
probed with antibodies against the anti-apoptotic BCL-2 family as well as tubulin, as 
a loading control (Fig. 4.1A). The HCT116 WT cells clearly demonstrated reasonable 
levels of most of the BCL-2 family proteins in the immunoblots including BAX, BAK, 
BIM (with all isoforms identified), BID, BAD, PUMA (identified by the lower, faint 
band), NOXA and BMF (lower band). HRK, BCL-2 and BIK were not detectable at 
the protein level in any of the HCT116 cells. As expected, BAX and BAK were not 
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present in the DKO cell lines, while the rest of the BCL-2 family were unaffected in 
the DKO cells. The 6 BH3-only proteins detectable by immunoblotting (BIM, BID, 
BAD, PUMA, NOXA, BMF) were not present in the 8KO cell lines. The anti-
apoptotic proteins MCL-1 and BCL-XL were detectable at similar levels across all 
three cell lines, suggesting that a lack of the BH3-only proteins does not influence 
levels of the anti-apoptotic proteins.  
Since HRK, BIK and BCL-2 and were not detectable at the protein level in any of the 
HCT116 cells, qPCR was performed using cDNA generated from the HCT116 WT, 
DKO and 8KO cells to look at the levels of mRNA. While the relative expression of 
BCL-2 mRNA was similar among the three cell lines, expression of BIK and HRK 
mRNA relative to the housekeeping gene, GAPDH, seemed to exhibit differences in 
the three cell lines (Figure 4.1B). BIK mRNA levels in the HCT116 8KO cells was 
marginally lower compared to the WT and DKO cells (Fig. 4.1D), whereas HRK 
mRNA seemed to be expressed at higher levels in the 8KO cells than in the WT or 
DKO cells. This seemed to indicate that the cells had residual HRK, although it was 
undetectable at the protein level (Fig. 4.1A). This was in discrepancy with the data 
presented in the original article showcasing the HCT116 8KO cells demonstrated that 
HRK was indeed knocked out by assessing the HCT116 cells for frameshift mutations 
of the CRISPR target region303. However, it must be noted that (1) the mRNA 
expression levels of BCL-2, BIK and HRK were overall extremely low (< 0.001 %) 
compared to GAPDH and (2) the knockouts were induced by frameshift mutations, 
which may not necessarily reduce mRNA expression, but which will block protein 
expression. This, along with the fact that HRK was undetectable at the protein level, 
confirmed that the 8KO cells were in fact devoid of the 8 BH3-only members, as 
reported by Professor Luo.303  
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Figure 4.1. HCT116 8KO cells do not appear to express the eight key BH3-only 
proteins. (A) HCT116 WT, DKO and 8KO cells were lysed in RIPA buffer and 
subjected to immunoblotting to determine the levels of the BCL-2 family proteins and 
confirm the knockout of the indicated proteins. Tubulin was detected as a loading 
control. Approximate molecular weights of proteins are indicated alongside the blots. 
(B, C, D) For proteins which were not detectable by immunoblotting, qPCR was 
performed to determine the relative expression of the proteins compared to the house-
keeping gene GAPDH.  
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4.3 Genetic suppression of MCL-1 and BCL-XL can induce apoptosis in the 
absence of the known BH3-only proteins. 
The original report showcasing the HCT116 8KO cells demonstrated that 
neutralisation of BCL-XL and MCL-1 could induce BAX activation and apoptosis in 
the absence of BH3-only proteins. This goes against the central dogma of apoptosis 
where BH3-only proteins are released from pro-survival counterparts to activate BAX 
and hinted at other mechanisms which can induce BAX activation.  
In order to validate this observation, the HCT116 WT, DKO and 8KO cells were 
subjected to a knockdown of either MCL-1 or BCL-XL alone or a combination of BCL-
XL and MCL-1, using short-interfering RNAs (siRNAs). Downregulation of both 
BCL-XL and MCL-1 together could induce significant apoptosis in both HCT116 WT 
and 8KO, with approximate values of 85% and 70% respectively, while the DKO cells 
did not undergo apoptosis, demonstrating on-target BAX and/or BAK dependent 
apoptosis (Fig. 4.2A). While knockdown of MCL-1 alone did not induce significant 
apoptosis in any of the three cell lines, knockdown of BCL-XL could induce significant 
apoptosis (~60%) in the WT cells. Interestingly, apoptosis observed following BCL-
XL downregulation occurred in a BH3-dependent manner, as 8KO cells failed to 
undergo apoptosis and behaved similar to DKO cells, unlike the WT cells (Fig. 4.2A). 
This suggested that there may be some key differences between MCL-1 and BCL-XL-
mediated apoptosis in terms of the requirement of BH3-only proteins in HCT116 cells. 
Knockdown of MCL-1 and BCL-XL was validated using immunoblotting – cells were 
incubated with siRNAs as previously described, collected and lysed for 
immunoblotting. While BCL-XL is almost completely knocked down in all three cell 
lines, only the top band of MCL-1 appeared to be knocked down. The top band of 
117 
 
MCL-1, as previously mentioned, is thought to be the isoform of MCL-1 which 
regulates apoptosis, however, therefore the loss of the upper band is sufficient to 
induce apoptosis in combination with knockdown of BCL-XL. It is interesting to note 
that when one anti-apoptotic BCL-2 member is silenced, there is slight but noticeable 
increase in expression of the partner anti-apoptotic protein in most cases, suggesting 
there may be some kind of compensatory mechanism in place to help cells survive 
(Fig. 4.2B, C, D).  
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Figure 4.2. Knockdown of pro-survival proteins can induce apoptosis in a BAX- 
and BAK-dependent but BH3-only protein-independent manner. (A) HCT116 
WT, DKO and 8KO cells were incubated with the indicated siRNAs for 72 hours and 
apoptosis was assessed by PS externalisation using Annexin V labelling in flow 
cytometry. (B, C, D) Knockdown efficiency of MCL-1 and BCL-XL in the three 
different cell lines was assessed by immunoblotting with GAPDH as a loading control. 
Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
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4.4 HCT116 8KO cells are similarly primed for death as their WT 
counterparts. 
In order to further explore the surprising ability of 8KO cells to undergo apoptosis to 
a similar extent to that of WT cells, HCT116 WT and 8KO cells were subjected to 
BH3 profiling. BH3 profiling is a novel technique developed by the Letai group which 
uses synthetic peptides to mimic the BH3 motif of pro-apoptotic BH3 proteins, such 
as BIM, BAD and NOXA, to determine the sensitivity of cells to undergo apoptosis 
following exposure to certain chemotherapeutic agents297. The extent of priming is 
quantified by assessing mitochondrial membrane potential following exposure to a 
single peptide or a mixture of peptides. This gives an indication of the extent of 
apoptosis that would be induced if the relative proteins were targeted using 
chemotherapy24,307. 
Here, the synthetic peptides BAD (which specifically binds BCL-XL) and MS-1 (a 
peptide specific to MCL-1308) were used alone and in combination to determine the 
priming of HCT116 WT and 8KO cells for apoptosis induction following BCL-XL 
and/or MCL-1 inhibition. FCCP (Carbonyl cyanide-4-phenylhydrazone), a 
mitochondrial un-coupler279, was used as a positive control for depolarisation which, 
as shown in Figure 4.3, induced complete depolarisation of mitochondria in 
comparison to the DMSO control. Mitochondrial depolarisation was assessed using 
TMRE, a dye which accumulates in active mitochondria and which is lost upon 
depolarisation of the mitochondrial membrane278. Addition of 10 µM BAD peptide 
resulted in ~30% depolarisation of the WT cells (but not the 8KO cells), confirming 
that the WT cells were somewhat dependent on either BCL-2, BCL-XL or BCL-w. 
This is in agreement with data in Fig. 4.2A, in which the WT cells appeared to exhibit 
some apoptosis following the genetic knockdown of BCL-XL. As expected, the extent 
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of mitochondrial depolarisation following BAD peptide in the 8KO cells was 
significantly less, further confirming previous data (Fig. 4.2A). Addition of the MCL-
1-specific MS-1 peptide also resulted in some mitochondrial depolarisation, however 
this was in fact higher in the 8KO cells compared to the WT, with ~25% depolarisation 
in the WT and ~35% in the 8KO cells. This data suggested that there may be a slight 
dependence on MCL-1 alone, although this was not detected when cells were 
previously exposed to S63845. A combination of the two peptides together induced 
extensive depolarisation of ~85% in both the WT and 8KO cells, as seen with the 
concurrent genetic inhibition of MCL-1 and BCL-XL. Thus, the 8KO cells behave in 
a very similar way to the WT cells, suggesting they are equally as primed for death 
when both MCL-1 and BCL-XL are inhibited but not when only BCL-XL alone is 
inhibited. 
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Figure 4.3. HCT116 WT and 8KO cells are equally primed for death following 
suppression of both MCL-1 and BCL-XL but not BCL-XL alone. The plasma 
membranes of HCT116 WT and 8KO cells were permeabilised and the indicated 
peptides or compound was incubated with the cells. TMRE was then combined with 
the mixture to assess mitochondrial depolarisation in flow cytometry. FCCP was used 
as a positive control. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 
0.001 
 
4.5 Inhibition of BCL-XL but not MCL-1 using BH3 mimetics can induce 
apoptosis in a BH3-dependent manner in HCT116 cells. 
Since genetic inhibition of BCL-XL but not MCL-1 could induce BH3-only protein- 
dependent cell death and since BH3 profiling data seemed to suggest that the BCL-
XL-specific BAD peptide could only induce significant depolarisation in the HCT116 
WT cells, it was anticipated that direct pharmacological inhibition of BCL-XL and 
MCL-1 would demonstrate similar differences. In order to test this, HCT116 WT and 
8KO cells were incubated with either A-1331852 or S63845 (both at 100 nM) for 4 h 
and apoptosis assessed by PS externalisation in flow cytometry. Indeed, exposure of 
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cells to A-1331852, but not S63845, resulted in enhanced apoptosis in HCT116 WT 
cells, with ~30% of cells undergoing apoptosis following exposure to A-1331852 (Fig. 
4.4). Remarkably, this apoptosis was not observed in the HCT116 8KO cells, in line 
with previous data presented here. 
 
 
 
Figure 4.4. Pharmacological inhibition of BCL-XL but not MCL-1 can induce 
apoptosis in a BH3-only protein-dependent manner. HCT116 WT and 8KO cells 
were exposed to 100 nM of A-1331852 or 100 nM S63845 for 4 h and apoptosis 
assessed by PS externalisation using Annexin V staining in flow cytometry. Error bars 
= Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 
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4.6 BCL-XL seems to be the major pro-survival protein in various cell lines. 
Although most solid tumours depend on both BCL-XL and MCL-1 for 
survival199,245,292–294,309, it is clear from previous data that, surprisingly, inhibition of 
BCL-XL alone can induce significant apoptosis in the colorectal carcinoma cell line, 
HCT116. In order to explore whether this trend extended to other solid tumour cell 
lines, a panel of five solid tumour cancer cell lines was exposed to either S63845 or 
A-1331852 (both at 100 nM) and apoptosis measured using PS externalisation at 
different timepoints. The five cell lines selected in addition to HCT116 WT cells were 
MDA-MB-231 (a breast cancer cell line), H1299, A549, PC-3 and SUIT-2. As 
expected, the HCT116 cells underwent ~50% apoptosis following 4 h exposure to A-
1331852, while S63845 did not induce significant apoptosis compared to the DMSO 
control (Fig. 4.5A). Extension of treatment times to 24, 48 and 72 h did not see a 
significant increase in the extent of apoptosis however, with the extent of apoptosis 
still at ~50% even at 72 h. This suggests that inhibition of BCL-XL alone is not enough 
to induce complete apoptosis in this cell line and that targeting of both BCL-XL and 
MCL-1 was required to induce complete apoptosis (as seen in Fig 3.12C). The other 
cell lines tested demonstrated varied responses to inhibition of BCL-XL over MCL-1. 
Treatment of the breast cancer cell line MDA-MB-231 with A-1331852 resulted in 
extensive apoptosis at 4 h (~60%), which increased moderately over time to ~80% at 
72 h, suggesting these cells are very sensitive to inhibition of BCL-XL (Fig. 4.5B). 
S63845 did not induce significant apoptosis at any time point in MDA-MB-231 cells. 
Meanwhile, in H1299 cells, neither S63845 nor A-1331852 alone could induce 
apoptosis at any timepoint, suggesting that inhibition of both MCL-1 and BCL-XL is 
required to induce death in this cell line (Fig. 4.5C), as alluded to in the previous 
chapter for various cell lines (Fig. 3.12). The other non-small cell lung carcinoma cell 
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line, A549, did undergo some apoptosis however, with A-1331852 inducing ~35% 
apoptosis, which fluctuated until 72 h, supporting the idea suggested in the previous 
chapter that cells derived from the same type of cancer can exhibit varying dependence 
on pro-survival proteins (Fig. 4.5D). The two other cell lines tested, PC-3 and SUIT-
2, mimicked A549 in undergoing moderate apoptosis following A-1331852 exposure, 
whereas S63845 did not induce more apoptosis than the DMSO control (Fig. 4.5E and 
F). The overall message from these experiments is that although inhibition of BCL-
XL can induce apoptosis in cells from various cancers, dual inhibition of MCL-1 and 
BCL-XL (and possibly even other pro-survival proteins) is often required to induce 
complete apoptosis, as most cells from solid tumours do not exclusively depend on 
one pro-survival protein.  
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Figure 4.5. Pharmacological suppression of BCL-XL but not MCL-1 is sufficient 
to induce apoptosis in some cell lines at extended timepoints. The indicated cell 
lines were exposed to either DMSO, A-1331852 (100 nM) or S63845 (100 nM) alone 
and collected at the indicated timepoints to be assessed for apoptosis by PS 
externalisation using Annexin-V labelling in flow cytometry. Error bars = Mean ± 
SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
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4.7 Dual inhibition of MCL-1 and BCL-XL with highly specific BH3 mimetics 
can induce apoptosis even in the absence of BH3-only proteins. 
It has been established in previous figures that inhibition of BCL-XL alone can induce 
apoptosis in the HCT116 WT but not HCT116 8KO cells (which lack the 8 key BH3- 
only proteins). To test whether dual inhibition of BCL-XL and MCL-1 would result in 
the same phenomenon, the HCT116 WT and 8KO cells were exposed to a combination 
of A-1331852 (100 nM) and a concentration range of S63845 for 4 h and apoptosis 
assessed using PS externalisation in flow cytometry. The parental WT control cells 
underwent significant apoptosis following a combination of inhibitors (both at 100 
nM), with ~80% death achieved following exposure to 1 µM S63845 and 100 nM A-
1331852 (Fig. 4.6). Remarkably, the HCT116 8KO cells also underwent a similar 
apoptosis, with slightly more cells dying at 100 nM of each drug than the WT but with 
approximately the same IC50 (around 100 nM). Thus, when both MCL-1 and BCL-XL 
are inhibited using BH3 mimetics in the HCT116 8KO cells, there is no requirement 
for the BH3-only proteins – unlike when just BCL-XL is inhibited. This data also 
extends the results of the original HCT116 8KO report303 by demonstrating that cells 
can undergo apoptosis without the eight key BH3-only members even when using 
highly specific BH3 mimetics to inhibit MCL-1 and BCL-XL. This goes against the 
accepted principle of how BH3 mimetics induce apoptosis and raises many questions 
about the BCL-2 family and BH3 mimetics in apoptosis, particularly regarding the 
mechanism of action of BH3 mimetics and how the effector proteins, BAX and BAK, 
behave in the HCT116 8KO cells. 
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Figure 4.6. BH3 mimetics can induce apoptosis in a BH3-only protein-
independent manner. HCT116 WT and 8KO cells were exposed to a concentration 
range of S63845 alongside a fixed concentration of A-1331852 (100 nM) for 4 h and 
the extent of cell death assessed by PS externalisation using Annexin V labelling in 
flow cytometry. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 
 
4.8 BH3 mimetic-induced apoptosis requires BAX but not BAK in HCT116 
cells. 
Since BH3-only proteins are not required for mediating BH3 mimetic-induced 
apoptosis in HCT116 cells, it is possible that BH3 mimetics could somehow directly 
activate BAX and/or BAK to induce apoptosis, perhaps by relieving their inhibition 
by pro-survival proteins. While previous data indicates that BH3 mimetics require the 
presence of the effector proteins to induce apoptosis, the exact requirement of BAX 
and/or BAK had not been established. Therefore, in order to determine the BAX/BAK 
requirement of the HCT116 cells in BH3 mimetic-induced death, four cell lines 
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(HCT116 WT, BAX KO, BAK KO and BAX/BAK DKO) were exposed to 100 nM 
A-1331852 with a concentration range of S63845 for 4 h and assessed for apoptosis 
by PS externalisation in flow cytometry (Fig. 4.7A). The WT cells underwent 
extensive apoptosis as expected, with an IC50 of ~100 nM of both S63845 and A-
1331852. Meanwhile, the BAK KO cells also underwent apoptosis, with a similar IC50 
to the WT cells, suggesting that BAK is not critical for apoptosis in HCT116 cells. 
However, BAX appeared to be essential for BH3 mimetic-induced apoptosis in 
HCT116 cells as neither the single BAX KO nor the BAX/BAK DKO cells underwent 
apoptosis following exposure to A-1331852 in combination with all concentrations of 
S63845. Knockout of the indicated proteins was confirmed by immunoblotting (Fig. 
4.7B). 
This data suggests that BAX is essential to BH3 mimetic induced apoptosis in HCT116 
cells and BAK cannot compensate for a lack of BAX. This is in line with previous 
studies which suggest that HCT116 relies rely on BAX over BAK for apoptosis310 and 
also suggests that even in the absence of BH3-only proteins, BAX is still an absolute 
requirement for HCT116 cells to undergo apoptosis.  
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Figure 4.7. A combination of S63845 and A-1331852 induces BAX-dependent but 
BAK-independent death in HCT116 cells. (A) HCT116 WT, BAX KO, BAK KO 
and BAX/BAK DKO cells were exposed to a concentration range of S63845 alongside 
a fixed concentration of A-1331852 (100 nM) for 4 h and the extent of cell death 
assessed by PS externalisation using Annexin V in flow cytometry. (B) Western blot 
validation of the knockout cell lines with GAPDH as a loading control. Error bars = 
Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 
 
4.9 BAX appears to be already activated in both HCT116 WT and 8KO cells. 
As described in the introduction, for a BAX-dependent apoptosis to occur, BAX must 
undergo a series of events, such as activation of monomeric BAX from its globular 
form where its key motifs are internalised, to an active form which then oligomerises 
to form a channel on the mitochondrial membrane, allowing the release of cytochrome 
c.  
BAX was shown to be key to BH3 mimetic-induced apoptosis in HCT116 cells, 
therefore in order to assess whether BAX was differentially activated in HCT116 WT 
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versus 8KO cells, the level of activated BAX following BH3 mimetic exposure was 
detected using the BAX 6A7 antibody. This antibody specifically recognises residues 
in the α-1 helix of BAX which is only exposed following apoptotic stimuli300,311. The 
BAX 6A7 antibody was therefore used to label cells exposed to 100 nM S63845 and 
A-1331852 and fluorescence intensity detected in in flow cytometry. Surprisingly, in 
HCT116 cells, it appears that using this method to detect BAX activation is not ideal, 
as almost all BAX, with and without treatment, appeared to be activated in both WT 
and 8KO cells (Fig. 4.8A). A similar activation of BAK (detected by the anti-BAK 
AB-1 antibody) was observed in both WT and 8KO cells (Fig. 4.8B), suggesting that 
HCT116 cells were inherently posing some difficulty with respect to this particular 
assay. To confirm this idea, BAX/BAK activation assays were also carried out in 
H1299 cells. Although activated BAX was not detectable in H1299 (as these cells do 
not express BAX), activated BAK was clearly observed in H1299 following a 
combination of S63845 and A-1331852, while no activated BAK was detectable in 
the DMSO control, suggesting that the assay was working as anticipated, at least in 
the H1299 cells. It could perhaps be proposed that this constant activation of BAX is 
not an artefact of the experiment and therefore could explain why 8KO cells undergo 
apoptosis following neutralisation of the pro-survival proteins. However, this is 
unlikely to be the case, as neither the HCT116 WT or 8KO cells have high levels of 
basal death which would be expected with cells with such extensive basal BAX/BAK 
activation. Thus, it is likely that the high levels of activated BAX/BAK are merely an 
artefact of the experimental protocol used here. 
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Figure 4.8. BAX and BAK activation are not detectable in HCT116 cells due to 
constant activation in all conditions. HCT116 WT and 8KO cells and H1299 cells 
(a positive control for the assay) were treated with a vehicle control or 100 nM S63845 
and A-1331852 for 4 h, permeabilised and incubated with antibodies against active 
BAX (A) or BAK (B). While H1299 cells presented their typical BAK activation 
status, both HCT116 WT and 8KO cells presented constant BAX and BAK activation, 
regardless of treatment. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 
0.001 
 
4.10 BAX translocates to the mitochondria even in the absence of BH3-only 
proteins. 
Despite the limitations of BAX activation assays in the HCT116 WT and 8KO cells, 
BAX activity could be measured in other ways in order to assess whether it was 
undergoing the typical chain of events leading to cytochrome c release in the absence 
of the BH3-only proteins. One of these events is the translocation of BAX from the 
cytosol to the mitochondria. To ensure this was occurring in the same way in both the 
HCT116 WT and 8KO cells during BH3 mimetic-mediated apoptosis, the cells were 
pre-treated with 20 µM Z-VAD-FMK for 30 min. Z-VAD-FMK is a caspase inhibitor, 
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therefore prevents cells from dying by blocking events downstream of MOMP – this 
permits observation of BAX activity without the presence of apoptosis related 
artefacts. Cells were then treated with either DMSO or 100 nM of S63845, A-1331852 
or a combination of the two for 2 h, before being fixed, permeabilised and incubated 
with an antibody against BAX. In the control (DMSO-treated) cells, BAX appeared in 
a speckled, dispersed pattern, all around the cell, typical of a cytosolic staining, in both 
HCT116 WT and 8KO cells (Fig. 4.9). However, upon treatment with the BH3 
mimetics, this dispersed pattern was lost and instead, BAX could be seen at distinct 
foci, clustered together in large spots. While this pattern is not a typical mitochondrial 
pattern (hyper networked and organised), this was BAX translocating to the 
mitochondria, likely forming spots of high-molecular weight oligomers in preparation 
for cytochrome c release. It is not surprising that the resulting pattern is not typically 
mitochondrial, as the BAX oligomers are unlikely to be present as a homogenous 
population across the mitochondria and instead, are thought to be present at distinct 
recruitment sites involving multiple proteins, such as VDAC2312 amongst others. 
Nevertheless, the translocation of BAX from the cytosol to the mitochondria was 
virtually indistinguishable between the WT and 8KO cells, with no mitochondrial 
BAX detected in the DMSO treated cells and BAX being mitochondrial in both WT 
and 8KO cells. It is interesting to note that, in support of previous findings, inhibition 
of BCL-XL by A-1331852 alone could induce partial BAX translocation in the WT but 
not 8KO cells, suggesting that the differences in regulation of apoptosis by MCL-1 
and BCL-XL occur at the level of BCL-2 family interactions, prior to Bax 
translocation. 
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Figure 4.9. Pharmacological inhibition of MCL-1 and BCL-XL can induce BH3-
only protein-independent BAX translocation to the mitochondria. HCT116 WT 
and 8KO cells were pre-treated with 20 µM Z-VAD-FMK for 30 min then exposed to 
100 nM of the indicated inhibitors for 2 h, fixed and stained for BAX to assess its 
localisation. Scale bar – 10 µm. 
 
4.11 BAX forms high molecular weight oligomers following exposure to BH3 
mimetics even in the absence of BH3-only proteins. 
Since BAX translocates from the cytosol to the mitochondria in the same manner in 
both HCT116 WT and 8KO cells following BH3 mimetics, the ability of BAX to form 
high molecular weight oligomers without BH3-only proteins was next assessed. To 
examine this, both cell lines were pre-treated with Z-VAD-FMK followed by 100 nM 
S63845 and A-1331852 for two hours, as performed previously for analysis of BAX 
translocation, and then subjected to gel filtration chromatography over a Superose 6 
column to separate protein complexes on the basis of their size. 
The collected HCT116 WT and 8KO cell fractions were probed for BAX to assess 
whether oligomerisation could be observed following BH3 mimetic exposure. Since 
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BAX is considered to be cytosolic and typically monomeric311 or possibly dimeric313 
it was anticipated to be present at low molecular weights (~20-50 kDa) in the control 
conditions. Indeed, in both HCT116 WT and 8KO, BAX could be seen in fractions 
which are proposed to be around 40-60 kDa in molecular weight, suggesting this pool 
of BAX exists at a low molecular weight - perhaps, in dimers (Fig. 4.10). Meanwhile, 
in the cells exposed to a combination of S63845 and A-1331852, BAX could be found 
largely at high molecular weights (~1500-2000 kDa) in both HCT116 WT and 8KO 
cells, suggesting it had oligomerised to high molecular weight complexes following 
exposure to BH3 mimetics to the same extent in both cell lines. 
 
 
Figure 4.10. BAX undergoes oligomerisation following S63845 and A-1331852 
treatment independently of the BH3-only proteins. HCT116 WT and 8KO cells 
were treated with 100 nM S63845 and A-1331852 for 2 h, lysed and proteins separated 
based on size using a Superose 6 column. High to low molecular weight fractions were 
then subjected to immunoblotting to detect the location of BAX. Vertical lines indicate 
separation of individual gels, with fractions ran in a non-continuous series. 
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4.12 Cytochrome c can be released by BH3 mimetics even in the absence of the 
known BH3-only proteins.  
BAX translocates and forms oligomers in the same way in both WT and 8KO cells 
therefore, in theory, cytochrome c should also release in the same way, unless the BH3 
mimetics are inducing cell death in the HCT116 8KO proteins in an unusual manner. 
To test this hypothesis, HCT116 WT and 8KO cells were exposed to S63845 and A-
1331852 for 2 h following Z-VAD-FMK pre-treatment (as above) and probed for 
cytochrome c. In the control cells, cytochrome c was clearly localised within the 
mitochondria as expected. However, upon addition of S63845 and A-1331852, this 
networked, filamentous labelling is completely lost as the cytochrome c exits the 
mitochondria and becomes dispersed in the cytosol. This occurred in both the WT and 
8KO cells in the same manner, suggesting that cytochrome c release can occur 
regardless of the presence of the BH3-only proteins following inhibition of MCL-1 
and BCL-XL. (Fig. 4.11). Again, it is worth nothing that partial cytochrome c release 
occurs in the HCT116 WT but not in 8KO cells following inhibition of BCL-XL with 
A-1331852. This suggests that these cells commit to apoptosis through cytochrome c 
release following inhibition of just one of the pro-survival proteins, perhaps suggesting 
distinct pools of cells with different dependencies on the BCL-2 family with a 
population. 
136 
 
 
 
Figure 4.11. Cytochrome c can be released by pharmacological inhibition of 
MCL-1 and BCL-XL independently of BH3-only proteins. HCT116 WT and 8KO 
cells were exposed to 100 nM of the indicated inhibitors for 2 h, fixed and stained with 
an anti-cytochrome c antibody to assess its localisation. Scale bar - 10 µm. 
 
4.13 BAX is not restrained directly by MCL-1 and BCL-XL or released following 
BH3 mimetics in HCT116 WT or 8KO cells. 
Since BAX appears to be absolutely necessary to induce death by BH3 mimetics in 
HCT116 cells, it could be suggested that BAX is directly sequestered by MCL-1 and 
BCL-XL and thus, when cells are exposed to BH3 mimetics, BAX could be displaced 
from the anti-apoptotic proteins and is somehow activated, moving to the 
mitochondrial membrane and initiating the apoptotic pathway, in a ‘mode 1’ style 
activation model. 
While the interactions of BAK with anti-apoptotic proteins, especially MCL-1, have 
been described314,315, interactions between BAX and anti-apoptotic proteins are poorly 
documented. Some reports have shown that BCL-2 and BAX can interact316,317 
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however there is little evidence of MCL-1 or BCL-XL interacting with BAX directly. 
BAX is typically thought to be a very dynamic protein however, moving between 
different compartments of the cell (mostly the cytosol and mitochondria) according to 
cellular status. To test the hypothesis of a BAX-MCL-1 and/or BCL-XL interaction 
mediating the BH3 mimetic-induced death in the HCT116 8KO cells, MCL-1 and 
BCL-XL were immunoprecipitated from both HCT116 WT and 8KO cells pre-treated 
with Z-VAD-FMK and then combination of S63845 and A-1331852 (both at 100 nM) 
and tested for interactions with BAX. As a positive control for the BAX band as well 
as a control for BAX activation by BH3 mimetics, an anti-BAX N-terminal antibody 
was also used to immunoprecipitate BAX. 
Despite significant levels of BCL-XL and MCL-1 being immunoprecipitated, as shown 
by their respective blots, no BAX could be seen bound to either MCL-1 or BCL-XL in 
either HCT116 WT or 8KO cells (Fig. 4.12A and B). The pulldown of BAX using the 
anti-N-terminal BAX antibody demonstrated that BAX was easily detectable in the 
blots however, confirming that the lack of BAX bands in the MCL-1/BCL-XL 
immunoprecipitation experiments was not a result of poor immunoblotting. From this 
data, it is reasonable to suggest that neither HCT116 WT not 8KO cells undergo 
apoptosis following exposure to BH3 mimetics as a result of a displacement of BAX 
from pro-survival proteins. This is not a surprising result, as even if MCL-1/BCL-XL 
did interact with BAX, the simple release of BAX from these proteins should not be 
enough to induce apoptosis, as the proposed bimodal activation of BAX requires 
another step of activation (typically by BH3-only proteins). This, along with the other 
data here, therefore suggests that other factors are in play than the currently known 
BCL-2 family.  
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Figure 4.12. Pro-survival proteins do not interact directly with BAX in HCT116 
cells to prevent its pro-apoptotic activity. (A) HCT116 WT and (B) 8KO cells were 
pre-treated with Z-VAD-FMK then exposed to 100 nM A-1331852 and S63845 for 4 
h. Collected cells were lysed and immunoprecipitation performed against MCL-1 and 
BCL-XL, then immunoblotting for the indicated proteins to detect any interacting 
BAX. An anti-BAX N-terminal antibody immunoprecipitation was performed as a 
positive control for treatment and efficient pulldown/immunoblotting of BAX. BC 
represents bead control and IP indicates immunoprecipitation. 
 
4.14 Discussion 
Until recently it had been thought that the major BH3-only proteins were essential to 
altering the fate of a cell and pushing it towards apoptosis. The study by O’Neill et 
al.303 however disproved this by showing that HCT116 cells devoid of the eight key 
BH3 only proteins could still undergo apoptosis following suppression of pro-survival 
proteins – an observation which was confirmed by data here showing that HCT116 
WT and 8KO cells undergo similar levels of apoptosis following concurrent 
knockdown of MCL-1 and BCL-XL. While this work was a very important and 
remarkable challenge to the accepted dogma of apoptosis, it did not address whether 
suppression of pro-survival proteins using highly specific BH3 mimetics, which are 
designed to displace pro-survival proteins from their pro-apoptotic counterparts within 
the cell, could still induce apoptosis in the absence of the 8 key BH3-only proteins. 
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Remarkably, it was demonstrated here that HCT116 8KO cells can still undergo 
apoptosis following exposure to S63845 and A-1331852, inhibitors of MCL-1 and 
BCL-XL respectively, suggesting that BH3 mimetics can function independently of 
BH3-only proteins to activate effector proteins and induce cell death (Fig. 4.13). 
Again, it is worth noting that the knockdown of MCL-1 appears to be incomplete as 
only the top band is knocked down, while the bottom band remains. While it is not 
clear why HCT116 cells display only two of the three major bands of MCL-1, it could 
be suggested that this lower band is in fact the mitochondrial matrix form, which 
would not play a role in apoptosis, which would explain why extensive apoptosis is 
seen with the combination of this knockdown of MCL-1 with a BCL-XL knockdown. 
Future work should aim to use a pool of MCL-1 siRNAs to maximise the knockdown 
so that this is not an issue, while also assessing the knockdown efficiency of MCL-1 
at earlier time-points, given the high turnover rate of MCL-1. Furthermore, apoptosis 
should be observed in the HCT116 WT and 8KO cells following S63845 and A-
1331852 treatment at 24, 48 and 72 hours in order to draw better comparisons between 
the inhibitor and siRNA treatments (where apoptosis assays were performed at 72 
hours). 
The apoptosis in the HCT116 cells was also BAX- but not BAK-dependent, 
highlighting the importance of BAX in BH3 mimetic-induced apoptosis. While BAX 
underwent its typical process of translocating from the cytosol to the mitochondria, 
oligomerising and releasing cytochrome c, how exactly BAX was being activated was 
not evident. It was clear that BAX was not being restrained by MCL-1 and BCL-XL 
directly (and therefore being released and activated following addition of BH3 
mimetics), thus another mechanism must be in place in the HCT116 8KO cells. It is 
possible that these cells are following the indirect model of apoptosis where BH3-only 
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proteins are not displaced from pro-survival proteins to activate BAX/BAK but 
instead, directly disrupt the interactions of pro-survival proteins and BAX instead. 
However, simply freeing BAX/BAK from pro-survival proteins is not enough to lead 
to their activation. Instead, a bimodal activation is proposed to occur, where BH3-only 
proteins are considered essential to activation of BAX/BAK. This, taken together with 
the data here, suggests that the underlying mechanism of effector protein activation 
may be even more complex than previously known. Of course, cells with normal levels 
of BH3-only proteins are likely to use BH3-only proteins to activate effector proteins 
and subsequent apoptosis, as this is likely the most efficient route, however this data 
reveals that there may be more flexibility in execution of the apoptotic pathway. 
While no interaction between BAX and MCL-1 or BCL-XL could be detected using 
immunoprecipitation, it is known that BAX is an extremely dynamic protein and 
therefore, could be interacting with an array of proteins, including the pro-survival 
proteins, in a transient manner. BAX is typically considered to be a cytosolic protein 
under non-apoptotic conditions, however recent work has suggested that it actually 
cycles between different compartments of cells, in particular the cytosol and the 
mitochondria318. An aggregation of mitochondrial BAX is clearly not an ideal situation 
for a cell that is not fated for apoptosis however, therefore it has been proposed that 
mechanisms exist to retro-translocate BAX to the cytosol in order to prevent 
mitochondrial BAX accumulation, auto-activation and subsequent apoptosis319. 
Multiple reports have indeed implicated the pro-survival BCL-2 family proteins in this 
retrotranslocation process, with suppression of MCL-1 and BCL-XL resulting in 
impaired shuttling of BAX back to the cytosol318–322. In this case, in the absence of the 
BH3-only proteins, BAX retro-translocation could be reduced following inhibition of 
MCL-1 and BCL-XL activity, leading to its accumulation at the mitochondria, perhaps 
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initiating spontaneous activation of BAX by the outer mitochondrial membrane303, 
leading to the apoptosis seen in the HCT116 8KO cells. Of note, it has been established 
that some detergents can induce conformational changes within BAX (and indeed 
other BCL-2 family proteins) that alter interactions with other BCL-2 family members 
and can even aberrantly activate BAX300. Such detergents have been used extensively 
to study effector protein behaviour in vitro. As an organelle which is densely populated 
by lipids which form the typical bilayer of biological membranes, the mitochondrial 
membrane shares a degree of properties with detergents, therefore this could support 
the notion of the mitochondrial membrane being able to activate BAX/BAK under 
certain conditions. Other studies have suggested that detergent-activated BAX does 
not assume the typical form of BAX capable of instigating pore-formation in the 
mitochondrial membrane however, and even suggest that BAX remains a monomer 
following activation by a detergent323. Thus, the capacity of the mitochondrial 
membrane to activate BAX in the absence of BH3-only proteins following 
neutralisation of pro-survival proteins therefore remains to be proven and will require 
extensive exploration and an improved understanding of the mitochondrial membrane 
during apoptosis. Furthermore, assessing the dynamic behaviour of BAX in both its 
translocation and potential interactions with MCL-1 and/or BCL-XL is important, 
particularly since it was only assessed at single time-points here. Live cell imaging of 
a fluorescently tagged BAX in conjunction with a mitochondrial tracker and tagged 
MCL-1/BCL-XL could provide further information regarding how BAX truly behaves 
in the absence of the BH3-only proteins. 
While the mitochondrial membrane represents a compelling potential activator of 
effector proteins in the absence of BH3-only proteins, it is certainly not the only 
explanation for a BH3-only protein-independent death. It could also be suggested that 
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an unknown BH3-only-like protein is activating BAX to induce apoptosis in the 
HCT116 8KO cells. In the case of such a ‘Protein X’ scenario, exposure of the 
HCT116 8KO cells to BH3 mimetics might cause the dissociation of BCL-XL and/or 
MCL-1 from the so-called ‘Protein X’ which might then activate BAX, thus initiating 
apoptosis. Indeed, as described in Chapter 1, the BH3 motif of BCL-2 family proteins 
is not a set sequence, rather a series of particular types of amino acids giving rise to a 
certain protein structure. Thus, identifying proteins with a BH3 motif is not straight-
forward, as the BH3 motif sequence can take many forms. This could suggest that 
many proteins exist with potential BH3-like motifs which could mediate interactions 
with members of the BCL-2 family and induce apoptosis following pro-survival 
protein neutralisation in HCT116 8KO cells. 
Further adding to the complexity of BH3-only protein-independent apoptosis and the 
possibility of a ‘Protein X’, it was remarked that induction of apoptosis following 
MCL-1 and BCL-XL suppression varied dramatically in dependence on the BH3-only 
proteins. Inhibition of BCL-XL but not MCL-1 by both pharmacological and genetic 
approaches resulted in increased apoptosis in the HCT116 WT but not 8KO cells, 
suggesting that apoptosis regulated by BCL-XL depends on the availability of BH3-
only proteins. However, this dependence on BH3-only proteins was overcome when 
both MCL-1 and BCL-XL were inhibited together. This could further support the 
notion of a ‘Protein X’ scenario, in which such a protein perhaps interacts specifically 
with MCL-1. Thus, there appears to be something inherently different about the 
interactions between BCL-XL and its partner proteins and MCL-1 and its partner 
proteins during regulation of apoptosis in the absence of the BH3-only proteins (and 
perhaps in normal apoptosis too). This could potentially be the existence of a ‘Protein 
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X’ which specifically binds MCL-1 and, during apoptosis, is released to activate BAX 
– a concept which is explored in the next chapter. 
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Figure 4.13 – Apoptosis in HCT116 8KO cells may occur through non-
conventional routes, perhaps involving an unknown BH3-only protein that 
activates BAX. BCL-2 family members differ in their dependence on pro-apoptotic 
BH3-only members to exert their anti-apoptotic functions. In HCT116 cells, multiple 
BH3-only proteins, such as BIM, BID, BAD and PUMA are sequestered by BCL-XL, 
whereas NOXA is the only BH3-only protein bound to MCL-1. While the 
displacement of BH3-only proteins from BCL-XL following A-1331852 is sufficient 
to induce apoptosis in these cells, displacement of NOXA from MCL-1 following 
S63845 failed to induce apoptosis. However, the combination of A-1331852 and 
S63845 released all the BH3-only proteins from the anti-apoptotic counterparts and 
resulted in pronounced apoptosis. In the absence of all eight BH3-only proteins, 
neither A-1331852 nor S63845 alone resulted in apoptosis. However, a combination 
of A-1331852 and S63845 still resulted in extensive apoptosis, even in the absence of 
all BH3-only proteins. This could be due to the release of another pro-apoptotic BH3 
motif-containing ‘Protein X’ from MCL-1 and/or BCL-XL, which in turn could 
activate BAX in the 8KO cells. Alternatively, BH3 mimetics could indirectly result in 
the accumulation of BAX (either by inhibition of retrotranslocation or by passive 
diffusion, following the neutralization of the anti-apoptotic members) in the outer 
mitochondrial membrane, which in turn could result in BAX activation by the OMM. 
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Chapter 5  
 
Identifying novel MCL-1 interacting 
proteins. 
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5.1 Background 
In the previous chapter, it was demonstrated that cells lacking the eight key BH3-only 
proteins can still undergo apoptosis following suppression of MCL-1 and BCL-XL by 
either RNAi or BH3 mimetics, suggesting that the known BH3-only proteins are 
dispensable for activation of BAX and subsequent apoptosis. Furthermore, 
neutralisation of MCL-1 or BCL-XL individually induced strikingly different levels of 
apoptosis. Inhibition of BCL-XL, but not MCL-1, induced ~50% apoptosis in HCT116 
cells in a BH3-only protein-dependent manner. Unlike BCL-XL, MCL-1 appeared to 
antagonise apoptosis in a manner independent of the known BH3-only proteins, as 
dual inhibition of MCL-1 and BCL-XL together could induce apoptosis in the absence 
of all known BH3-only proteins. Various hypotheses were proposed to explain this 
BH3-only protein-independent apoptosis, including the possibility of the existence an 
unknown, BH3-only-like protein, or even multiple proteins, which may function as 
activators of BAX in the HCT116 8KO. This protein (or collection of proteins), herein 
referred to as ‘Protein X’, might also have a binding preference for MCL-1 over BCL-
XL, since it appeared that the BH3-only proteins were required for apoptosis when 
only BCL-XL was inhibited.  
As discussed in Chapter 1, MCL-1 is quite a promiscuous member of the anti-
apoptotic BCL-2 proteins. It has several known binding partners within the BCL-2 
family including BIM and NOXA (shown both in the literature and in Chapter 3), in 
addition to various other non-BCL-2 family member protein binding partners 
including SUFU324, CDK1177 and many more. MCL-1 also possesses a unique, 
elongated structure with more domains (namely PEST regions) than other BCL-2 
family members76, as described in Chapter 1. Thus, it has been proposed that MCL-1 
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may have a more complex biology than other anti-apoptotic proteins, regulating much 
more than just survival. It is not unrealistic therefore, to imagine that a number of 
MCL-1 interacting partners remain undiscovered and perhaps one of these could be a 
‘Protein X’ which can promote apoptosis in the absence of the 8 key BH3-only 
proteins. The BH3 motif, the key and universal unit of BCL-2 family proteins, is 
proposed to be extremely variable in nature and therefore may exist in various distinct 
sequences which permit interactions between the pro- and anti-apoptotic BCL-2 
family members65, thus it is not unlikely that proteins with undiscovered potential 
BH3-like motifs exist which could bind to a number of the BCL-2 family proteins. 
Indeed, some studies have highlighted the existence of BH3-like motifs in non-BCL-
2 family member proteins (for example SUFU324), suggesting that novel BH3-only-
like proteins could potentially be displaced from MCL-1 by BH3 mimetics to induce 
the canonical model of apoptosis.   
To explore this hypothesis, novel MCL-1 interacting proteins were explored here 
using subcellular fractionation, immunoprecipitation and mass spectrometry to 
identify novel interactions which could potentially be mediating the BH3 mimetic-
induced apoptosis seen in HCT116 8KO cells. 
5.2 MCL-1 is present as three major complexes of different molecular weights 
in multiple cell lines. 
To first explore whether MCL-1 exists as distinct complexes interacting with different 
protein subsets within the cell, gel filtration chromatography was performed to 
separate protein lysates according to molecular weight. H23 and H929 cells were lysed 
and fractionated on Superose 6 and Superdex 200 gel filtration columns, allowing for 
broad separation of protein pools from 2 megadaltons (MDa) to < 30 kilodaltons (kDa) 
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with extremely good resolution of distinct protein pools. The eluted fractions were 
mixed with loading dye and subjected to immunoblotting using antibodies raised 
against distinct epitopes of MCL-1.  
In H23 cells, MCL-1 appeared to exist in what seemed to be three major complexes 
of vastly different molecular weights (Figure 5.1A). The largest detected complex 
(termed the high molecular weight (HMW) complex) was approximately 1700-2000 
kDa in size, as marked by the red arrow beginning at the 2000 kDa molecular weight 
marker. A second complex (termed the medium molecular weight (MMW) complex) 
was detected at a lower molecular weight of around 500-700 kDa, however MCL-1 
was in fact detectable in all fractions between the 2000 kDa and 600 kDa fractions, 
albeit at varying levels. The third complex of MCL-1 was detectable at a much lower 
molecular weight (and thus termed the low molecular weight (LMW) complex) of 
around 60-150 kDa and small amounts of MCL-1 were also present, most likely as 
monomeric MCL-1, at around 30 kDa. The HMW MCL-1-containing fractions 
indicate that MCL-1 is perhaps in a large complex with many other proteins, whereas 
the LMW 150 kDa fraction is perhaps indicative of some of the known interactions of 
MCL-1, such as complexes with proteins like BIM and NOXA. The different isoforms 
of MCL-1, proposed to be linked to distinct functions of MCL-1 and observed 
typically as three bands of distinct molecular weights, varied in expression levels 
across the different fractions, with at least two of the isoforms being detectable in most 
fractions. 
Similar to the complexes observed in H23 cells, MCL-1 also appeared to exist in a 
large 2000 kDa HMW, a MMW and a LMW complex in the H929 cells (Fig 5.1B). 
The relative distribution of MCL-1 in these complexes was slightly different between 
the H23 and H929 cells however, with more MCL-1 present in the HMW complex in 
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H929 cells. Additionally, little monomeric MCL-1 was detectable in H929 cells. These 
complexes were also detectable in a panel of other cancer cell lines from different 
kinds of tumours, suggesting that the existence of MCL-1 in these complexes may be 
universal (data not shown).  
To further examine the MCL-1 complexes and determine if distinct complexes might 
be linked to distinct roles of MCL-1, pools of pro-apoptotic BCL-2 family members 
were also identified. This revealed that the two effector proteins, BAX and BAK, co-
eluted in the HMW and MMW MCL-1 complexes. BAK is a well-known interacting 
partner of MCL-1 so it is not surprising to see co-elution of BAK with the two large 
MCL-1 complexes. These interactions are likely to occur on the outer mitochondrial 
membrane since this is where the majority of BAK localises59. Meanwhile, BAX could 
be detected in multiple fractions of different molecular weights – including at the 
lowest molecular weights, indicative of monomeric BAX as previously described. 
Surprisingly, BAX could also be seen at similar levels in the MMW fractions and at 
low levels in the HMW complex, co-eluting with MCL-1. This could perhaps be 
indicative of the retrotranslocation of BAX by the BCL-2 family members – it is 
proposed that BAX cycles constantly between the mitochondria and cytosol, with 
shuttling back to the cytosol mediated, at least in part, by multiple members of the 
anti-apoptotic BCL-2 family319,321,322. 
In addition to the effector proteins, several known interacting BH3-only protein 
partners of MCL-1 also co-eluted with multiple MCL-1 complexes. BID, known to 
interact with MCL-1 in its truncated form325, was not detected co-eluting with any of 
the major MCL-1 complexes and was exclusively found at very low molecular weight 
fractions, suggesting it was predominantly monomeric. This is not surprising since 
little tBID should be present in basal conditions. Meanwhile, BIM, could be seen co-
151 
 
eluting with MCL-1 in both the HMW and MMW complexes. PUMA was only 
detectable at low levels but could also be observed co-eluting with MCL-1 in all three 
of the major MCL-1 complexes. Furthermore, NOXA, a key MCL-1 interacting 
protein and regulator, could be seen co-eluting with all three of the major MCL-1 
complexes, suggesting NOXA might be bound to most pools of MCL-1. This is not 
surprising, since NOXA is believed to play an essential role in the stability and 
turnover of MCL-1123,285. 
Overall, this suggested that all the major complexes of MCL-1 may in fact be linked 
to its anti-apoptotic activity through interactions with various BH3-only proteins. The 
interactions with BIM or BAK in the high molecular weight complexes do not account 
for the total molecular weight (for example 2 MDa) of the larger complexes however, 
suggesting that MCL-1 may be in complex with various other proteins alongside the 
BH3-only proteins, perhaps in a scaffold structure that facilitates the diverse functions 
of MCL-1. As previously mentioned, MCL-1 is believed to be linked to multiple 
functions within the cell from its obvious roles in promoting cell survival, to regulation 
of lipid metabolism and DNA repair184,326. It could therefore be envisioned that each 
major complex, while able to regulate apoptosis, might be linked to different 
subcellular localisations and therefore functions of MCL-1. Protein X, which could be 
mediating the BH3-only protein independent apoptosis in HCT116 cells, could be 
present in any of these three major complexes given their molecular weights, therefore 
exploring the complexes and their subcellular localisation further could reveal the 
pool(s) where Protein X exists. 
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Figure 5.1. MCL-1 exists in three major complexes and a monomeric form in 
MCL-1-addicted cell lines. Lysates from the MCL-1-addicted cell lines H23 (A) and 
H929 (B) were separated using gel filtration with the indicated columns and the 
fractions containing protein complexes of different molecular weights were subjected 
to immunoblotting to detect where MCL-1 and associated BCL-2 family proteins were 
present. Approximate molecular weights of fractions are indicated above the blots and 
molecular weight markers of the immunoblots to the right. Red arrows indicate the 
three major MCL-1 complexes identified. Vertical lines between immunoblots 
indicate separate gels, with Superose 6 and Superdex 200 fractions loaded over 3 
different gels. 
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5.3 MCL-1 is present in all the major subcellular fractions of HELA cells. 
MCL-1 is an important regulator of the cell, not just in anti-apoptotic roles but also in 
multiple other roles as previously described. Moreover, MCL-1 has been proposed to 
have broad subcellular localisation supporting the multi-faceted nature of its roles 
within the cell. To explore the notion of different MCL-1 pools being linked to 
different subcellular localisations, four types of HELA cell fractions, generated by 
subcellular fractionation, were probed to explore the distribution of MCL-1 
complexes. The fractions used were an ‘extranuclear’ fraction (including everything 
within the cell apart from the nucleus), a nucleus-enriched fraction (‘nuclear’), a 
cytosolic (‘S100’) fraction (named after the 100,000 x g spin used to generate it327) 
and a mitochondria-enriched fraction (‘mitochondria’). These fractions were 
purchased pre-prepared from Ipracell (Ipratech, Belgium) as generating large amounts 
of these different fractions, particularly the mitochondrial fraction, in the laboratory 
would require extremely large numbers of cells and hence, would not be cost-effective. 
To first ensure that the fractions were indeed enriched for the components described, 
each fraction was lysed in 1% CHAPS buffer and protein markers specific to each 
compartment detected to demonstrate purity. MCL-1 was also detected to identify 
where it localises. BAP31 and GM130 were used to detect the endoplasmic 
reticulum328 and Golgi apparatus329 respectively, while cytoskeletal components 
tubulin330 and vimentin331 were used as markers for the cytosol. NDUFA9 and ATPB, 
two components of the mitochondria-localised electron transport chain332,333, were 
used to detect mitochondria and poly-ADP ribose polymerase (PARP)334 was used to 
validate the nuclear fraction (Fig 5.2).  Both BAP31 and GM130 were detectable in 
the extranuclear and mitochondrial fractions, suggesting that the mitochondrial 
fractions are not exclusively mitochondria and may also contain some heavy 
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membranes from the ER and Golgi apparatus.  Meanwhile, tubulin and vimentin were 
enriched in the extranuclear and S100 fractions, with very small amounts detectable 
in the nucleus and mitochondria, indicating that the S100 fraction is indeed cytosolic 
and that the nuclear and mitochondrial fractions are not contaminated with cytosolic 
proteins. Similarly, NDUFA9 and ATPB were present in large amounts in both the 
extranuclear and mitochondrial fractions, suggesting that the mitochondrial fraction is 
indeed mitochondrially-enriched, and the nuclear and cytosolic fraction contain little 
contaminating mitochondria. Finally, PARP was detectable in the nuclear fraction and 
a small amount in the extranuclear fraction, suggesting it is a pure nuclear fraction and 
indicating that the other fractions do not contain nuclear proteins.  
MCL-1 was detectable in all of the subcellular fractions at relatively similar levels, 
although with some stark differences in the presence of the three major isoforms. In 
the extranuclear fraction, the three typical isoforms relating to the different functions 
of MCL-1 (as described previously) were identified as expected and the same was seen 
for the mitochondrial fraction. Moreover, in the extranuclear fraction the two upper 
isoforms were more dominant, whereas in the mitochondrial fraction, there was a more 
even distribution of the three isoforms, with the middle isoform being the most 
dominant. In the nuclear fraction, all three isoforms were also detectable and, while 
the two lower bands appeared at a similar molecular weight as seen for the 
extranuclear fraction, the upper band seemed to run slightly higher than in any of the 
other fractions, possibly indicative of a post-translational modification of the upper 
band required for MCL-1 to be in the nucleus. While MCL-1 has previously been 
detected in the nucleus and is proposed to play roles in regulation of DNA 
repair177,184,326, the nuclear-localised isoform(s) of MCL-1 are not well described, 
however this may shed some light on the characteristics of how MCL-1 behaves in the 
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nucleus. Further differences were detectable in the cytosolic S100 fraction, where the 
two larger bands of MCL-1 were detectable, but the lower band was not present at all, 
suggesting this isoform of MCL-1 does not function in the cytosol. Indeed, this lower 
isoform has been proposed to be localised to the mitochondria175,183, thus it is not 
surprising that it is not identifiable in the cytosol, however its presence in the nucleus 
remains a mystery. With MCL-1 present in all of the major subcellular compartments 
of the cell and in at least 3 distinct molecular weight complexes, it is not unreasonable 
to imagine that it has a vast array of binding partners, with a potential Protein X 
candidate existing in one or multiple fractions in partnership with MCL-1.  
Figure 5.2. MCL-1 isoforms are detectable in all of the major subcellular 
compartments of HELA cells. The indicated subcellular fractions were lysed and 
immunoblotting performed to detect markers of the major subcellular compartments 
alongside MCL-1. Approximate molecular weights of bands are indicated to the right 
of the immunoblots. The vimentin band identified is the lower band indicated by the 
asterisk, while the double band of PARP is likely to represent whole and cleaved 
PARP. 
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5.4 MCL-1 complexes vary in different subcellular compartments. 
Once the subcellular fractions had been validated, each one was loaded on to Superose 
6 and Superdex 200 columns as performed previously to identify MCL-1 complexes. 
Gel filtration requires a large volume of starting material in order to detect protein in 
immunoblotting and, since the mitochondrial fraction was limited in quantity and large 
volumes also required for subsequent experiments, gel filtration was not performed on 
the mitochondrial fraction. 
In the tested fractions, MCL-1 was detectable in various complexes and to different 
extents in each of the subcellular compartments (Fig 5.3). In the extranuclear lysate, 
the HMW and MMW complexes of MCL-1 (2000 kDa and 500-700 kDa) were readily 
detectable and the complex at the 150 kDa range was detectable although at lower 
levels. Little monomeric MCL-1 was detectable in the extranuclear fraction. This 
reflects the data seen previously when identifying the MCL-1 complexes and further 
confirms the existence of distinct pools of MCL-1 with dramatically different 
molecular weights.  Meanwhile in the nuclear fraction, no HMW MCL-1 complex was 
detectable, while moderate levels of the MMW and LMW complexes were observed. 
No monomeric MCL-1 was detected. This suggested that the HMW complex might 
be present outside of the nucleus, confirmed by the fact that this complex was 
detectable in the extranuclear fraction. It also suggested that monomeric MCL-1 might 
be present at low levels in HELA cells as it was not detectable here or in the 
extranuclear fraction. 
In the cytosolic fraction however, MCL-1 (especially the uppermost band) was 
detectable in almost all fractions from very high to very low molecular weight equally, 
but unlike the other subcellular compartments, only the largest isoform of MCL-1 was 
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detectable in most fractions (as suggested by the presence of the higher bands), with 
the lower band being detectable at very low levels in some cases. These results indicate 
various possibilities about the localisations of the MCL-1 complexes in each 
subcellular compartment. Firstly, the ‘missing’ HMW MCL-1 complex is likely 
present in bulk on the mitochondria and other membranous organelles, as it is 
detectable at high levels in the extranuclear fraction, moderate levels in the cytosolic 
fraction and not at all in the nuclear fraction. The second band is especially lacking in 
the nuclear and cytosolic fractions in the HMW complex, perhaps suggesting that it is 
mostly present on membranes, likely the mitochondria, where it can efficiently 
antagonise death175. Secondly, it would seem that nuclear MCL-1 is present in lower 
molecular weight complexes compared to other organelles, although it may still be 
associated with multiple proteins in the MMW complex which could be linked to the 
nuclear functions of MCL-1 and its associations with various DNA repair 
proteins177,184,335. Finally, the presence of the upper band of MCL-1 across all fractions 
in the cytosolic compartment could suggest that MCL-1 is a very versatile protein with 
many possible interacting partners in the cytosol. Monomeric MCL-1 is also readily 
detectable only in the cytosolic fraction, suggesting that perhaps some MCL-1 remains 
free in the cytosol in these cells to sequester pro-apoptotic proteins and prevent 
unwanted cell death. 
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Figure 5.3. The presence of MCL-1 complexes varies in different subcellular 
compartments of HELA cells. Subcellular fractions of HELA cells were lysed and 
separated on gel filtration columns then subjected to immunoblotting to detect MCL-
1 complexes, indicated by red arrows. Approximate molecular weights of fractions are 
indicated above the blots and molecular weight markers to the right. Red arrows 
indicate the major complexes of MCL-1 previously identified. 
 
5.5 Mass spectrometry strategies for identifying novel MCL-1 interacting 
partners. 
From the data above, it is clear that MCL-1 has a broad subcellular distribution. This, 
in combination with the multi-faceted roles of MCL-1, supports the idea of a 
potentially vast network of MCL-1-interacting proteins. Thus, it is highly likely that 
novel MCL-1 interacting partners exist which have not yet been detected and these 
interacting partners could potentially be the Protein X that was previously alluded to 
in Chapter 4. Given the data in Chapter 4, this Protein X could be bound to MCL-1 
and, in the absence of the 8 key BH3-only proteins in the HCT116 8KO cells, be 
released following exposure of the cells to BH3 mimetics (or genetic suppression of 
the pro-survival proteins), allowing BAX activation and thus inducing apoptosis. 
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To explore the MCL-1 interaction network and potentially identify a Protein X 
candidate, mass spectrometry was utilised to analyse MCL-1-interacting proteins in 
the different MCL-1 complexes and subcellular compartments. Two strategies were 
developed to isolate and explore MCL-1-interacting proteins. The first involved 
immunoprecipitation of endogenous MCL-1 from each of the major subcellular 
compartments (extranuclear, nuclear, mitochondria, cytosolic) and analysis of the 
proteins which interact with MCL-1 using mass spectrometry (Figure 5.4A). The 
second strategy was designed to isolate the three major MCL-1 complexes (as 
identified in Figure 5.1) by pooling the lysates of the different MCL-1 complex 
fractions. For example, the first major MCL-1 complex appeared in fractions 16-20 of 
the Superose 6 column. These fractions would be pooled, the endogenous MCL-1 
immunoprecipitated and the eluate studied by mass spectrometry, thus identifying the 
different interacting partners in each complex (Figure 5.4B). 
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Figure 5.4. Two approaches to isolating distinct pools of MCL-1 and its 
interacting partners for mass spectrometry analysis. (A) Endogenous MCL-1 was 
isolated from four subcellular fractions by immunoprecipitation and eluted to detect 
interacting proteins. (B) Fractions of lysates ran on gel filtration columns were pooled 
according to the major MCL-1 complexes and endogenous MCL-1 
immunoprecipitated to detect interacting proteins in immunoblotting and mass 
spectrometry. MCL-1 subcellular localisation image modified from 
https://www.genecards.org/cgi-bin/carddisp.pl?gene=MCL1 
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5.6 MCL-1 can be immunoprecipitated from different subcellular pools and its 
interacting proteins detected by Coomassie labelling. 
Prior to mass spectrometry, optimisation experiments were carried out for both the 
immunoprecipitation of MCL-1 from the different subcellular pools of MCL-1. Since 
MCL-1 had previously successfully been immunoprecipitated in Chapters 3 and 4, the 
same antibody (Abcam Y-37) was used, while minor changes were made to the normal 
immunoprecipitation protocol for mass spectrometry, as outlined in Chapter 2. To 
optimise pulldown of MCL-1 in the pre-prepared subcellular fractions, the 
extranuclear fraction was subjected to MCL-1 immunoprecipitation and the amount of 
MCL-1 immunoprecipitated detected by both immunoblotting and EZBlue 
(Coomassie) staining (Figure 5.5A). This experiment confirmed that (1) 
immunoprecipitation in the Ipratech fractions could successfully pull out MCL-1 and 
(2) MCL-1-interacting proteins could also be pulled down and detected in Coomassie 
gels, suggesting that ample peptides would be present for identification of new MCL-
1-interacting proteins in mass spectrometry. 
For the MCL-1 complex immunoprecipitation approach, a large-scale gel filtration of 
HELA cells using Superose 6 and Superdex 200 columns was performed and lysates 
pooled into the appropriate complexes for subsequent immunoprecipitation. A small 
volume of lysate was also subjected to immunoblotting to ensure that the expected 
MCL-1 complexes were present (data not shown). While multiple steps had been 
undertaken to maintain protein-protein interactions in the gel filtration, it was 
important to identify whether MCL-1 could still be immunoprecipitated from pooled 
fractions of the MCL-1 complex experiments and furthermore, whether other proteins 
were pulled with it, as seen for the subcellular immunoprecipitation optimisation. 
MCL-1 could be readily immunoprecipitated from the pooled fractions of the HMW 
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complex of MCL-1 (~2 MDa) and furthermore, a higher level of global proteins is 
detectable in the immunoprecipitation compared to the bead control of the Coomassie 
gel (Figure 5.5B), suggesting that MCL-1 interacting proteins are indeed co-
immunoprecipitating and that, therefore, this approach should yield many MCL-1 
interacting proteins in mass spectrometry.  
In addition to optimisation of the immunoprecipitation protocol, optimisation was 
carried forward to mass spectrometry. One sample from each immunoprecipitation 
strategy was subjected to mass spectrometry in order to confirm detection of peptides 
and therefore validate the approach for future studies. MCL-1 (and many other 
proteins) could be readily detected in mass spectrometry from the immunoprecipitated 
eluate of the extranuclear fraction of the subcellular approach. This was encouraging 
enough to pursue similar analysis for other subcellular fractions. However, 
preliminary optimisation studies using the HMW fractions of HELA cell lysates did 
not detect MCL-1 by mass spectrometry, therefore subsequent experiments focused 
on the subcellular compartment localisations of MCL-1 (data not shown). All mass 
spectrometry analysis was carried out by Deborah Simpson of the mass spectrometry 
facility at The Centre for Proteome Research at The University of Liverpool. 
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Figure 5.5. Immunoprecipitation of MCL-1 is effective at isolating MCL-1 and 
co-immunoprecipitated protein is detectable on Coomassie gels.  MCL-1 was 
immunoprecipitated from either (A) the extranuclear subcellular fraction of HELA 
cells or (B) pooled FPLC fractions of the HMW complex of HELA cells and two gels 
ran – one to detect MCL-1 by immunoblotting and one to detect global protein 
pulldown using a Coomassie dye. Immunoprecipitation (IP) samples were compared 
to a bead control (BC) to ensure no non-specific pulldown was occurring and flow-
through (FT) ran on gels to show immunoprecipitation efficiency. Approximate 
molecular weights are indicated to the right of the immunoblots. The box on the whole 
protein gels highlights where the most protein was detectable. 
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5.7 Many proteins co-immunoprecipitate with MCL-1 in the extranuclear 
fraction of HELA cells. 
To identify the proteins which interact with MCL-1 and potentially identify candidates 
for Protein X, eluates from MCL-1 immunoprecipitations in the different subcellular 
fractions were submitted, alongside bead controls, to the mass spectrometry facility at 
The Centre for Proteome Research at The University of Liverpool. Three replicates 
were submitted for each individual sample. The resulting data was returned as a list of 
identified peptides, along with other information including the peptide counts (the 
number of times a particular peptide was detected, along with unique peptides for a 
particular protein), confidence scores of each individual protein, p values for 
significance over three replicates and q values – an adjusted p value to incorporate a 
false detection rate due to the high peptide numbers found. Maximum fold changes 
that highlight the difference in the levels of immunoprecipitated peptides compared to 
the bead control were also included. 
In the case of the extranuclear lysate, a staggering number (>800) of peptides were 
identified (Table 5.1). Encouragingly, MCL-1 was identified in the peptide list as a 
reliable hit – found to be 33-fold higher in the immunoprecipitation than the bead 
control with a peptide count of 12 and a unique peptide count of 10. This suggested 
that the pulldown was effective and reliable. Moreover, to further support the efficacy 
of the immunoprecipitation, several known MCL-1-interacting partners were also 
identified with high confidence, including BIM (205-fold higher in the 
immunoprecipitation versus bead control) and NOXA (181-fold higher in 
immunoprecipitation versus bead control). A full list of proteins identified in the 
extranuclear fraction is available in Supplementary Table 5.1. 
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Due to the nature of immunoprecipitation and mass spectrometry analysis, it was 
proposed that many of the peptides identified may have appeared as false-positives, 
partly owing to the ‘sticky’ nature of many proteins. Thus, in order to isolate 
significant hits and better identify true potential MCL-1 interacting partners, multiple 
stringent triages were performed. The first filter applied to the peptide list excluded 
any peptides which appeared to be higher in the bead control samples compared to the 
immunoprecipitation samples which would indicate non-specific binding to the beads. 
Subsequently, only proteins with two or more spectral counts (meaning they were 
detected at least twice) were considered. Next, the peptide list was compared to the 
CRAPome (http://crapome.org/) - an online protein database which has data from over 
400 mass spectrometry experiments336. Comparing the peptide lists generated from 
immunoprecipitation of MCL-1 to a repository of mass spectrometry peptide lists 
allowed identification of proteins which are repeatedly found in mass spectrometry 
analyses and are, therefore, likely to be contaminating proteins which are not actually 
proteins of interest. Using a cut-off of 10%, meaning that only peptides which occurred 
in less than 10% of mass spectrometry experiments in the CRAPome database were 
accepted, the peptide list was reduced from 598 to 203. The cut-off point of 10% 
CRAPome frequency was utilised following successful identification of a novel MCL-
1 interacting partner in similar experiments performed previously183 and further 
stringent filters applied in this article were also applied to the data here. Of the proteins 
remaining following CRAPome analysis, only those with a 5-fold change in the 
immunoprecipitation versus bead control were accepted, further reducing the list to 
198. Finally, only proteins with a q value, which incorporates a false discovery rate in 
experiments with large volumes of data, were included, leaving 196 proteins identified 
in the extranuclear fraction in total. 
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Table 5.1.  Many MCL-1 interacting proteins are detectable in the extranuclear 
fraction of HELA cells. Analysis of the eluate of an MCL-1 immunoprecipitation in 
the extranuclear fraction of HELA cells yielded 813 protein hits in total. The protein 
list was reduced to 196 by a series of triages as indicated in the table.  
 
 
 
 
 
 
 
 
 
Since the list of candidate proteins was still extensive even after removing many non-
specific hits, the peptide list was subjected to a pathway analysis using the Reactome 
(https://reactome.org/) - an online tool which groups proteins based on major cellular 
functions337. This analysis revealed that MCL-1 may play a role in, or at least be linked 
to, many different aspects of cellular activity through its interacting partners, from 
protein and lipid metabolism to the cell cycle and membrane trafficking (Figure 5.6). 
Indeed, as described earlier, MCL-1 is known to function in more than just the 
apoptotic pathway. For example, MCL-1 was recently linked to lipid metabolism 
through an interaction with VLCAD183. Furthermore, MCL-1 is believed to have a 
Fraction:  Extranuclear Peptides 
Total proteins identified 813 
Maximum fold change > 2 812 
> 2 spectral counts 598 
< 10% CRAPome frequency 203 
> 5-fold change IP vs BC 198 
< 0.02 FDR/q value 196 
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regulatory role in the cell cycle through its interaction with CDK1177. Many of the 
major pathways enriched in extranuclear mass spectrometry analysis are linked to the 
mitochondria or are mitochondrially-localised, such as the citric acid cycle, fatty acid 
metabolism and mitochondrial biogenesis. Since key roles for MCL-1 at the 
mitochondria in apoptosis have been demonstrated, this data could suggest that MCL-
1 may in fact be responsible for regulation of much more mitochondrial activity than 
currently known. Indeed, some reports have linked MCL-1 and mitochondrial 
oxidative phosphorylation and dynamics, showing that MCL-1 is critical to the 
dynamics of the mitochondria and ATP production, amongst other functions175,338. 
Thus, MCL-1 may have a range of mitochondrial roles, some of which it may exert 
via the proteins enriched in the pathways identified here. 
Since the focus of this study was on the role of MCL-1 in apoptosis, the proteins 
identified in cell death pathways by the Reactome analysis were of particular interest. 
These four proteins were BIM, NOXA, STAT3 and NMT1. As BH3-only proteins, it 
is already well known that BIM and NOXA interact with MCL-1194,339 (also shown in 
Chapter 3). These two proteins were therefore not of interest as a Protein X, since they 
are (1) known BH3-only proteins and (2) already knocked out in the HCT116 8KO 
cells therefore could not mediate the apoptosis in these cells.  
Meanwhile, the transcription factor, STAT3 has also previously been linked to MCL-
1. It has been suggested that STAT3 can upregulate the transcription of MCL-1168,340, 
thereby promoting cell survival. STAT3 has also been shown to directly interact with 
MCL-1 in MCF-7 cells and this interaction is proposed to alter the epithelial-
mesenchymal transition by increasing apoptosis341. Since it is believed that the 
association of MCL-1 and STAT3 increases apoptosis, it is an unlikely candidate for 
a Protein X, which would in theory be displaced from MCL-1 following exposure of 
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a cell to BH3 mimetics to then activate BAX. Finally, N-myristoyltransferase-1 
(NMT1) regulates the addition of fatty acid myristate groups to a protein as a post-
translational modification. While no direct links between MCL-1 and NMT-1 exist, it 
has been predicted that MCL-1 is an extremely likely candidate for myristoylation due 
to the domains it contains and that this could promote the caspase cleavage of MCL-
1, leading to apoptosis342. Other work has shown that NMT1 can also negatively 
regulate apoptosis however – downregulation of NMT1 can lead to increased 
apoptosis343. While many interesting MCL-1 interacting candidates were identified in 
this fraction, the four proteins identified that have been linked to apoptosis did not 
represent hits that we wanted to pursue in this study. Of course, this is not to say that 
many of the interactions could be validated and later linked to apoptosis or perhaps 
other functions of MCL-1. However, for an initial study, it was decided that only 
proteins with prior links to apoptosis would be focused on. 
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Figure 5.6. Candidates for MCL-1 interacting partners are wide-ranged in 
function in the extranuclear subcellular fraction of HELA cells. Filtered peptide 
lists from mass spectrometry analysis of an MCL-1 pulldown in the extranuclear lysate 
of HELA cells were grouped in a pathway analysis using the Reactome online 
database, revealing the major potential subcellular roles that MCL-1 may be linked to 
through its various interacting proteins. 
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5.8 Only MCL-1 can be identified as a significantly pulled-down protein in the 
nuclear fraction of HELA cells. 
While many potential MCL-1-interacting proteins and Protein X candidates were 
revealed in the extranuclear lysate fraction, considerably fewer proteins were 
identified in the nuclear fraction. The exact same process was carried out for the 
immunoprecipitation and mass spectrometry experiments in the nuclear subcellular 
fractions as performed for the extranuclear fraction and the same parameters applied 
to the resulting peptides during triage and analysis (Table 5.2). 
160 proteins were identified overall in the nuclear fraction as potential MCL-1-
interacting partners, however this list was reduced to 31 following exclusion of 
proteins with a fold change of < 2 in the immunoprecipitation versus the bead control. 
Once processed by the CRAPome, only 3 proteins remained: MCL-1, 
Methyltransferase-Like 3 (METTL3) and SP100. Subsequent triage, however, meant 
that the only protein identified in the nuclear fraction which could be considered 
significant was MCL-1 itself. While this did confirm that the pulldown of MCL-1 was 
effective and that the approach was valid, the lack of significantly co-
immunoprecipitated proteins suggested that MCL-1 does not have many, if any, 
nuclear-localised interaction partners in HELA cells under basal conditions. 
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Table 5.2. – No candidate MCL-1 interacting partners were identified in the 
analysis of the nuclear extract of HELA cells. Analysis of the eluate of an MCL-1 
immunoprecipitation in the nuclear fraction of HELA cells yielded 160 proteins in 
total. The protein list was reduced to 1 by a series of triages as indicated in the table. 
 
Fraction: Nuclear Peptides 
Total proteins identified 160 
Maximum fold change > 2 31 
> 2 spectral counts 19 
 < 10% CRAPome frequency 3 
> 5-fold change IP vs BC 3 
< 0.02 FDR/q value 1 
 
 
5.9 The cytosol contains a small number of candidates for novel MCL-1-
interacting proteins in HELA cells. 
For the cytosolic S100 fraction, mass spectrometry and analysis of the resulting 
peptides were carried out as done for the previous fractions. Like the nucleus, the 
cytosolic fraction yielded considerably fewer potential MCL-1-interacting proteins 
compared to the extranuclear fraction (Table 5.3) 
Initially, 156 proteins were revealed as potential interacting partners of MCL-1, which 
was reduced to 154 following exclusion of peptides with a fold change of < 2. 
Removing proteins which were only identified by a single peptide further reduced the 
number to 125, while analysis of the peptide list using the CRAPome database left just 
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23 proteins, including MCL-1. Further triage (as previously performed and indicated 
in Table 5.3) reduced the final list of cytosolic MCL-1-interacting candidates to just 5 
proteins which are described in Supplementary Table 5.3. None of these proteins had 
been previously linked to MCL-1 although some may play a role in regulation of the 
cell cycle (AURKA344) and the autophagic response (TFEB345), both of which are 
closely associated with apoptosis. No known MCL-1 interacting proteins were 
identified in the cytosolic fraction, suggesting that, despite MCL-1 being present in 
the cytosol, the interactions of MCL-1 with known BCL-2 family members (such as 
BIM and NOXA) may occur on membranes, particularly the mitochondrial membrane. 
 
Table 5.3 – Few proteins are detectable as candidate novel MCL-1 interacting 
partners in the cytosolic fraction of HELA cells. Analysis of the eluate of an MCL-
1 immunoprecipitation in the cytosolic fraction of HELA cells yielded 156 proteins in 
total. The protein list was reduced to 5 by a series of triages as indicated in the table.  
 
 
 
 
 
 
 
 
Fraction: Cytosol Peptides 
Total proteins identified 156 
Maximum fold change > 2 154 
> 2 spectral counts 125 
 < 10% CRAPome frequency 23 
> 5-fold change IP vs BC 16 
< 0.02 FDR/q value 5 
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5.10 Many potential MCL-1 interacting proteins can be identified from the 
mitochondrially-enriched fraction of HELA cells. 
While few MCL-1-interacting proteins were reliably identified in the cytosolic and 
nuclear fraction mass spectrometry analysis, a strikingly vast number was found in the 
mitochondrially enriched fraction, which may come as no surprise, since large 
amounts of MCL-1 are found at the mitochondria, linked to both its apoptotic and non-
apoptotic roles  
Overall, exactly 1000 proteins were identified in the mass spectrometry, reduced to 
998 following selection of peptides with at least a 2-fold change in the 
immunoprecipitation versus bead control and furthermore to 668 by removing proteins 
identified by a single peptide. Subsequent CRAPome analysis (again, with a cut-off 
of 10% frequency), left 315 proteins, while looking at only proteins with a minimum 
of a 5-fold change left 308. Finally, considering only the proteins with a q value of 
<0.02 left 296 potential MCL-1 interacting proteins, which was evidently still an 
enormous number of proteins to assess (Table 5.4). MCL-1 itself was readily 
detectable while several known MCL-1 interacting proteins, including BID325 and 
DAD1346 were also identified, giving confidence to the immunoprecipitation. A full 
list of the proteins identified is available in Supplementary Figure 5.4. 
To functionally group proteins, pathway analysis was performed using the Reactome 
(Fig. 5.7). Proteins were grouped similarly to that seen previously for the extranuclear 
lysate analysis – protein and lipid metabolism were enriched pathways while 
membrane trafficking proteins and signal transduction proteins were also enriched. 
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Table 5.4 – Many proteins are detectable as possible novel MCL-1 interacting 
partners in the mitochondrial fraction of HELA cells. Analysis of the eluate of an 
MCL-1 immunoprecipitation in the mitochondrial fraction of HELA cells yielded an 
enormous 1000 proteins in total. The protein list was reduced to 296 by a series of 
triages as indicated in the table.  
 
 
 
 
 
 
 
 
In the pathway analysis, four proteins (plus MCL-1) which had previously been linked 
to apoptosis were identified: BID, STAT3, DRP-1 (also known as DNM1L) and 
BAP31 (also known as BCAP31). BID is a BH3-only protein, known MCL-1 
interacting partner325 and furthermore, knocked out in the HCT116 8KO cells and 
therefore was disregarded as a Protein X candidate. Furthermore, as previously 
discussed, STAT3 is a transcriptional regulator and known interacting partner of 
MCL-1. This left BAP31 and DRP-1 as two potential candidate MCL-1 interacting 
partners/Protein X with prior links to apoptosis. 
DRP-1 is the major regulator of mitochondrial fission and was proposed to be a curious 
potential MCL-1-interacting partner and Protein X candidate for multiple reasons: (1) 
mitochondrial fission and DRP-1 are known to be important to apoptosis347 (2) MCL-
Fraction: Mitochondria Peptides 
Total proteins identified 1000 
Maximum fold change > 2 998 
> 2 spectral counts 668 
 < 10% CRAPome 
frequency 
315 
> 5-fold change IP vs BC 308 
< 0.02 FDR/q value 296 
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1-mediated regulation of mitochondrial dynamics has been linked to apoptosis338 and 
(3) DRP-1 is known to associate with BAX348. Thus, DRP-1 has strong prior links to 
apoptosis and regulation of mitochondrial integrity. Meanwhile, BAP31, an 
endoplasmic reticulum-localised protein, also presented a potentially interesting hit, 
especially as it has been shown to form a complex with BCL-2/BCL-XL and pro-
caspase-8 that, during FAS-induced apoptotic signalling, can be cleaved and then 
induce apoptosis, possibly by further regulation of caspase-8349,350. Further studies 
have suggested that BAP31 mediates ER-mitochondria cross-talk during apoptosis 
and also provides feedback during ER-stress351. Thus, both DRP-1 and BAP31 have 
strong links to apoptosis and could be envisioned as MCL-1-interacting proteins which 
might get displaced following BH3 mimetic exposure to mediate apoptosis in the 
absence of the 8 key BH3-only proteins. 
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Figure 5.7. Candidates for MCL-1 interacting partners are wide-ranged in 
function in the mitochondrial fraction of HELA cells. Filtered peptide lists from 
mass spectrometry analysis of an MCL-1 pulldown in a mitochondria-enriched 
fraction of HELA cells were grouped following a pathway analysis using the 
Reactome, revealing further potential subcellular roles that MCL-1 may be linked to 
through its various interacting proteins. 
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5.11 Validation of the MCL-1-DRP-1 and MCL-1-BAP31 interactions. 
As described above, the two most enticing novel MCL-1-interacting partners and 
Protein X candidates were BAP31 and DRP-1. In order to validate the interactions 
observed in mass spectrometry between MCL-1 and DRP-1/BAP31, MCL-1 was 
immunoprecipitated in H1299 cells and the eluate subsequently subjected to 
immunoblotting to detect MCL-1, BAP31 and DRP-1 (Fig. 5.8). 
MCL-1 was pulled very efficiently, as demonstrated by the large amount of MCL-1 
present in the MCL-1 immunoprecipitation lane compared to the bead control and 
furthermore, by the lack of MCL-1 in the immunoprecipitation flow-through. Both 
DRP-1 and BAP31 appeared to co-immunopreciptate with MCL-1 as shown in the 
immunoprecipitation lanes for each protein, validating the interactions identified in 
mass spectrometry. The amount of DRP-1 and BAP31 pulled appeared to be 
significant, however the amount of DRP-1 and BAP31 remaining in the flow-through 
is relatively high compared to the bead control flow-through, suggesting that there are 
other pools of these proteins which MCL-1 is not bound to. Nevertheless, both 
interactions with MCL-1 were validated, confirming both BAP31 and DRP-1 as novel 
MCL-1 interacting proteins and potential Protein X candidates. 
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Figure 5.8. MCL-1 interacts with both DRP-1 and BAP31. MCL-1 was 
immunoprecipitated in H1299 cells and the eluate subjected to immunoblotting to 
detect interactions with DRP-1 and BAP31. Input represents whole cell lysate, BC 
represents bead control, IP indicates immunoprecipitation, FT BC represents the bead 
control flow-through, FT IP represents the IP flow-through. Approximate molecular 
weights of bands are indicated to the right of the immunoblots. 
 
5.12 BAP31 is not required for BH3 mimetic-induced apoptosis in H1299 cells. 
It was demonstrated that BAP31 can bind to MCL-1, however the functional 
consequences of this interaction and whether BAP31 might be a Protein X, along with 
its potential role in BH3 mimetic-induced apoptosis, remained unclear. In order to 
explore the function of the MCL-1-BAP31 interaction in this context, BAP31 was 
knocked down in H1299 cells using RNA interference and the cells exposed to a 
combination of S63845 and A-1331852. Assessment of the extent of apoptosis 
revealed that knockdown of BAP31 alone induced a very slight increase in apoptosis, 
increasing ~10% compared to the control siRNA (Fig. 5.9). Knockdown of BAP31 
179 
 
under BH3 mimetic conditions did not alter the levels of apoptosis, however, with 
similar levels of apoptosis observed between control and BAP31 siRNA conditions 
following S63845 and A-1331852 treatment. If BAP31 was to function like a Protein 
X, a decrease in apoptosis following BH3 mimetic exposure would be expected when 
BAP31 was removed – as is the case following depletion of BH3-only proteins352–354. 
Thus, this suggested that BAP31 does not play a role in BH3 mimetic-induced 
apoptosis in H1299 cells, further implying that it may not be the anticipated Protein 
X. The interaction between MCL-1 and BAP31 is of great interest, however. BAP31 
is an ER resident protein328 and has been suggested to contain a BH3-like motif and 
interact with other BCL-2 family members under particular conditions349,350. With the 
growing connections between the mitochondria and endoplasmic reticulum during 
apoptosis355, future exploration of this interaction might reveal some very exciting 
results about ER-mitochondria junctions, as well as a role for MCL-1 in mediating this 
cellular function. 
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Figure 5.9. BAP31 does not appear to play a significant role in mediating BH3 
mimetic induced apoptosis in H1299 cells. (A) H1299 cells were incubated with 
either a control siRNA or siRNA against BAP31 for 72 h then treated with 100 nM 
each of both S63845 and A-1331852 for 4 h before being collected for assessment of 
apoptosis by PS externalisation in flow cytometry. (B) Knockdown of BAP31 was 
validated by immunoblotting with GAPDH as a loading control. Error bars = Mean ± 
SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
 
5.13 DRP-1 is required for BH3 mimetic-induced apoptosis in H1299 cells. 
The DRP-1-MCL-1 interaction was explored further in the same way as the MCL-1-
BAP31 interaction but yielded very different results. Again, in theory, removing DRP-
1 from the cell should function like removal of a BH3-only protein - if DRP-1 
functions as a Protein X, this would result in abrogated levels of apoptosis following 
BH3 mimetics. As mentioned in the mass spectrometry results, previous studies have 
already linked DRP-1 to apoptosis. Early work demonstrated that DRP-1 can 
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translocate from the cytosol to the mitochondria to induce mitochondrial fission during 
apoptosis and furthermore, inhibition of DRP-1 activity abrogates cytochrome c 
release induced by staurosporine356. This effect could not be overcome by 
overexpression of BAX, suggesting that DRP-1 performs a function that is essential 
to apoptosis356. The role for DRP-1 in apoptosis is extremely complex and somewhat 
controversial however, as it has also been shown that inhibition of DRP-1-mediated 
mitochondrial fragmentation does not completely block apoptosis - instead it causes a 
delay of cytochrome c release via modulation of OPA1 activity357. Further adding to 
the complexity of DRP-1 in apoptosis, other studies have shown that inhibiting DRP-
1 can sometimes enhance apoptosis358.  In support of an interaction between MCL-1 
and DRP-1, during the preparation of this study, it was shown that MCL-1 can interact 
with DRP-1 in multiple reports in both apoptotic and non-apoptotic scenarios182,338. 
The studies suggested that MCL-1 interacts with DRP-1 in order to regulate 
mitochondrial dynamics, with MCL-1 potentially functioning as a scaffold on the 
mitochondrial membrane for DRP-1 translocation in both cancer cells and stem 
cells182,338. Thus, DRP-1 is clearly an important interacting partner of MCL-1, 
affirming its potential as a Protein X that may be able to induce apoptosis in the 
absence of the major BH3-only proteins. 
To explore the MCL-1/DRP-1 functional axis in apoptosis, DRP-1 was knocked down 
in H1299 cells for 72 h and the cells were subsequently exposed to either DMSO or 
S63845 and A-1331852 (both at 100 nM) for 4 h (Figure 5.10A). The combination of 
S63845 and A-1331852 resulted in ~65% apoptosis in the control siRNA cells 
compared to the DMSO control with less than 10% apoptotic cells. Knockdown of 
DRP-1 alone did not induce significant apoptosis in the H1299 cells and remarkably, 
knockdown of DRP-1 in combination with the BH3 mimetics could partially reduce 
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apoptosis, with ~35% of cells undergoing apoptosis in the combination treatment. This 
suggested that DRP-1 is required for BH3 mimetic induced apoptosis in H1299 cells 
and could therefore potentially function like a Protein X. Knockdown of DRP-1 was 
validated in both control and treated conditions, demonstrating complete loss of DRP-
1 in both cases (Figure 5.10B). 
 
 
 
Figure 5.10 Knockdown of DRP-1 partially rescues BH3 mimetic-induced 
apoptosis in H1299 cells. (A) H1299 cells were incubated with either a control siRNA 
or siRNA against DRP-1 for 72 h then treated with 100 nM each of S63845 and A-
1331852 for 4 h before being collected for assessment of apoptosis by PS 
externalisation in flow cytometry. (B) Knockdown of DRP-1 was validated by 
immunoblotting with GAPDH used as a loading control. Error bars = Mean ± SEM; 
*p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
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5.14 DRP-1 co-elutes with MCL-1 and re-distributes to high molecular weight 
fractions following exposure to BH3 mimetics. 
To further explore the interaction between MCL-1 and DRP-1 and assess which of the 
previously identified MCL-1 complexes contain DRP-1, H1299 cells were exposed to 
BH3 mimetics, lysed and fractionated using Superose 6 and Superdex 200 FPLC 
columns. MCL-1 appeared in its expected fractions (HMW, MMW, LMW), while 
DRP-1 seemed to elute between 150-600 kDa, suggesting the DRP-1 identified bound 
to MCL-1 in the mass spectrometry and immunoprecipitation may be linked to the 
LMW MCL-1 complex under control conditions (Fig 5.11). When treated with the 
MCL-1 inhibitor A-1210477 however, the distribution of both MCL-1 and DRP-1 was 
vastly different. Considerably less MCL-1 was detected in the HMW complex, while 
virtually no MCL-1 was detected in the two lower molecular weight complexes. 
Instead, a large amount of very low molecular weight, possibly monomeric MCL-1 
was detected. While MCL-1 became less distributed following exposure to an MCL-
1 inhibitor, DRP-1 became more widely distributed across the different molecular 
weight fractions, with a large portion of DRP-1 apparently shifting to where the HMW 
2 MDa complex of MCL-1 can typically be found. This could suggest that following 
BH3 mimetic treatment, MCL-1 and DRP-1 dissociate and DRP-1 oligomerises in a 
HMW complex to mediate death and perhaps, activate BAX. Indeed, DRP-1 has 
previously been shown to facilitate BAX translocation to/oligomerisation at the 
mitochondria during apoptosis348,359,360, supporting a role for DRP-1 in mediating 
aspects of BAX forming pores in the mitochondrial membrane during apoptosis. It is 
also known that DRP-1 forms high molecular weight oligomers during mitochondrial 
fission as it forms rings to constrict the mitochondria361, therefore, it could be 
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envisaged that the HMW fraction of DRP-1 detected following exposure to A-
1210477 is indicative of these oligomers and thus, mitochondrial fission.  
 
 
 
Figure 5.11. MCL-1 shifts to a low molecular weight and DRP-1 to a high 
molecular weight following treatment with an MCL-1 inhibitor. H1299 cells were 
exposed to DMSO or 10 µM A-1210477 for 4 h and cells lysed and ran on Superose 
6 and Superdex 200 FPLC columns. Collected fractions were subjected to 
immunoblotting to detect MCL-1 and DRP-1. Approximate molecular weights of 
fractions are indicated above the blots and molecular weight markers of bands are 
indicated to the right. Red arrows indicate the 3 major MCL-1 complexes identified. 
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5.15 Inhibition of MCL-1 enhances DRP-1-mediated mitochondrial fission. 
The previous data suggested that following inhibition of MCL-1 by BH3 mimetics, 
DRP-1 moves to a HMW complex, perhaps indicating that DRP-1 is forming an 
oligomer. It is well known that oligomers of DRP-1 form a constrictive ring around 
the mitochondria during mitochondrial fission361. Interestingly, previous studies have 
alluded to MCL-1 having a role in regulating mitochondrial dynamics and 
bioenergetics309,338.  Furthermore, putative inhibitors of MCL-1 have been shown to 
induce extensive mitochondrial fission294,362,363. Therefore, it could be suggested that 
the interaction between MCL-1 and DRP-1 is one way by which MCL-1 could be 
involved in mitochondrial dynamics. In order to test this hypothesis, H1299 cells were 
plated on coverslips and DRP-1 knocked down using RNAi. The cells were then 
exposed to A-1210477, fixed and labelled with a HSP60 antibody (a mitochondrial 
marker294) to assess the state of the mitochondrial network. As expected, under control 
conditions, the mitochondrial network was highly filamentous, while A-1210477 
induced extensive mitochondrial fission, as shown by the punctate appearance of the 
mitochondrial network in the treated cells (Fig. 5.12A). Knockdown of DRP-1 alone 
resulted in a hyperfilamentous mitochondrial network and, remarkably, the 
mitochondrial fission seen following MCL-1 inhibition was significantly prevented 
with a DRP-1 knockdown, suggesting that the BH3 mimetic-induced mitochondrial 
fission is DRP-1-dependent. Quantification of the extent of fission revealed that the 
knockdown of DRP-1 almost completely diminished fission induced by the inhibition 
of MCL-1, with the extent of fission dropping from ~95% to less than 20% following 
DRP-1 knockdown (Figure 5.12B).  
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Figure 5.12. Inhibition of MCL-1 induces mitochondrial fission in a DRP-1 
dependent manner. (A) H1299 cells were grown on coverslips in the presence of 
either a control siRNA or DRP-1 siRNA for 72 h and subsequently treated with 10 
µM A-1210477 for 2 h and mitochondrial structure assessed by labelling of cells with 
HSP60. (B) The extent of fission or rescue in cells was assessed by counting the 
number of cells with mitochondrial fission over 3 independent replicates. (C) 
Knockdown of DRP-1 was assessed by immunoblotting. Approximate molecular 
weight markers of bands are indicated to the right of the blots. 
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5.16 DRP-1 contains a BH3-like motif but the MCL-1-DRP-1 interaction does 
not appear to occur via the BH3-motif. 
Previous data has demonstrated that (1) MCL-1 interacts with DRP-1 and (2) DRP-1 
moves to a HMW complex, away from its co-elution with MCL-1, following exposure 
to the MCL-1 inhibitor A-1210477. This suggested that A-1210477 facilitated the 
disruption of the MCL-1/DRP-1 interaction, and the subsequent release and 
oligomerisation of DRP-1, thus placing DRP-1 as a potential candidate for Protein X. 
For DRP-1 to function like a BH3-only protein, it would be assumed that it may 
contain a domain or motif which is structurally similar to the BH3 motif, which would 
allow it to heterodimerise with MCL-1 and perhaps other BCL-2 family proteins. 
Thus, the DRP-1 protein sequence was analysed to identify any regions which might 
indicate a potential BH3 motif and the sequence compared to that of the known BH3-
only proteins, PUMA and NOXA. Indeed, sequence alignment revealed that DRP-1 
appears to contain region resembling a BH3 motif (Figure 5.13A), with a conserved 
glutamine residue, a conserved hydrophobic residue (isoleucine) and conserved basic 
residues (arginine and lysine). As previously described, the BH3 motif is highly 
flexible in which amino acids it may contain and there is even sequence variation 
between isoforms of the same protein (for example PUMA, as shown in Figure 5.13A) 
therefore the variability in the sequence of DRP-1 compared to the other BH3-only 
proteins is not surprising. Thus, the presence of these distinct amino acids with 
hydrophobic and basic properties suggests this domain may indeed be a BH3-like 
motif and therefore, MCL-1 and DRP-1 could interact via this motif. 
To further explore whether DRP-1 and MCL-1 interact in a BH3-dependent manner, 
immunoprecipitation of MCL-1 was performed, as previously described (Fig. 5.8), 
using both control and A-1210477-treated H1299 cells. DRP-1 could clearly be seen 
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co-immunoprecipitating with MCL-1 in the control fraction, while the activity of A-
1210477 was confirmed by stabilisation of MCL-1 in the treated samples (Fig. 5.13B). 
Surprisingly however, exposure of cells to A-1210477 did not result in decreased 
MCL-1/DRP-1 interaction as expected. Instead, it appeared that more DRP-1 was 
detectable bound to MCL-1 following A-1210477 treatment, though this could be a 
result of more MCL-1 being pulled due to its stabilisation. Thus, DRP-1 and MCL-1 
do not dissociate following inhibition of MCL-1 with a BH3 mimetic, at least not in 
the context of an immunoprecipitation. While this may argue against DRP-1 being the 
Protein X candidate, it is evident from the previous data that DRP-1 and MCL-1 
interact and that this interaction might change under conditions of BH3 mimetics, 
which may potentially affect mitochondrial fission and/or apoptosis. Therefore, it is 
quite possible that DRP-1 and MCL-1 interact with each other in a highly dynamic 
manner, which could make it difficult to detect their dependence on BH3 motifs for 
such an interaction, at least using current techniques. Alternatively, it could also be 
proposed that MCL-1 and DRP-1 interact via a motif distinct of this proposed BH3 
motif. 
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Figure 5.13. DRP-1 contains a BH3-like motif but the MCL-1-DRP-1 interaction 
occurs in a BH3-independent manner. (A) Sequence alignment of a BH3-like motif 
in DRP-1 compared to the BH3 motifs of known BH3-only proteins. Orange indicates 
conserved glutamine residues, yellow indicates a conserved hydrophobic residue and 
green, conserved basic residues. (B) MCL-1 was immunoprecipitated in H1299 
exposed to 10 µM A-1210477 for 4 h and the eluate subjected to immunoblotting to 
detect DRP-1. Input represents whole cell lysate, BC represents bead control, IP 
indicates immunoprecipitation, FT represents flow-through. Approximate molecular 
weights are indicated to the right of the immunoblots.  
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5.17 DRP-1 plays a very different role in BH3 mimetic-induced apoptosis in 
HCT116 cells. 
DRP-1 is required in H1299 cells for apoptosis, suggesting it could potentially behave, 
in part, like a BH3-only protein, though its potential as a Protein X as alluded to 
previously remained unclear. While DRP-1 appears to contain a BH3-like domain, it 
seemed that the interaction between MCL-1 and DRP-1, surprisingly, does not occur 
via the BH3 regions, as the BH3 mimetic A-1210477 could not displace DRP-1 from 
MCL-1. Regardless of this, to assess if DRP-1 could still be a potential candidate for 
Protein X, HCT116 WT and 8KO cells were incubated with a control or DRP-1 siRNA 
then exposed to a combination of S63845 and A-1331852 for 4 h and apoptosis 
assessed by PS externalisation in flow cytometry. The rationale behind this study was 
that DRP-1 would still interact with MCL-1 in the 8KO cells and could therefore drive 
apoptosis following BH3 mimetics in these cells, even in the absence of all 8 BH3-
only proteins. In other words, silencing of DRP-1 should technically abolish BH3 
mimetic-induced apoptosis in the 8KO cells, similar to the results previously observed 
in H1299 cells.  
In HCT116 WT cells, S63845 and A-1331852 induced ~75% apoptosis as expected, 
with basal death ~10% (Figure 5.14A). Remarkably, knockdown of DRP-1 
exacerbated cell death and could even induce apoptosis alone (~60% apoptosis), which 
was significantly enhanced to ~90% death when these cells were further exposed to a 
combination of S63845 and A-1331852. This is in direct contrast with what was seen 
for H1299 cells and other studies, where knockdown of DRP-1 protected cells from 
BH3 mimetic-induced death. Similar results were observed in the HCT116 8KO cells 
(Figure 5.14B). Again, as expected, a combination of S63845 and A-1331852 induced 
significant death of ~65% under control siRNA conditions, compared to less than 10% 
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in the DMSO treated cells. Knockdown of DRP-1 alone in the HCT116 8KO also 
induced significant apoptosis of almost 40%, although remarkably this was much 
lower than that seen in the HCT116 WT cells, suggesting that the siDRP-1-induced 
death may be somewhat dependent on the BH3-only proteins in the HCT116 cells. 
When knockdown of DRP-1 was combined with S63845 and A-1331852 however, 
apoptosis exceeded 80% in the 8KO cells, reflecting the results seen in the HCT116 
WT cells, suggesting that the requirement of the BH3-only proteins for DRP-1-
induced death is overcome when MCL-1 and BCL-XL are inhibited. Knockdown 
efficiency of DRP-1 was confirmed by immunoblotting and showed that almost all 
DRP-1 was knocked down in both cell lines (Figure 5.14C and D). This data, taken 
together with previous data, suggested that DRP-1 is not a likely Protein X candidate 
and is, instead, critical for survival in the HCT116 cells. 
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Figure 5.14 Loss of DRP-1 induces apoptosis in HCT116 cells. (A) HCT116 WT 
and (B) 8KO cells were incubated with either control or DRP-1 siRNA for 72 h then 
exposed to DMSO or a combination of 100 nM S63845 and A-1331852 for 4 h before 
being collected for assessment of apoptosis by PS externalisation in flow cytometry. 
(C, D) Knockdown of DRP-1 was validated by immunoblotting with GAPDH as a 
loading control. Error bars = Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. 
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5.18 Apoptosis induced by DRP-1 downregulation is BAX-dependent. 
It was previously established in Chapter 4 and in other studies that HCT116 cells rely 
on BAX and not BAK for apoptosis310. Since depletion of DRP-1 could induce 
apoptosis in both HCT116 WT and 8KO cells (Fig 5.14) and since BAX and DRP-1 
have previously been linked348,359,360, it was asked whether apoptosis induced by DRP-
1 downregulation requires BAX. For this, HCT116 BAX-/- and HCT116 DKO 
(lacking BAX and BAK) were incubated with a control or DRP-1 siRNA for 72 h then 
exposed to S63845 and A-1331852 (both at 100 nM) and analysed for apoptosis 
(Figure 5.15A). In the absence of BAX, it was clear that neither BH3 mimetics nor the 
DRP-1 siRNA could induce significant apoptosis in these cells (Figures 5.15A and C), 
though a slight increase in apoptosis was seen in the BAX-/- cells following 
knockdown of DRP-1. This may suggest that knockdown of DRP-1 was inducing low 
levels of BAX-independent, non-specific death. Knockdown efficiency of DRP-1 was 
confirmed by immunoblotting and showed that almost all DRP-1 was knocked down 
in both cell lines (Figure 5.15B and D). This suggested that the apoptosis seen in the 
HCT116 cells following DRP-1 downregulation is therefore largely BAX-dependent 
and that perhaps DRP-1-BAX can indeed regulate each other but not in the anticipated 
manner. 
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Figure 5.15. Knockdown of DRP-1 induces death in a BAX-dependent manner in 
HCT116 cells.  HCT116 BAX-/- (A) and DKO cells (C) were incubated with either 
control or DRP-1 siRNA for 72 h then exposed to DMSO or a combination of 100 nM 
S63845 and A-1331852 for 4 h before being collected for assessment of apoptosis by 
PS externalisation in flow cytometry. (B, D) Knockdown of DRP-1 was validated by 
immunoblotting with GAPDH as a loading control. Error bars = Mean ± SEM; *p ≤ 
0.05, **p ≤ 0.01 and ***p ≤ 0.001.  
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5.19 Discussion 
MCL-1 is a unique and complex member of the BCL-2 protein family which likely 
has a biology that is even more intricate than currently known. Here it was shown that 
not only is MCL-1 identifiable in all of the major subcellular compartments of the cell 
but it also exists in novel, distinct complexes of varying molecular weight which may 
be indicative of its multi-faceted functions. Indeed, MCL-1 has been previously shown 
to have diverse functions which would require distinct cellular localisations, including 
regulation of DNA repair in the nucleus177,179,184,326,335 and regulation of respiration 
and lipid metabolism on the inner mitochondrial membrane175,183. Studying the 
different pools of MCL-1 also revealed differences in the dominant localisations of 
the controversial MCL-1 isoforms. MCL-1 is detected in immunoblotting, under 
reducing conditions, as at least three bands corresponding to its different isoforms, 
which have all been attributed to its varying molecular functions. Although no article 
exists which clearly attributes each individual isoform to a particular function, it has 
been proposed that the longest isoform is the major apoptotic regulator of the three 
bands. In contrast, the shortest isoform is suggested to be localised to the IMM where 
it mediates non-apoptotic mitochondrial activity172,175,181. Indeed, here, the shortest 
isoform was expressed most highly in the mitochondrial fraction and was not present 
at all in the cytosolic fraction. Interestingly, a seemingly modified version of the 
longest MCL-1 isoform was detectable in the nuclear fraction, running slightly above 
the weights of the other three bands in the other isoforms. Previous reports have linked 
the short forms of MCL-1 to its nuclear activities177 while a long, modified form has 
not been previously described in the nucleus, however this could suggest that some 
isoforms of MCL-1 must be modified to enter the nucleus, perhaps undergoing a 
phosphorylation event which alters its molecular weight. While the full extent of the 
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role of MCL-1 in the nucleus remains obscure, it is clear from this data that all three 
bands (perhaps in modified forms) are present and thus may be performing some of 
the described nuclear roles of MCL-1. With further layers of complexity being added 
to the existence of MCL-1 isoforms, it is imperative that future studies focus on 
defining these isoforms and their roles within the cell. 
In order to further explore the complexity of MCL-1 pools with the goal of identifying 
potential candidates for a Protein X in the HCT116 8KO cells, mass spectrometry was 
utilised to assess the protein members of different pools of MCL-1. This study 
attempted to use two approaches – the first being immunoprecipitation of MCL-1 from 
the major subcellular compartments and the second being immunoprecipitation of 
MCL-1 from the novel MCL-1 complexes identified through FPLC. Despite these two 
strategies using the same approach and same antibodies, the outcome for each was 
quite different, namely because in the resulting peptide list of the subcellular fraction, 
MCL-1 was readily identifiable in each subcellular compartment along with multiple 
known MCL-1 interacting proteins. However, in the mass spectrometry involving 
fractions corresponding to distinct MCL-1 complexes (HMW, MMW, LMW), MCL-
1 was not detectable in the peptide lists during optimisation, despite many proteins 
being apparently pulled down with it. This result was disappointing as identifying the 
differences between the major MCL-1 complexes may have revealed a great deal 
about the biology of MCL-1, including its various pools, novel interacting partners 
and potentially some candidates for Protein X. It will be important to establish whether 
the MCL-1 complexes can be isolated in another approach which allows for maximal 
maintenance of protein-protein interactions in situ, perhaps using a recombinant, 
tagged MCL-1 system. 
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Despite the lack of success in the mass spectrometry involving fractions corresponding 
to distinct MCL-1 complexes, MCL-1 was readily identifiable along with many 
candidate interacting proteins in the subcellular fractionation approach. In both the 
extranuclear and mitochondrial fractions, the initial number of peptides identified by 
mass spectrometry was very high, meaning that stringent sorting of the peptide lists 
was required. As described, a recent article identified a novel MCL-1 interacting 
protein (VLCAD) using a similar approach (albeit a pull-down of tagged MCL-1 
rather than immunoprecipitation)183. Therefore, the same stringencies applied to their 
list of peptides was applied here. This greatly reduced the numbers of peptides in the 
two fractions and allowed efficient grouping of identified peptides into pathways using 
the Reactome pathway analysis tool. In order to simplify the approach of identifying 
significant Protein X candidates, the resulting enriched pathways were analysed for 
proteins linked to cell death – this is how DRP-1 and BAP31 were identified. It is 
almost certain, however, that some, if not many, of the other identified proteins might 
be novel MCL-1 interacting partners, which could be linked to either the anti-apoptotic 
roles of MCL-1 or perhaps its more diverse roles such as regulation of metabolism. 
Notably, VLCAD was identified as an MCL-1 interacting partner in the mass 
spectrometry performed here, supporting the principle of the technique and subsequent 
analysis. Many of the other proteins previously identified could be associated with the 
metabolic regulatory roles of MCL-1, such as ATP5F1, part of the ATP synthase 
structure. MCL-1 has previously shown to promote the assembly of the ATP synthase 
complex175 therefore a possible interaction may shed new light on this mechanism. 
Proteins associated with post-translational modifications were also enriched in both 
the extranuclear and mitochondrial extracts, such as YES, a tyrosine kinase364. 
Exploration of such proteins may reveal previously unreported post-translational 
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modifications of MCL-1 and perhaps, some more unexpected links – MCL-1 has been 
linked to regulation of tyrosine kinase signalling during metastasis, further widening 
its potential diverse roles within the cell365. Future work should aim to identify the 
significant proteins from these enriched pathways, validate the interactions and add to 
the understanding of the complex biology of MCL-1. It is worth nothing that 
significant numbers of proteins were not co-immunoprecipitated with MCL-1 in the 
nuclear or cytosolic fraction, particularly in the case of the nucleus where MCL-1 has 
been proposed to interact with highly abundant proteins, such as γ-H2AX184. The lack 
of co-immunoprecipitated proteins in these cases may be a result of the state of the 
cells – these interactions are linked to various types of DNA repair and if low levels 
of DNA repair were being carried out at the time of cell collection, the interactions 
may not be identifiable by mass spectrometry. Future experiments investigating MCL-
1 interactions should aim to validate many of the potential candidate interacting 
partners identified here, perhaps using improve control conditions and a different 
approach to isolating MCL-1. An isotype control and an immunoprecipitation in 
MCL-1-null cells would help identify non-specific candidate interacting proteins. 
Moreover, generating individual subcellular fractions in the lab would allow for 
precise control of conditions of the experiment from start to finish, including lysis of 
cells and storage conditions. This may allow for improved maintenance of endogenous 
interactions and minimal presence of interactions induced by processing of samples, 
which may have potentially occurred during processing of the purchased subcellular 
fractions. A further improvement would be to use a tagged, immobilised MCL-1 
target, rather than MCL-1 isolated by IP. 
The two validated, novel MCL-1 interacting proteins identified here are DRP-1 and 
BAP31, with the functional consequences of the MCL-1-DRP-1 interaction explored 
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further. Following validation of the interaction between MCL-1 and DRP-1, it was 
shown that DRP-1 co-elutes with the MMW complex of MCL-1. Furthermore, 
inhibition of MCL-1 seemed to cause DRP-1 to shift to a high molecular weight, 
suggesting that BH3 mimetics can cause the dissociation of MCL-1 and DRP-1 and 
that this, in turn, might be what is mediating the excessive mitochondrial fission 
observed during apoptosis following MCL-1 inhibition. The proposed mechanism of 
action of DRP-1 involves formation of oligomers at the mitochondrial membrane 
which form rings to physically constrict and pinch off mitochondrial membranes from 
one other, leading to fissed mitochondria361. This is an important event not just in the 
context of mitochondrial fission and maintenance of mitochondrial membrane 
dynamics, but also during apoptosis as mitochondrial fission has been implicated as a 
possible prerequisite for the efficient execution of the intrinsic pathway of 
apoptosis356. In agreement, DRP-1 oligomerisation resulted in not just mitochondrial 
fission but also apoptosis in H1299 cells, as cells devoid of DRP-1 underwent 
significantly less apoptosis following BH3 mimetics. However, it must be noted that 
BH3 mimetic-mediated mitochondrial fission and apoptosis can also be uncoupled as 
the fissed mitochondrial phenotype observed following A-1210477 in H1299 cells 
does not necessarily result in death. These cells depend not just on MCL-1 but also on 
BCL-XL for survival, and as a result, inhibition of MCL-1 and the ensuing 
mitochondrial fission is not sufficient to induce apoptosis, unless BCL-XL is also 
neutralised. Thus, it seems that DRP-1-mediated mitochondrial fission plays a central 
role in apoptosis but is not a direct inducer of apoptosis, at least in these cells. This 
goes against DRP-1 being a candidate Protein X, despite it seemingly having a BH3-
like domain, interacting with MCL-1 and leading to decreased apoptosis when 
downregulated. 
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One surprising result observed was that despite the apparent dissociation of MCL-1 
and DRP-1 in gel filtration analysis, A-1210477 could not disrupt the interaction 
between MCL-1 and DRP-1 in immunoprecipitation. One possible explanation for this 
could be the fact that DRP-1 is an extremely dynamic protein which moves 
continuously between the mitochondria and cytosol. It could therefore be proposed 
that in this immunoprecipitation experiment, DRP-1 had already carried out its fission 
activity at the mitochondrial membrane and rapidly translocated back to its previous 
interacting partners – meaning that the fission process was perhaps not ‘caught’ at the 
right time. Thus, it is not impossible that MCL-1 and DRP-1 dissociate in 
immunoprecipitation approaches but to detect this, alternative strategies such as time-
lapse high-resolution confocal microscopy, might be needed to capture the MCL-1-
DRP-1 interactions at the right moment. 
In addition to validating the physical interaction between MCL-1 and DRP-1 and 
observing its dissociation in gel filtration following inhibition of MCL-1, the 
interaction was also functionally validated. DRP-1 is required for BH3 mimetic 
induced apoptosis in H1299 cells but how it precisely functions in the apoptotic 
signalling pathway is unclear and whether this is linked to a proposed ‘Protein X’ 
function is unclear. What is clear is the fact that in both the HCT116 WT and 8KO 
cells, loss of DRP-1 itself induces extensive apoptosis. In this case, it almost appears 
that DRP-1 functions like a pro-survival protein rather than a pro-apoptotic BH3-only 
like protein, though there are many potential ways that loss of DRP-1 could induce 
death. Perhaps HCT116 cells are very sensitive to perturbations of their mitochondrial 
network and therefore a loss of mitochondrial fission results in altered mitochondrial 
bioenergetics which in turn induces high levels of stress and, therefore apoptosis. The 
DRP-linked death appears to be BAX dependent however, demonstrating that the 
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death seen is organised and not a type of necrosis or other form of cell death. Some 
reports have indeed suggested that, in opposition to the majority of the literature, 
inhibiting DRP-1 by pharmacological or genetic approaches can enhance apoptosis 
induced by BH3 mimetics in specific cell lines (melanoma) while inhibiting apoptosis 
in other types of cancer cell lines (breast cancer)358. Thus, the role of DRP-1 in 
apoptosis may be dependent upon the type and status of a cell and thus, colon 
carcinoma cells like HCT116 require DRP-1 for survival. 
This study reveals that the complexities of the BCL-2 protein family and their 
interacting proteins in apoptosis extend way beyond what is currently known. Future 
therapeutic targeting of the BCL-2 family must be approached with care until the 
nexus of interactions and functional consequences is fully understood, particularly 
when it comes to MCL-1 now that there is a strong possibility that it could be targeted 
in the clinic in the imminent future using the novel MCL-1 inhibitors. 
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6.1 The changing shape of the MCL-1 inhibitor field 
The pro- and anti-apoptotic proteins of the BCL-2 family are the major regulators of 
cell survival, whose expression levels play an extremely important role in the 
development of various diseases, including cancer. The interactions between the 
proteins in this family are believed to be what dictates the survival or death of a cell. 
As such, an emphasis has been placed on developing compounds which target these 
interactions so that inhibitors can be used in therapeutic strategies to induce apoptosis 
in cancer cells and therefore aid in the clearance of tumours. Years of development 
have yielded several highly specific and potent inhibitors of the BCL-2 family (termed 
BH3 mimetics), including ABT-263246 and the now FDA-approved ABT-199256 as 
well as various MCL-1 inhibitors, such as the novel S63845269 which was assessed in 
this study. S63845, has proven itself as a very promising MCL-1 inhibitor with great 
therapeutic potential, in addition to use as a tool to study MCL-1, both here and in 
other studies202,269,271,366. The promise of potent and highly specific MCL-1 inhibitors 
is incredibly exciting to the cancer therapy field, as MCL-1 is among the top ten of the 
most amplified genes across many cancer types195. In addition to S63845, during the 
preparation of this manuscript, another novel, highly potent and specific MCL-1 
inhibitor, AZD5991367 was published, which gave extremely promising results and 
further adds another agent to the BH3 mimetic armamentarium. MCL-1 has never 
before been in such a strong position as a druggable target in cancer, thus further 
development of these inhibitors which have the potential to enter the clinic are likely 
to greatly improve chemotherapeutic regimens as both single agents and in 
combination with other therapies. 
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6.2 The dispensability of BH3-only proteins in apoptosis 
BH3 mimetics, including S63845, are proposed to induce apoptosis by disrupting the 
interactions between the BCL-2 family members, including the BH3-only proteins and 
their pro-survival counterparts. Thus, the role of the BH3-only proteins in BH3 
mimetic-induced apoptosis has been firmly cemented in the field by a plethora of 
studies (reviewed in 61). Recent work, however, has suggested that the BH3-only 
proteins may be dispensable for apoptosis following suppression of the pro-survival 
proteins220,303,304, with the so called ‘octa-knockout’ cells (lacking the 8 major BH3-
only proteins) delivering a massive blow to the accepted models of activation of BAX 
and BAK303.  
Here, using highly specific BH3 mimetics, it was first established that the mere 
interaction between a pro-survival protein and a pro-apoptotic protein may not 
necessarily dictate the sensitivity of a cell to specific BH3 mimetics. For example, in 
a cell line that depends on either BCL-2 or MCL-1 for survival, like the MV-4-11 cell 
line (which undergoes extensive apoptosis with either ABT-199 or S63845), one 
would expect similar binding patterns of the BH3-only members to both BCL-2 and 
MCL-1. In this cell line, BIM was largely bound to BCL-2 with relatively little bound 
to MCL-1. Furthermore, ABT-199 failed to release BIM from BCL-2 whereas S63845 
appeared to release a small amount of BIM from MCL-1. Despite this discrepancy, 
both of these inhibitors, individually, induced extensive apoptosis in these cells. This 
pattern was observed in several suspension and adherent cell lines from 
haematological and solid cancers. This suggested that BIM may not be the critical 
deciding factor in dictating whether the cells should undergo apoptosis, and in fact 
multiple BH3-only members may have to act together in making that critical decision. 
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Having raised questions about the importance of the BH3-only proteins in determining 
sensitivity of a cell to undergo apoptosis, the HCT116 8KO cells were utilised to 
further explore how BH3 mimetics induce apoptosis. The validity of the HCT116 8KO 
cells was confirmed in this study and it was demonstrated that concurrent knockdown 
of both MCL-1 and BCL-XL in these cells could induce the same extent of apoptosis 
in the 8KO cells as in the wild-type cells, suggesting a dispensability of the BH3-only 
proteins in apoptosis, as originally reported
303. 
It was next of interest to assess the apoptosis of the HCT116 8KO cells with respect 
to BH3 mimetics that induce rapid apoptosis (< 4 h compared to the ~72 h that is 
normally required to silence expression of proteins) and are proposed to displace pro-
apoptotic proteins (which are missing in the 8KO cells) from their pro-survival 
counterparts to induce apoptosis. This was made possible by the recent introduction 
of S63845 as a bona fide MCL-1 inhibitor. Remarkably, despite the proposed 
mechanism of BH3 mimetic action, the cells that lack all the 8 major BH3-only 
proteins could still undergo BH3 mimetic-induced apoptosis, confirming previous 
studies which have implied that some, if not all, of the major BH3-only proteins, are 
dispensable for apoptosis induction induced by various stimuli220,301,304. Despite the 
on-going controversies of effector protein activation219,220,301,304, this concept goes 
against the central dogma of apoptosis and the mechanism of BH3 mimetic action, 
where BH3-only proteins, in some way or another, promote MOMP by activating 
BAX/BAK.  
One theory put forward to explain the dispensability of the BH3-only proteins in 
apoptosis was the possibility of a passive interaction of BAX with the mitochondrial 
membrane, which undergoes activation due to yet-to-be-characterised mechanism(s). 
As previously discussed, the interaction of BAX with the OMM is believed to be 
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prevented by the pro-survival proteins217 and it is believed that BAX is being 
constantly cycled between the cytosol and OMM (translocation and retrotranslocation) 
by pro-survival proteins319–322. Thus, when the pro-survival proteins are suppressed, 
BAX may accumulate at the OMM and could somehow be activated by the OMM. 
Indeed, as previously alluded to, the lipid-rich mitochondrial membrane may have the 
capacity to activate BAX under certain conditions, as lipid detergents have previously 
been shown to be capable of activating BAX300,323. Therefore, perhaps as a result of 
re-organisation of BAX by the OMM and the fact that certain activation domains of 
BAX are no longer sequestered by anti-apoptotic proteins86, BAX can indeed become 
activated and form pores in the absence of BH3-only proteins. Indeed, experiments in 
a further modified cell line of the HCT116 8KO cells supported this. Forced 
expression of BAX under control of a tetracycline-inducible system in the presence of 
Z-VAD-FMK in the ‘allKO’ cells (where all major members of the BCL-2 family 
including BAX and BAK were knocked out) resulted in BAX being largely 
mitochondrially-localised, suggesting spontaneous interaction of BAX with the OMM 
when neither pro- nor anti-apoptotic proteins are present301.,  
If BAX accumulation at the mitochondria following suppression of BCL-XL and 
MCL-1 is the rate-limiting step in the induction of apoptosis, then it is reasonable to 
speculate that BAX would interact with BCL-XL, and/or MCL-1 under control 
conditions and BH3 mimetics would disrupt this interaction to allow BAX to 
accumulate at the mitochondria. In support of this hypothesis, cytosolic and/or extra-
mitochondrial pools of BCL-XL and MCL-1 have been characterised both in this study 
and other reports170,368–370. However, in this study, BAX did not bind MCL-1 or BCL-
XL either under control conditions or following BH3 mimetics, thus casting doubts on 
potential interactions of BAX with the anti-apoptotic BCL-2 family members, at least 
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in this context. Having said that, it must be noted that these conclusions were drawn 
from immunoprecipitation studies, and the nature of BAX’s interaction with any 
protein other than itself appears to be extremely dynamic. Therefore, it is possible that 
other strategies such as in vitro assessment of binding or, perhaps proximity labelling 
assays must be used to study these dynamic interactions in the future. 
6.3 Novel BH3-only-like proteins could regulate BH3 mimetic-induced 
apoptosis in the absence of the major BH3-only proteins 
An alternative conclusion to these results would be that perhaps another mechanism 
is in place which mediates the BAX-dependent but BH3-only protein independent 
BH3 mimetic-induced apoptosis in the HCT116 8KO cells. One such mechanism was 
proposed to be the existence of proteins with BH3-like, pro-apoptotic qualities which 
might activate BAX to facilitate apoptosis in the absence of the 8 major BH3-only 
proteins. Indeed, since the characterisation of the major BH3-only proteins (like BIM, 
PUMA, NOXA), more proteins have been identified with BH3-like motifs which can 
bind to different pro-survival proteins. For instance, SUFU can bind to MCL-1, BCL-
2 and BCL-XL via a BH3 motif and be displaced from the pro-survival proteins 
following BH3 mimetic exposure. However, SUFU has been shown to have no roles 
to play in BH3 mimetic-mediated apoptosis324. Thus, a scenario where novel BH3 
motif-containing proteins, other than the 8 characterised BH3-only members, can bind 
to anti-apoptotic proteins and regulate BH3 mimetic-induced death is not unlikely.  
Identification of a novel BH3-only-like protein is not straightforward however – partly 
owing to the fact that the BH3 motif is not a well-defined sequence65 and partly due 
to the promiscuous binding patterns of the BCL-2 family. While the individual pro-
survival proteins all perform the same function by promoting cell survival, they also 
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share binding partners. For instance, BIM can bind multiple pro-survival BCL-2 
family members while NOXA specifically binds MCL-1 and BCL-2A1, as described 
in Chapter 1. Therefore, if a novel BH3-only-like protein that drives BH3 mimetic-
mediated apoptosis exists, then it may bind more than one of the pro-survival BCL-2 
family members. The data here, however, supported the notion of a novel BH3-only-
like protein interacting specifically with MCL-1 in the HCT116 8KO cells, since 
apoptosis observed following the inhibition of BCL-XL alone appeared to depend on 
the presence of one or more of the 8 BH3-only proteins. Strikingly, this requirement 
of the BH3-only proteins was mitigated when MCL-1 was simultaneously inhibited in 
these cells, suggesting that the two anti-apoptotic proteins may regulate death by 
different mechanisms, at least in HCT116 cells. It was therefore hypothesised that, 
while BCL-XL mediates apoptosis through its typical BH3-only protein binding 
partners (BAD, BIM etc), MCL-1 might have novel interacting proteins (‘Protein X’) 
which, when displaced following BH3 mimetic exposure, might mediate the apoptosis 
seen in HCT116 8KO cells. The study therefore focused on novel MCL-1-interacting 
proteins and their function in BH3 mimetic-induced apoptosis. 
6.4 MCL-1 – a key pro-survival protein with multi-faceted functions 
Here, MCL-1 was found to exist in all the major cellular compartments with distinct 
localisations of its three major isoforms. For example, the IMM-specific 36 kDa 
isoform175,183 of MCL-1 is not present in the cytosol but could clearly be detected in 
other subcellular compartments. This suggested that the three major isoforms of MCL-
1 may each have their own unique expression patterns within the cell, further 
underscoring the many layers of the complicated biology of MCL-1. This study also 
demonstrated, for the first time, the existence of distinct molecular weight pools of 
MCL-1, termed MCL-1 complexes. This observation suggested that MCL-1 exists in 
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large pools with other proteins, which are perhaps linked to its diverse functions. 
Indeed, the existence of the complexes seemed to vary between major subcellular 
fractions, suggesting each MCL-1 complex might have distinct subcellular 
localisations. This supported the notion of novel MCL-1-interacting proteins and 
implied that MCL-1 might exist in multiple high molecular pools with a large number 
of other proteins. Analysis of MCL-1 interacting partners by mass spectrometry 
revealed that MCL-1 has a vast potential interaction network, especially in the 
mitochondria, where hundreds of purported interacting proteins were identified, even 
after stringent filtering. Pathway analysis of the peptides identified in the 
mitochondrial and whole cell lysate subgroups supported the idea of MCL-1 being an 
extremely multi-faceted protein. Not only were known MCL-1-interacting partners 
linked to both its pro-survival functions as well as its more diverse functions identified 
(VLCAD183), but many other proteins linked to cellular roles where MCL-1 has been 
implicated were identified, such as proteins linked to the ATP synthase subunits175. 
The striking numbers of proteins linked to key mitochondrial functions identified as 
potential interacting partners further supports the need for intensive exploration of 
MCL-1 outside of its pro-survival roles. It is very possible that MCL-1 has essential, 
non-pro-survival related functions in certain cell types which could be altered by 
inhibition of MCL-1 with potent inhibitors such as S63845. It has been proposed that 
non-apoptotic, mitochondrial functions of MCL-1 are important to maintenance of 
cardiac tissue in mice276, as suppression of MCL-1 leads to severe mitochondrial 
abnormalities. Inhibition of MCL-1 could therefore, like BCL-XL in platelets, have 
adverse effects on the healthy cells. While the S63845 pilot study found no toxic side 
effects of pharmacological inhibition of MCL-1 in mice202, whether this translates to 
211 
 
humans over an extended period of treatment (potentially in combination with other 
therapies) remains unclear.  
It could be suggested that, since several of the non-apoptotic mitochondria-associated 
roles of MCL-1 are attributed to the shortest MCL-1 isoform (also termed ‘matrix 
MCL-1’), pharmacological inhibition of MCL-1 might not affect these functions, since 
BH3 mimetics target the protein-protein interactions of proteins bound by the BH3 
motif. However, it has been shown that at least some of the novel interaction partners 
MCL-1 bind to MCL-1 via its BH3 domain, including VLCAD175,183. Thus, MCL-1 
inhibitors could disrupt this interaction and negatively influence the mitochondrial 
matrix functions of MCL-1. Moreover, the fact that MCL-1 inhibitors could clearly 
bind to and stabilise all the major MCL-1 isoforms and also induce mitochondrial 
fragmentation clearly demonstrates the potential for activity of MCL-1 inhibitors that 
may lie outside the apoptotic spectrum. Thus, it is important to understand the entire 
complex biology of MCL-1, especially the non-apoptotic mitochondrial roles, before 
compounds like S63845 are used extensively in cancer therapy. 
6.5 The DRP-1 and MCL-1 interaction in regulation of apoptosis 
Mitochondrial dynamics, including fission and fusion, are closely related to apoptosis. 
DRP-1, the major mitochondrial fission regulator, has been controversially linked to 
apoptosis for many years. Early studies suggested that loss of DRP-1-mediated 
mitochondrial fission can protect against apoptosis356. Multiple studies supported this 
and suggested it occurred as a result of the loss of mitochondrial fission, leading to 
decreased OPA1 release and subsequently meaning cytochrome c is not efficiently 
released from the mitochondria into the cytosol as a result of altered cristae 
remodelling357,371–373. It was also highlighted that loss of DRP-1 simply delays but 
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does not block the onset of apoptosis. This suggested that mitochondrial fission and 
apoptosis were distinct and that the former was not a pre-requisite for the latter. 
DRP-1 has also been associated with apoptosis at the level of BAX oligomerisation 
on mitochondrial membranes348,359,360. Mass spectrometry analysis of the 
mitochondrial pool of MCL-1 identified DRP-1 as a potential interacting partner, thus 
warranting further studies into this interaction and its physiological functions. 348,359,360 
Initial exploration of DRP-1 as an MCL-1 interacting partner and Protein X candidate 
was promising. The MCL-1-DRP-1 interaction was validated (and was further 
validated by reports published during the production of this study182,338), while 
knockdown of DRP-1 in H1299 cells presented significant protection against BH3 
mimetic-induced apoptosis. This suggested that DRP-1 could possibly be a factor 
required for BAX/BAK activation and, as such, a Protein X. This is in line with 
previous studies demonstrating the cytoprotective nature of DRP-1 
deficiency356,357,371,372. However, whether this was a result of DRP-1 functioning like 
Protein X, with BH3-only protein-like qualities, remained unclear. Subsequent data 
showed that a BH3 mimetic-induced dissociation of the DRP-1/MCL-1 complex, can 
lead to the translocation of DRP-1 to very HMW fractions in H1299 cells. This 
supported the idea of BH3 mimetics being able to displace DRP-1 from MCL-1, 
potentially thereby activating BAX to result in apoptosis.  This shift in molecular 
weight to an oligomeric complex could also be associated with the role of oligomeric 
DRP-1 in facilitating BAX translocation/oligomerisation at the mitochondria, 
however. 
Surprisingly, in immunoprecipitation experiments where the MCL-1-DRP-1 
interaction was interrogated directly, although a convincing interaction between MCL-
1 and DRP-1 was observed, this was not disrupted by BH3 mimetics, suggesting that 
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the interaction was not dependent on the BH3 motif of MCL-1 or proposed BH3-like 
motif of DRP-1. This observation further suggested that DRP-1 could not be a 
candidate for Protein X as for DRP-1 to be Protein X it had to meet three major 
requirements: (1) It should interact with MCL-1, (2) it should be displaced from MCL-
1 following exposure to S63845 indicating a BH3-motif dependency and (3) upon 
release, it should drive apoptosis in cells. While DRP-1 appeared to fit the first and 
third requirement, its inability to displace from MCL-1 following S63845 diminished 
its possibility of being a suitable candidate for Protein X. 
However, if a Protein X scenario is to be considered, it could be suggested that DRP-
1, MCL-1 and BAK/BAX are in a transient complex, which can be disrupted by 
addition of BH3 mimetics with two possible outcomes. When only MCL-1 is 
inhibited, the MCL-1-DRP-1-BAK/BAX complex is disrupted, thereby somehow 
allowing DRP-1 to form oligomers on the mitochondrial membrane, resulting in 
fission. Apoptosis is not seen following this fission however, as BAX/BAK can be 
attenuated by counterpart anti-apoptotic proteins, in this case, BCL-XL. Thus, when 
both MCL-1 and BCL-XL are inhibited, the effector proteins are no longer sequestered 
by anti-apoptotic proteins and DRP-1 is no longer restrained by MCL-1. This could 
mean DRP-1 facilitates oligomerisation of BAX/BAK which are then be free to form 
pores in the mitochondria, with downstream events being further facilitated by DRP-
1. This hypothesis would require DRP-1 to directly activate BAX/BAK however, or, 
perhaps demarcate sites on the mitochondria where BAX/BAK accumulate, leading to 
autoactivation and oligomerisation. Extensive studies would have to be carried out to 
support this hypothesis, first starting by demonstrating an interaction between DRP-1 
and the effector proteins and observing whether DRP-1 can indeed activate BAX 
rather than just simply provide sites for its translocation348,360 
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While the above scenario is not impossible, it is also reasonable to argue that DRP-1 
simply modulates BH3-mimetic-induced apoptosis through its previously proposed 
mechanisms. In such a case, DRP-1 may be aiding the re-modelling of the cristae to 
tease out cytochrome c357,371, thus when knocked down, apoptosis is attenuated. This 
may seem like a more enticing mechanism since studies have already demonstrated 
this, however it remains a controversial topic and does not account for the link between 
MCL-1 and DRP-1. Perhaps MCL-1 and DRP-1 associate and mediate cristae 
remodelling together, as previously implied338. 
Overall, DRP-1 is clearly important to BH3 mimetic-induced apoptosis in solid cancer 
cell lines but is unlikely to serve as our proposed Protein X. In further support of this, 
studies in the HCT116 WT and 8KO cells revealed even more complex behaviour of 
DRP-1 in apoptosis. In WT and 8KO cells, knockdown of DRP-1 induced significant 
cell death on its own, while further enhancing BH3 mimetic-induced apoptosis. 
Moreover, this death appeared to be at least partially BH3-only protein- and BAX-
dependent, as BAX KO cells did not undergo as significant apoptosis following DRP-
1 siRNA or BH3 mimetic exposure. It therefore appears that DRP-1 plays a critical 
role in maintaining viability of HCT116 cells. It is not clear why HCT116 cells 
undergo such extensive apoptosis following knockdown of DRP-1, however the 
induction of apoptosis as a result of loss of DRP-1 has been observed in multiple cell 
types in previous studies, suggesting the protective role of DRP-1 in apoptosis may be 
cell type-dependent374,375. It could be suggested that knockdown of DRP-1 leads to a 
hyperfilamentous mitochondria in the HCT116 cells which might alter their 
metabolism and lead to stress and in turn, BAX-dependent apoptosis. Indeed, previous 
studies have shown that knockdown of DRP-1 does indeed negatively alter oxidative 
phosphorylation, resulting in decreased oxygen consumption in complex II of the 
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electron transport chain357. This could be linked to the death seen in the HCT-116 
cells. Remarkably, the apoptosis seen following knockdown of DRP-1 could also be 
associated with replication stress and genome instability. Lack of mitochondrial 
fission caused by knockdown of DRP-1 has been shown to influence replication stress 
and DNA damage during the cell cycle, as normal mitochondrial fission/fusion cycles 
are essential to genome stability in some cell lines374.  
Thus, it appears that the roles of DRP-1 in apoptosis cannot be defined by looking at 
specific cell types as it has distinctly opposite roles in two cell types studied here, 
further supported by previous literature. Future assessment of DRP-1 in cell death 
pathways should consider multiple types of cells and try to establish what causes the 
difference in response following loss of DRP-1. 
6.6 Implications and future studies 
Despite the complexities surrounding the BCL-2 family and BH3 mimetics, the entry 
of BH3 mimetics into the clinic for cancer treatment represents a huge milestone in 
the field. In particular, the development of S63845 and other MCL-1 inhibitors should 
greatly impact not only the BH3 mimetic field but also other chemotherapeutic 
approaches, since upregulation of MCL-1 is a key factor in drug resistance 
mechanisms in various therapeutic approaches in multiple cancers172,203,204,209. By 
exploring and understanding the BCL-2 family to the greatest extent, these therapeutic 
agents can be refined to a very high calibre and will almost certainly help improve the 
lives of cancer patients in the future.  
While these compounds are likely to be excellent additions to the chemotherapeutic 
armamentarium, their mechanism of action has been challenged by this study, 
alongside various recently published articles, highlighting that the apoptotic signalling 
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pathway, particularly at the level of BCL-2 protein family interactions, is still not 
completely understood. Determining the full scale and dispensability of BCL-2 family 
interactions in apoptosis is of great importance. In particular, further developing 
models of 8KO cell lines to other cell types and to have additional knockouts of 
proteins of interest, is essential. Exploring the recently proposed mechanism of retro-
translocation of BAX/BAK by the pro-survival proteins in the 8KO cells is also of 
great interest and could support the idea of suppression of MCL-1/BCL-XL leading to 
diminished cycling of BAX/BAK, therefore allowing it to be activated by the OMM. 
Moreover, how the OMM might lead to activation of BAX/BAK without the known 
BH3-only proteins is an absolutely essential question to answer and will require some 
complex membrane studies. Establishing more intricate models of BAX/BAK 
activation will vastly improve our understanding of apoptosis and the dispensability 
of BH3-only proteins. 
Finally, identifying other novel interacting partners of the BCL-2 protein family, 
should reveal more about the complex nature of the master regulators of apoptosis, 
particularly the increasingly complex biology of MCL-1 which has proven itself as 
not just a regulator of apoptosis but also many other cellular functions. This study has 
focused on just a few targets based on identified proteins having previous links to 
apoptosis, however with the multi-faceted nature of MCL-1, it is likely that there is a 
lot more to uncover. Understanding these functions is key to its targeting and may help 
establish MCL-1 as a prominent therapeutic target in the clinic. 
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6.7 Concluding remarks 
The major findings of this study contribute multiple novel points to the field of 
apoptosis: 
• S63845 is a highly potent and specific MCL-1 inhibitor which can be 
combined with other BH3 mimetics to induce rapid apoptosis in many types 
of cancer cell lines. 
• The interactions of pro-survival proteins with distinct pro-apoptotic BH3-only 
proteins might not always dictate sensitivity of a cell line to specific BH3 
mimetics. 
• The eight key BH3-only proteins are dispensable for apoptosis following 
suppression of MCL-1 and BCL-XL however BAX remains critical. 
• BH3-only proteins are indispensable for induction of apoptosis induced by 
inhibition of BCL-XL, however this can be overcome by further inhibition of 
MCL-1. 
• MCL-1 exists in complexes of distinct molecular weights which may be linked 
to its various subcellular roles. 
• The subcellular roles of MCL-1 may be even more extensive than what is 
currently known as it has a vast number of potential unidentified interacting 
partners. 
• DRP-1 is one such novel interacting partner with critical roles to play in BH3 
mimetic-induced apoptosis. 
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Supplementary Table 5.1 – The full list of candidate interacting proteins 
identified in the extranuclear lysate detected in mass spectrometry. Fold change, 
p values and q values are indicated for each protein, while known interacting 
partners of MCL-1 are shown in bold font. 
Protein 
Identifier 
Protein name Fold 
change 
p value q value 
CEP85  Centrosomal protein of 85 kDa  55.9 0.0002 0.0024 
CARS  Cysteine--tRNA ligase, cytoplasmic  42.5 0.0002 0.0024 
FBXO2  F-box only protein 2  32.2 0.0001 0.0024 
KTN1  Kinectin  49.3 0.0005 0.0035 
CEBPZ  CCAAT/enhancer-binding protein zeta  36.5 0.0006 0.0041 
CPT1A  Carnitine O-palmitoyltransferase 1, liver isoform  24.7 0.0006 0.0041 
SP100  Nuclear autoantigen Sp-100  253.6 0.0009 0.0042 
BCL2L11  Bcl-2-like protein 11  205.8 0.0011 0.0042 
NOMO2  Nodal modulator 2  174.9 0.0010 0.0042 
ESF1  ESF1 homolog  60.2 0.0008 0.0042 
SEC61B  Protein transport protein Sec61 subunit beta  13.5 0.0010 0.0042 
RBM4B  RNA-binding protein 4B  98.5 0.0015 0.0045 
AURKA  Aurora kinase A  70.5 0.0016 0.0045 
FARSB  Phenylalanine--tRNA ligase beta subunit  26.9 0.0021 0.0045 
DHCR7  7-dehydrocholesterol reductase  20.9 0.0017 0.0045 
STT3B  Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B  
19.1 0.0021 0.0045 
IDH2  Isocitrate dehydrogenase [NADP], mitochondrial  13.2 0.0014 0.0045 
GALK1  Galactokinase  9.8 0.0013 0.0045 
IPO4  Importin-4  49.9 0.0022 0.0046 
SRPRB  Signal recognition particle receptor subunit beta  20.0 0.0023 0.0046 
CPS1  Carbamoyl-phosphate synthase [ammonia], 
mitochondrial  
14.4 0.0027 0.0046 
TMED9  Transmembrane emp24 domain-containing 
protein 9  
14.3 0.0024 0.0046 
STT3A  Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A  
12.6 0.0028 0.0046 
UGDH  UDP-glucose 6-dehydrogenase  9.6 0.0028 0.0046 
APOBEC3C  DNA dC->dU-editing enzyme APOBEC-3C  103.8 0.0044 0.0047 
FAM171A2  Protein FAM171A2  48.3 0.0037 0.0047 
BZW2  Basic leucine zipper and W2 domain-containing 
protein 2  
30.9 0.0036 0.0047 
ZMPSTE24  CAAX prenyl protease 1 homolog  25.7 0.0037 0.0047 
FANCI  Fanconi anemia group I protein  24.1 0.0030 0.0047 
NOC2L  Nucleolar complex protein 2 homolog  23.8 0.0041 0.0047 
DHCR24  Delta(24)-sterol reductase  12.1 0.0038 0.0047 
DNAJA3  DnaJ homolog subfamily A member 3, 
mitochondrial  
11.2 0.0041 0.0047 
ATP5H  ATP synthase subunit d, mitochondrial  10.8 0.0043 0.0047 
FDFT1  Squalene synthase  78.9 0.0053 0.0049 
RRP8  Ribosomal RNA-processing protein 8  1666.7 0.0064 0.0049 
DDX24  ATP-dependent RNA helicase DDX24  113.2 0.0068 0.0049 
CUL1  Cullin-1  67.4 0.0070 0.0049 
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HEXIM1  Protein HEXIM1  51.1 0.0065 0.0049 
TRMT112  Multifunctional methyltransferase subunit 
TRM112-like protein  
42.5 0.0067 0.0049 
MCL1  Induced myeloid leukaemia cell differentiation 
protein Mcl-1  
33.9 0.0062 0.0049 
CSNK2A2  Casein kinase II subunit alpha'  28.4 0.0057 0.0049 
TMEM33  Transmembrane protein 33  23.3 0.0060 0.0049 
A2M  Alpha-2-macroglobulin  11.9 0.0058 0.0049 
HLA-A  HLA class I histocompatibility antigen, A-68 
alpha chain  
10.7 0.0070 0.0049 
BSG  Basigin  5.8 0.0061 0.0049 
NCLN  Nicalin  22.6 0.0071 0.0050 
EDC3  Enhancer of mRNA-decapping protein 3  13.0 0.0077 0.0050 
EIF2B2  Translation initiation factor eIF-2B subunit beta  122.6 0.0089 0.0051 
C7orf50  Uncharacterized protein C7orf50  117.7 0.0091 0.0051 
SQLE  Squalene monooxygenase  99.2 0.0087 0.0051 
AP2M1  AP-2 complex subunit mu  84.6 0.0092 0.0051 
HLTF  Helicase-like transcription factor  69.9 0.0085 0.0051 
UPF1  Regulator of nonsense transcripts 1  43.2 0.0091 0.0051 
TJAP1  Tight junction-associated protein 1  39.2 0.0081 0.0051 
SRP9  Signal recognition particle 9 kDa protein  32.5 0.0091 0.0051 
PTRH2  Peptidyl-tRNA hydrolase 2, mitochondrial  27.4 0.0095 0.0051 
CPNE3  Copine-3  26.1 0.0087 0.0051 
CNP  2',3'-cyclic-nucleotide 3'-phosphodiesterase  24.9 0.0093 0.0051 
VAPB  Vesicle-associated membrane protein-associated 
protein B/C  
13.6 0.0085 0.0051 
ATP5D  ATP synthase subunit delta, mitochondrial  11.0 0.0096 0.0051 
RBM42  RNA-binding protein 42  7.9 0.0093 0.0051 
VAPA  Vesicle-associated membrane protein-associated 
protein A  
6.2 0.0093 0.0051 
ATP5F1  ATP synthase F(0) complex subunit B1, 
mitochondrial  
10.4 0.0099 0.0052 
EIF2AK2  Interferon-induced, double-stranded RNA-
activated protein kinase  
373.1 0.0108 0.0053 
DDX52  Probable ATP-dependent RNA helicase DDX52  248.8 0.0104 0.0053 
CIAO1  Probable cytosolic iron-sulfur protein assembly 
protein CIAO1  
30.9 0.0107 0.0053 
LRRC47  Leucine-rich repeat-containing protein 47  15.2 0.0108 0.0053 
PMAIP1  Phorbol-12-myristate-13-acetate-induced 
protein 1  
181.0 0.0114 0.0054 
SLC7A5  Large neutral amino acids transporter small 
subunit 1  
5.1 0.0115 0.0054 
LMAN1  Protein ERGIC-53  15.0 0.0118 0.0055 
NDUFA4  Cytochrome c oxidase subunit NDUFA4  14.3 0.0119 0.0055 
SEC11A  Signal peptidase complex catalytic subunit 
SEC11A  
10.2 0.0117 0.0055 
TMEM97  Transmembrane protein 97  7.8 0.0122 0.0056 
NDUFS3  NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 3, mitochondrial  
15.0 0.0126 0.0056 
TRIM25  E3 ubiquitin/ISG15 ligase TRIM25  183.6 0.0129 0.0056 
NMT1  Glycylpeptide N-tetradecanoyltransferase 1  170.1 0.0135 0.0056 
STAT3  Signal transducer and activator of transcription 
3  
119.3 0.0136 0.0056 
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RNH1  Ribonuclease inhibitor  15.1 0.0139 0.0057 
PFKM  ATP-dependent 6-phosphofructokinase, muscle 
type  
29.2 0.0145 0.0057 
MYO1E  Unconventional myosin-Ie  97.5 0.0152 0.0058 
ABCF2  ATP-binding cassette sub-family F member 2  83.1 0.0159 0.0058 
SLC16A3  Monocarboxylate transporter 4  7.4 0.0155 0.0058 
RBM33  RNA-binding protein 33  99.9 0.0163 0.0059 
ACADM  Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
5.3 0.0178 0.0061 
TATDN3  Putative deoxyribonuclease TATDN3  332.4 0.0181 0.0061 
RBM4  RNA-binding protein 4  139.5 0.0182 0.0061 
POLR1C  DNA-directed RNA polymerases I and III 
subunit RPAC1  
238.8 0.0184 0.0061 
NOB1  RNA-binding protein NOB1  326.3 0.0192 0.0061 
LARP4B  La-related protein 4B  52.2 0.0192 0.0061 
TMED10  Transmembrane emp24 domain-containing 
protein 10  
22.4 0.0189 0.0061 
GALNT2  Polypeptide N-acetylgalactosaminyltransferase 2  13.3 0.0190 0.0061 
POLR2L  DNA-directed RNA polymerases I, II, and III 
subunit RPABC5  
111.1 0.0195 0.0062 
DNAJC9  DnaJ homolog subfamily C member 9  54.0 0.0195 0.0062 
TRIP13  Pachytene checkpoint protein 2 homolog  43.1 0.0196 0.0062 
MARK2  Serine/threonine-protein kinase MARK2  139.5 0.0199 0.0062 
ZNF598  Zinc finger protein 598  2029.7 0.0202 0.0062 
SPATS2L  SPATS2-like protein  114.7 0.0204 0.0062 
LSS  Lanosterol synthase  16.3 0.0203 0.0062 
NIP7  60S ribosome subunit biogenesis protein NIP7 
homolog  
518.3 0.0213 0.0063 
DHX29  ATP-dependent RNA helicase DHX29  120.9 0.0217 0.0064 
ANAPC5  Anaphase-promoting complex subunit 5  299.1 0.0219 0.0064 
PRKCI  Protein kinase C iota type  20.2 0.0223 0.0064 
DHX16  Putative pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX16  
204.2 0.0229 0.0065 
DIS3  Exosome complex exonuclease RRP44  85.0 0.0227 0.0065 
RRM1  Ribonucleoside-diphosphate reductase large 
subunit  
9.7 0.0234 0.0065 
ORC5  Origin recognition complex subunit 5  118.7 0.0241 0.0066 
GPATCH4  G patch domain-containing protein 4  34.1 0.0242 0.0066 
XRN1  5'-3' exoribonuclease 1  197.6 0.0248 0.0066 
PCF11  Pre-mRNA cleavage complex 2 protein Pcf11  168.6 0.0245 0.0066 
LARP4  La-related protein 4  135.8 0.0247 0.0066 
PPFIA1  Liprin-alpha-1  124.8 0.0251 0.0066 
S100A16  Protein S100-A16  116.7 0.0250 0.0066 
PCYT1B  Choline-phosphate cytidylyltransferase B  33.8 0.0248 0.0066 
IDH1  Isocitrate dehydrogenase [NADP] cytoplasmic  5.6 0.0250 0.0066 
CIT  Citron Rho-interacting kinase  127.4 0.0257 0.0067 
DCAF7  DDB1- and CUL4-associated factor 7  484.7 0.0262 0.0068 
TM9SF2  Transmembrane 9 superfamily member 2  10.1 0.0268 0.0068 
AGFG1  Arf-GAP domain and FG repeat-containing 
protein 1  
274.7 0.0270 0.0068 
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MUC13  Mucin-13  20.7 0.0276 0.0068 
YTHDF3  YTH domain-containing family protein 3  427.9 0.0279 0.0069 
WDR43  WD repeat-containing protein 43  286.9 0.0283 0.0069 
TRIM31  E3 ubiquitin-protein ligase TRIM31  221.0 0.0292 0.0070 
ACSL1  Long-chain-fatty-acid--CoA ligase 1  15.2 0.0293 0.0070 
TOPBP1  DNA topoisomerase 2-binding protein 1  80.3 0.0299 0.0070 
DPF2  Zinc finger protein ubi-d4  185.2 0.0300 0.0070 
TMA16  Translation machinery-associated protein 16  154.5 0.0302 0.0070 
LSG1  Large subunit GTPase 1 homolog  181.7 0.0303 0.0070 
PACSIN3  Protein kinase C and casein kinase substrate in 
neurons protein 3  
47.3 0.0305 0.0071 
TYMS  Thymidylate synthase  12.6 0.0306 0.0071 
SEPT10  Septin-10  391.4 0.0314 0.0071 
NARS  Asparagine--tRNA ligase, cytoplasmic  13.1 0.0313 0.0071 
CTNND1  Catenin delta-1  114.3 0.0317 0.0071 
PAK1IP1  p21-activated protein kinase-interacting protein 1  111.4 0.0317 0.0071 
NOL10  Nucleolar protein 10  60.6 0.0316 0.0071 
POLR2C  DNA-directed RNA polymerase II subunit RPB3  531.3 0.0319 0.0071 
CMAS  N-acylneuraminate cytidylyltransferase  63.8 0.0325 0.0071 
DTX3L  E3 ubiquitin-protein ligase DTX3L  166.1 0.0333 0.0072 
KRI1  Protein KRI1 homolog  106.6 0.0333 0.0072 
USP10  Ubiquitin carboxyl-terminal hydrolase 10  90.1 0.0338 0.0072 
NTPCR  Cancer-related nucleoside-triphosphatase  74.1 0.0340 0.0072 
B2M  Beta-2-microglobulin  13.0 0.0336 0.0072 
TUBGCP3  Gamma-tubulin complex component 3  41.5 0.0349 0.0073 
LTA4H  Leukotriene A-4 hydrolase  7.1 0.0353 0.0073 
PDCD11  Protein RRP5 homolog  142.5 0.0357 0.0073 
YES1  Tyrosine-protein kinase Yes  558.2 0.0366 0.0074 
TCEB2  Transcription elongation factor B polypeptide 2  47.0 0.0366 0.0074 
VPS16  Vacuolar protein sorting-associated protein 16 
homolog  
291.5 0.0369 0.0074 
NBN  Nibrin  85.7 0.0371 0.0074 
ZC3H15  Zinc finger CCCH domain-containing protein 15  27.4 0.0372 0.0074 
CLINT1  Clathrin interactor 1  176.6 0.0376 0.0074 
TBL1XR1  F-box-like/WD repeat-containing protein 
TBL1XR1  
105.8 0.0378 0.0075 
CD3EAP  DNA-directed RNA polymerase I subunit RPA34  606.0 0.0381 0.0075 
ACADVL  Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
9.1 0.0383 0.0075 
ZNF143  Zinc finger protein 143  123.2 0.0387 0.0075 
CUX1  Protein CASP  1007.5 0.0391 0.0076 
PKP3  Plakophilin-3  47.9 0.0391 0.0076 
ACOT9  Acyl-coenzyme A thioesterase 9, mitochondrial  8.8 0.0390 0.0076 
LARP7  La-related protein 7  8.1 0.0391 0.0076 
FLII  Protein flightless-1 homolog  60.8 0.0397 0.0076 
ILK  Integrin-linked protein kinase  52.3 0.0397 0.0076 
SHANK2  SH3 and multiple ankyrin repeat domains protein 
2  
219.1 0.0403 0.0076 
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PPIG  Peptidyl-prolyl cis-trans isomerase G  130.6 0.0401 0.0076 
TRRAP  Transformation/transcription domain-associated 
protein  
36.3 0.0400 0.0076 
MCM8  DNA helicase MCM8  20.0 0.0403 0.0076 
LIMCH1  LIM and calponin homology domains-containing 
protein 1  
316.3 0.0412 0.0076 
RBM22  Pre-mRNA-splicing factor RBM22  127.3 0.0413 0.0076 
PYGB  Glycogen phosphorylase, brain form  28.1 0.0415 0.0076 
PWP2  Periodic tryptophan protein 2 homolog  100.8 0.0419 0.0077 
EIF1  Eukaryotic translation initiation factor 1  13.4 0.0424 0.0077 
CDC42BPB  Serine/threonine-protein kinase MRCK beta  19.2 0.0427 0.0078 
VIL1  Villin-1  142.9 0.0433 0.0078 
EIF4G2  Eukaryotic translation initiation factor 4 gamma 2  20.8 0.0447 0.0079 
MED4  Mediator of RNA polymerase II transcription 
subunit 4  
4444.3 0.0448 0.0079 
POLR1E  DNA-directed RNA polymerase I subunit RPA49  841.1 0.0449 0.0079 
EIF2A  Eukaryotic translation initiation factor 2A  44.6 0.0455 0.0079 
CTNNA1  Catenin alpha-1  9.4 0.0454 0.0079 
CDK11A  Cyclin-dependent kinase 11A  34.2 0.0456 0.0079 
PPP6R3  Serine/threonine-protein phosphatase 6 regulatory 
subunit 3  
3052.0 0.0460 0.0079 
VPS18  Vacuolar protein sorting-associated protein 18 
homolog  
324.9 0.0459 0.0079 
CWF19L2  CWF19-like protein 2  66.3 0.0461 0.0079 
COPE  Coatomer subunit epsilon  23.1 0.0460 0.0079 
ASS1  Argininosuccinate synthase  7.6 0.0461 0.0079 
TRIP6  Thyroid receptor-interacting protein 6  59.2 0.0463 0.0080 
RRS1  Ribosome biogenesis regulatory protein homolog  103.3 0.0466 0.0080 
POLR1B  DNA-directed RNA polymerase I subunit RPA2  164.0 0.0467 0.0080 
GTF3C1  General transcription factor 3C polypeptide 1  48.6 0.0472 0.0080 
RACGAP1  Rac GTPase-activating protein 1  265.2 0.0477 0.0081 
KDM1A  Lysine-specific histone demethylase 1A  73.7 0.0476 0.0081 
ALKBH5  RNA demethylase ALKBH5  165.5 0.0484 0.0081 
KIAA1033  WASH complex subunit 7  341.1 0.0486 0.0081 
AP2A1  AP-2 complex subunit alpha-1  122.9 0.0489 0.0081 
ZFC3H1  Zinc finger C3H1 domain-containing protein  96.5 0.0487 0.0081 
KIF2A  Kinesin-like protein KIF2A  20.8 0.0487 0.0081 
LMAN2  Vesicular integral-membrane protein VIP36  18.7 0.0491 0.0082 
DHX8  ATP-dependent RNA helicase DHX8  152.2 0.0496 0.0082 
CIRH1A  Cirhin  65.6 0.049648 0.0082 
 
Supplementary Table S5.2 – The full list of candidate MCL-1 interacting proteins 
identified in the nuclear fraction detected by mass spectrometry. Fold change, p values 
and q values are indicated for each protein. 
Protein 
Identifier 
Protein name Fold 
change 
p value q value 
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MCL-1 Induced myeloid leukemia cell differentiation 
protein Mcl-1 
10.8 1.96E-05 0.0118 
 
 
 Supplementary Table S5.3 – The full list of candidate MCL-1 interacting proteins 
identified in the cytosolic fraction detected by mass spectrometry. Fold change, p values 
and q values are indicated for each protein. 
Protein 
Identifier 
Protein name Fold 
change 
p value q value 
CARS Cysteine--tRNA ligase, cytoplasmic  45.2 0.000115 0.0033 
TFEB Transcription factor EB  108 0.000172 0.00353 
FBXO2 F-box only protein 2  57.8 0.0005 0.008 
AURKA Aurora kinase A  81 0.002 0.019 
MCL-1 Induced myeloid leukemia cell differentiation 
protein Mcl-1 
34 0.0037 0.021 
 
 
Supplementary Table S5.4 – The full list of candidate MCL-1 interacting proteins 
identified in the mitochondrial fraction detected by mass spectrometry. Fold 
change, p values and q values are indicated for each protein. 
Protein 
Identifier 
Protein name Fold 
change 
p value q value 
ILVBL Acetolactate synthase-like protein  264.9 2.32E-07 4.23E-05 
FADS1 Fatty acid desaturase 1  48.7 4.28E-07 5.81E-05 
RETSAT All-trans-retinol 13,14-reductase  125.6 9.71E-07 8.14E-05 
RDH11 Retinol dehydrogenase 11  98.9 1.17E-06 8.14E-05 
PGRMC2 Membrane-associated progesterone receptor 
component 2  
61.5 1.79E-06 8.14E-05 
STT3B Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B  
55.2 1.12E-06 8.14E-05 
TMEM33 Transmembrane protein 33  51.4 1.42E-06 8.14E-05 
ERGIC2 Endoplasmic reticulum-Golgi intermediate 
compartment protein 2  
34.9 1.51E-06 8.14E-05 
TRIM25 E3 ubiquitin/ISG15 ligase TRIM25  23.8 9.91E-07 8.14E-05 
CAPG Macrophage-capping protein  15.3 1.86E-06 8.14E-05 
SNX3 Sorting nexin-3  14.4 1.47E-06 8.14E-05 
STX7 Syntaxin-7  11.2 1.85E-06 8.14E-05 
DNAJB12 DnaJ homolog subfamily B member 12  97.8 2.32E-06 8.89E-05 
DAD1 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit DAD1  
45.0 3.67E-06 9.97E-05 
COPZ1 Coatomer subunit zeta-1  28.5 3.66E-06 9.97E-05 
PAFAH1B1 Platelet-activating factor acetylhydrolase IB 
subunit alpha  
12.4 4.54E-06 9.97E-05 
ERGIC1 Endoplasmic reticulum-Golgi intermediate 
compartment protein 1  
64.1 5.22E-06 0.0001021 
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SEC61A1 Protein transport protein Sec61 subunit alpha 
isoform 1  
43.5 5.08E-06 0.0001021 
FAM171A2 Protein FAM171A2  42.1 5.09E-06 0.0001021 
CISD2 CDGSH iron-sulfur domain-containing protein 2  112.8 5.53E-06 0.0001062 
SIGMAR1 Sigma non-opioid intracellular receptor 1  51.8 5.76E-06 0.0001067 
HEXIM1 Protein HEXIM1  49.0 5.84E-06 0.0001067 
ARL1 ADP-ribosylation factor-like protein 1  45.0 6.07E-06 0.0001067 
NSF Vesicle-fusing ATPase  52.2 6.83E-06 0.0001106 
TRIP13 Pachytene checkpoint protein 2 homolog  15.8 6.66E-06 0.0001106 
TMED5 Transmembrane emp24 domain-containing 
protein 5  
72.9 8.85E-06 0.000121 
ARF6 ADP-ribosylation factor 6  37.2 9.07E-06 0.000121 
PYGL Glycogen phosphorylase, liver form  34.6 8.16E-06 0.000121 
CPS1 Carbamoyl-phosphate synthase [ammonia], 
mitochondrial  
29.4 9.07E-06 0.000121 
TMEM97 Transmembrane protein 97  22.0 8.72E-06 0.000121 
VAPB Vesicle-associated membrane protein-associated 
protein B/C  
62.4 9.28E-06 0.0001212 
ERLIN1 Erlin-1  68.5 9.48E-06 0.000122 
TMEM109 Transmembrane protein 109  77.8 1.05E-05 0.0001226 
TMED9 Transmembrane emp24 domain-containing 
protein 9  
26.1 1.01E-05 0.0001226 
VIMP Selenoprotein S  85.8 1.11E-05 0.0001262 
BRI3BP BRI3-binding protein  92.2 1.21E-05 0.0001321 
HMOX2 Heme oxygenase 2  87.1 1.22E-05 0.0001321 
TFEB Transcription factor EB  187.6 1.32E-05 0.000138 
UBE2K Ubiquitin-conjugating enzyme E2 K  11.3 1.31E-05 0.000138 
HLA-A HLA class I histocompatibility antigen, A-68 
alpha chain  
31.6 1.35E-05 0.0001389 
TBL2 Transducin beta-like protein 2  112.0 1.36E-05 0.0001392 
DHCR7 7-dehydrocholesterol reductase  115.0 1.42E-05 0.0001408 
TMX1 Thioredoxin-related transmembrane protein 1  54.6 1.39E-05 0.0001408 
EMC1 ER membrane protein complex subunit 1  53.9 1.47E-05 0.0001408 
PPME1 Protein phosphatase methylesterase 1  36.5 1.44E-05 0.0001408 
TMUB1 Transmembrane and ubiquitin-like domain-
containing protein 1  
114.1 1.58E-05 0.0001438 
CHORDC1 Cysteine and histidine-rich domain-containing 
protein 1  
48.1 1.69E-05 0.0001447 
LGALS3BP Galectin-3-binding protein  28.6 1.66E-05 0.0001447 
UGT1A6 UDP-glucuronosyltransferase 1-6  24.1 1.79E-05 0.0001474 
DNM1L Dynamin-1-like protein  55.6 1.82E-05 0.0001483 
ERMP1 Endoplasmic reticulum metallopeptidase 1  41.4 1.83E-05 0.0001485 
RAB14 Ras-related protein Rab-14  85.6 1.92E-05 0.0001528 
STT3A Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3A  
72.9 1.96E-05 0.0001528 
CTAGE5 cTAGE family member 5  56.1 1.92E-05 0.0001528 
EI24 Etoposide-induced protein 2.4 homolog  216.9 2.47E-05 0.0001725 
PTRH2 Peptidyl-tRNA hydrolase 2, mitochondrial  120.1 2.39E-05 0.0001725 
ECEL1 Endothelin-converting enzyme-like 1  46.7 2.34E-05 0.0001725 
RAC1 Ras-related C3 botulinum toxin substrate 1  16.5 2.51E-05 0.0001725 
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DDRGK1 DDRGK domain-containing protein 1  138.0 2.59E-05 0.0001759 
RAB34 Ras-related protein Rab-34  23.0 2.59E-05 0.0001759 
TMCO1 Transmembrane and coiled-coil domain-
containing protein 1  
136.2 2.63E-05 0.0001773 
EMC7 ER membrane protein complex subunit 7  84.5 2.88E-05 0.0001912 
CD55 Complement decay-accelerating factor  12.6 3.11E-05 0.0002012 
ACBD5 Acyl-CoA-binding domain-containing protein 5  118.5 3.19E-05 0.0002016 
CEP85 Centrosomal protein of 85 kDa  55.5 3.21E-05 0.0002016 
HSD17B12 Very-long-chain 3-oxoacyl-CoA reductase  48.0 3.19E-05 0.0002016 
DHCR24 Delta(24)-sterol reductase  71.7 3.35E-05 0.0002095 
TMED4 Transmembrane emp24 domain-containing 
protein 4  
45.3 3.69E-05 0.0002219 
COPE Coatomer subunit epsilon  56.4 3.77E-05 0.0002242 
LMAN1 Protein ERGIC-53  34.3 3.77E-05 0.0002242 
THEM6 Protein THEM6  22.6 3.81E-05 0.0002251 
RAB3GAP1 Rab3 GTPase-activating protein catalytic subunit  8.3 4.04E-05 0.0002311 
MGST1 Microsomal glutathione S-transferase 1  19.9 4.15E-05 0.0002357 
TXNDC5 Thioredoxin domain-containing protein 5  59.6 4.37E-05 0.0002413 
ITPK1 Inositol-tetrakisphosphate 1-kinase  35.7 5.01E-05 0.000263 
VAPA Vesicle-associated membrane protein-associated 
protein A  
72.9 5.09E-05 0.0002649 
SEC31A Protein transport protein Sec31A  43.7 5.28E-05 0.0002698 
TRMT112 Multifunctional methyltransferase subunit 
TRM112-like protein  
30.4 5.30E-05 0.0002698 
MIA3 Melanoma inhibitory activity protein 3  47.6 5.40E-05 0.0002707 
ATP13A1 Manganese-transporting ATPase 13A1  128.5 6.16E-05 0.000297 
DNM2 Dynamin-2  35.0 6.31E-05 0.0003012 
FLVCR1 Feline leukemia virus subgroup C receptor-
related protein 1  
9.7 6.41E-05 0.0003038 
PTPN1 Tyrosine-protein phosphatase non-receptor type 1  84.6 6.46E-05 0.0003045 
MOSPD2 Motile sperm domain-containing protein 2  85.8 6.51E-05 0.0003053 
CSRP1 Cysteine and glycine-rich protein 1  26.5 6.53E-05 0.0003053 
PFKM ATP-dependent 6-phosphofructokinase, muscle 
type  
28.5 6.61E-05 0.0003077 
COX5A Cytochrome c oxidase subunit 5A, mitochondrial  29.1 6.79E-05 0.0003083 
LPP Lipoma-preferred partner  18.5 6.73E-05 0.0003083 
YKT6 Synaptobrevin homolog YKT6  69.8 6.87E-05 0.0003105 
SGPL1 Sphingosine-1-phosphate lyase 1  207.4 7.05E-05 0.000316 
VRK1 Serine/threonine-protein kinase VRK1  111.3 7.20E-05 0.0003178 
RAB18 Ras-related protein Rab-18  41.8 7.19E-05 0.0003178 
NUP62 Nuclear pore glycoprotein p62  122.0 7.45E-05 0.0003235 
NUP98 Nuclear pore complex protein Nup98-Nup96  45.9 7.94E-05 0.0003355 
ITPR1 Inositol 1,4,5-trisphosphate receptor type 1  42.5 7.79E-05 0.0003355 
GFPT1 Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1  
29.2 8.01E-05 0.0003371 
ESYT2 Extended synaptotagmin-2  42.2 8.14E-05 0.00034 
EHD1 EH domain-containing protein 1  37.4 8.31E-05 0.0003401 
LPCAT3 Lysophospholipid acyltransferase 5  33.0 8.37E-05 0.0003401 
RAB20 Ras-related protein Rab-20  29.3 8.35E-05 0.0003401 
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ALDH3A2 Fatty aldehyde dehydrogenase  31.5 8.81E-05 0.0003527 
GLRX3 Glutaredoxin-3  24.4 9.14E-05 0.0003569 
ABCD3 ATP-binding cassette sub-family D member 3  45.5 0.0001032 0.0003906 
TES Testin  26.1 0.0001071 0.0003943 
UBE2L3 Ubiquitin-conjugating enzyme E2 L3  12.9 0.0001074 0.0003943 
ASS1 Argininosuccinate synthase  67.3 0.0001124 0.0004093 
ARL6IP5 PRA1 family protein 3  48.7 0.0001134 0.0004093 
ATP1B3 Sodium/potassium-transporting ATPase subunit 
beta-3  
20.7 0.0001141 0.0004093 
TAP1 Antigen peptide transporter 1  134.9 0.0001198 0.0004231 
TMED1 Transmembrane emp24 domain-containing 
protein 1  
34.6 0.0001198 0.0004231 
SRPR Signal recognition particle receptor subunit alpha  24.9 0.0001199 0.0004231 
LPCAT1 Lysophosphatidylcholine acyltransferase 1  15.4 0.0001225 0.0004254 
ABCD1 ATP-binding cassette sub-family D member 1  41.2 0.0001266 0.000437 
CLPTM1L Cleft lip and palate transmembrane protein 1-like 
protein  
5.7 0.0001276 0.0004378 
ECI2 Enoyl-CoA delta isomerase 2, mitochondrial  56.9 0.0001351 0.000451 
CDK5RAP3 CDK5 regulatory subunit-associated protein 3  52.4 0.0001372 0.0004512 
SEC61B Protein transport protein Sec61 subunit beta  37.0 0.0001367 0.0004512 
FAF2 FAS-associated factor 2  208.1 0.0001394 0.0004546 
MOGS Mannosyl-oligosaccharide glucosidase  29.4 0.000141 0.0004553 
CHD1L Chromodomain-helicase-DNA-binding protein 1-
like  
40.2 0.0001463 0.0004673 
TMEM161A Transmembrane protein 161A  20.6 0.0001481 0.0004684 
SPCS2 Signal peptidase complex subunit 2  76.8 0.0001501 0.0004704 
VAMP8 Vesicle-associated membrane protein 8  7.0 0.0001511 0.0004722 
PGRMC1 Membrane-associated progesterone receptor 
component 1  
107.4 0.0001576 0.0004845 
SEC24C Protein transport protein Sec24C  5.1 0.0001635 0.0004974 
RRM1 Ribonucleoside-diphosphate reductase large 
subunit  
14.9 0.0001647 0.0004992 
SACM1L Phosphatidylinositide phosphatase SAC1  71.0 0.0001682 0.0005055 
ZMPSTE24 CAAX prenyl protease 1 homolog  151.1 0.0001714 0.0005078 
CYP51A1 Lanosterol 14-alpha demethylase  42.3 0.0001699 0.0005078 
ESF1 ESF1 homolog  144.7 0.0001727 0.0005092 
ALG3 Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-
mannosyltransferase  
36.2 0.0001767 0.0005185 
NUP210 Nuclear pore membrane glycoprotein 210  38.7 0.0001847 0.0005346 
ASPH Aspartyl/asparaginyl beta-hydroxylase  103.8 0.0001917 0.000549 
KTN1 Kinectin  21.6 0.0001988 0.0005621 
NCLN Nicalin  26.5 0.0002002 0.0005637 
RAB9A Ras-related protein Rab-9A  7.1 0.0002031 0.0005698 
SLC33A1 Acetyl-coenzyme A transporter 1  7.6 0.0002039 0.0005704 
DTX3L E3 ubiquitin-protein ligase DTX3L  38.9 0.0002114 0.0005841 
NUP88 Nuclear pore complex protein Nup88  8.5 0.0002182 0.0005954 
CERS2 Ceramide synthase 2  85.3 0.0002214 0.0006024 
CLINT1 Clathrin interactor 1  14.1 0.0002227 0.0006032 
LONP2 Lon protease homolog 2, peroxisomal  373.6 0.0002254 0.0006044 
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POR NADPH--cytochrome P450 reductase  48.4 0.0002417 0.0006373 
NCEH1 Neutral cholesterol ester hydrolase 1  30.2 0.0002439 0.0006413 
GYS1 Glycogen [starch] synthase, muscle  45.0 0.0002503 0.0006552 
RAB13 Ras-related protein Rab-13  22.1 0.0002634 0.0006786 
SPTLC2 Serine palmitoyltransferase 2  36.5 0.0002705 0.000693 
PIGS GPI transamidase component PIG-S  34.9 0.0002768 0.0007052 
HTATIP2 Oxidoreductase HTATIP2  20.1 0.0002899 0.0007249 
LSG1 Large subunit GTPase 1 homolog  47.5 0.0003034 0.000751 
SAR1B GTP-binding protein SAR1b  20.6 0.0003047 0.0007525 
MISP Mitotic interactor and substrate of PLK1  17.8 0.0003136 0.0007692 
TMX2 Thioredoxin-related transmembrane protein 2  88.9 0.0003161 0.0007736 
ANXA7 Annexin A7  27.7 0.0003179 0.0007762 
JAGN1 Protein jagunal homolog 1  22.6 0.0003225 0.0007841 
TRIM26 Tripartite motif-containing protein 26  28.7 0.0003338 0.0008043 
SURF4 Surfeit locus protein 4  89.5 0.0003509 0.000842 
SCD Acyl-CoA desaturase  14.0 0.0003518 0.0008421 
AIFM2 Apoptosis-inducing factor 2  107.8 0.0003705 0.0008754 
SEC63 Translocation protein SEC63 homolog  86.1 0.0003698 0.0008754 
UMPS Uridine 5'-monophosphate synthase  37.2 0.000369 0.0008754 
NPC1 Niemann-Pick C1 protein  19.4 0.0003771 0.0008873 
HMOX1 Heme oxygenase 1  107.2 0.0003899 0.0009134 
MCL1 Induced myeloid leukemia cell differentiation 
protein Mcl-1  
120.2 0.0003946 0.0009186 
PREB Prolactin regulatory element-binding protein  63.8 0.0003942 0.0009186 
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic  68.5 0.0004247 0.0009762 
PIGU Phosphatidylinositol glycan anchor biosynthesis 
class U protein  
52.1 0.0004243 0.0009762 
TAP2 Antigen peptide transporter 2  18.6 0.000436 0.0009938 
EFHD2 EF-hand domain-containing protein D2  15.7 0.0004448 0.0010088 
MYOF Myoferlin  15.1 0.000451 0.0010191 
TMBIM6 Bax inhibitor 1  185.6 0.0004574 0.0010297 
SAR1A GTP-binding protein SAR1a  11.9 0.0004739 0.0010583 
NFXL1 NF-X1-type zinc finger protein NFXL1  20.4 0.0004911 0.0010854 
CHP1 Calcineurin B homologous protein 1  121.8 0.0005019 0.0011007 
GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2  15.1 0.0005233 0.0011405 
IDI1 Isopentenyl-diphosphate Delta-isomerase 1  45.3 0.000529 0.0011505 
PHLDA2 Pleckstrin homology-like domain family A 
member 2  
62.7 0.000567 0.0012139 
PEX13 Peroxisomal membrane protein PEX13  46.0 0.0005706 0.0012169 
PYGB Glycogen phosphorylase, brain form  21.6 0.0005921 0.0012504 
SORD Sorbitol dehydrogenase  40.0 0.0005964 0.0012571 
MBOAT7 Lysophospholipid acyltransferase 7  56.8 0.0006047 0.0012674 
SRP54 Signal recognition particle 54 kDa protein  399.1 0.000616 0.0012813 
TMED2 Transmembrane emp24 domain-containing 
protein 2  
79.2 0.0006154 0.0012813 
SLC27A2 Very long-chain acyl-CoA synthetase  27.4 0.0006141 0.0012813 
GPAA1 Glycosylphosphatidylinositol anchor attachment 
1 protein  
29.0 0.0006257 0.0012989 
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SOAT1 Sterol O-acyltransferase 1  86.5 0.0006331 0.0013092 
RHOG Rho-related GTP-binding protein RhoG  26.1 0.0006327 0.0013092 
MAGOHB Protein mago nashi homolog 2  188.2 0.0006454 0.0013249 
TTLL12 Tubulin--tyrosine ligase-like protein 12  56.2 0.0006467 0.0013249 
A2M Alpha-2-macroglobulin  18.8 0.0006458 0.0013249 
SEC23A Protein transport protein Sec23A  97.7 0.0006545 0.0013359 
SPCS3 Signal peptidase complex subunit 3  188.1 0.0006634 0.0013441 
SCFD1 Sec1 family domain-containing protein 1  48.5 0.0006711 0.0013546 
FLOT2 Flotillin-2  60.9 0.0006748 0.001356 
BZW2 Basic leucine zipper and W2 domain-containing 
protein 2  
51.1 0.0006817 0.001356 
EPHX1 Epoxide hydrolase 1  46.1 0.0006766 0.001356 
FLOT1 Flotillin-1  29.1 0.0006807 0.001356 
TMED10 Transmembrane emp24 domain-containing 
protein 10  
45.0 0.0007109 0.0013987 
FA2H Fatty acid 2-hydroxylase  64.0 0.0007264 0.001423 
TYMS Thymidylate synthase  19.5 0.000732 0.0014274 
MUC13 Mucin-13  12.7 0.0007354 0.0014302 
UBTF Nucleolar transcription factor 1  94.3 0.000771 0.0014825 
ITGB5 Integrin beta-5  7.1 0.0007709 0.0014825 
FYTTD1 UAP56-interacting factor  90.0 0.0007903 0.0015169 
CDKAL1 Threonylcarbamoyladenosine tRNA 
methylthiotransferase  
76.6 0.0008204 0.0015637 
ANP32E Acidic leucine-rich nuclear phosphoprotein 32 
family member E  
14.6 0.0008597 0.0016271 
STX8 Syntaxin-8  157.3 0.0008711 0.0016362 
IKBIP Inhibitor of nuclear factor kappa-B kinase-
interacting protein  
16.3 0.0008719 0.0016362 
TMEM259 Membralin  17.2 0.0009028 0.0016826 
LYN Tyrosine-protein kinase Lyn  41.5 0.0009181 0.0017023 
AGPAT6 Glycerol-3-phosphate acyltransferase 4  48.8 0.0009291 0.0017169 
RHEB GTP-binding protein Rheb  26.4 0.0009277 0.0017169 
SRPRB Signal recognition particle receptor subunit beta  15.1 0.0009457 0.0017446 
MLEC Malectin  17.1 0.0009664 0.0017799 
BZW1 Basic leucine zipper and W2 domain-containing 
protein 1  
16.4 0.00098 0.0017958 
CNP 2',3'-cyclic-nucleotide 3'-phosphodiesterase  7.4 0.0010452 0.0019026 
EMC3 ER membrane protein complex subunit 3  34.8 0.0010502 0.0019085 
CCDC47 Coiled-coil domain-containing protein 47  134.2 0.0010594 0.001922 
STAT3 Signal transducer and activator of transcription 
3  
29.3 0.0010921 0.0019587 
PEX14 Peroxisomal membrane protein PEX14  5.4 0.0011405 0.0020288 
SEL1L Protein sel-1 homolog 1  28.3 0.0011817 0.0020886 
NDUFA4 Cytochrome c oxidase subunit NDUFA4  134.4 0.0012173 0.0021479 
B2M Beta-2-microglobulin  9.2 0.0012355 0.002166 
UFL1 E3 UFM1-protein ligase 1  18.6 0.0012444 0.0021781 
SEC11A Signal peptidase complex catalytic subunit 
SEC11A  
39.3 0.0012515 0.0021871 
TMEM214 Transmembrane protein 214  49.9 0.001265 0.0022073 
SPTLC1 Serine palmitoyltransferase 1  259.0 0.0012932 0.0022459 
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OS9 Protein OS-9  18.3 0.0014296 0.0024475 
PON2 Serum paraoxonase/arylesterase 2  64.5 0.0014544 0.0024862 
DPM1 Dolichol-phosphate mannosyltransferase subunit 
1  
31.4 0.0014854 0.0025312 
SEC62 Translocation protein SEC62  11.3 0.0015641 0.0026446 
SQLE Squalene monooxygenase  70.5 0.0015788 0.0026614 
BSG Basigin  6.9 0.0015975 0.0026846 
ATL3 Atlastin-3  14.6 0.0016061 0.0026908 
PTGES Prostaglandin E synthase  50.2 0.0016433 0.0027404 
NOMO3 Nodal modulator 3  67.4 0.0017506 0.0028886 
VMP1 Vacuole membrane protein 1  101.2 0.0018017 0.0029638 
FDFT1 Squalene synthase  135.0 0.001854 0.0030347 
ABCE1 ATP-binding cassette sub-family E member 1  6.3 0.0019505 0.0031564 
MYO18A Unconventional myosin-XVIIIa  133.3 0.0019966 0.0032176 
TFE3 Transcription factor E3  15.6 0.0020141 0.0032403 
IGF2R Cation-independent mannose-6-phosphate 
receptor  
7.3 0.0020648 0.0033073 
RAB3GAP2 Rab3 GTPase-activating protein non-catalytic 
subunit  
11.0 0.002149 0.003427 
MAGT1 Magnesium transporter protein 1  13.5 0.0025592 0.0039713 
OXSR1 Serine/threonine-protein kinase OSR1  91.8 0.0026101 0.0040388 
PARP14 Poly [ADP-ribose] polymerase 14  7.8 0.0027466 0.004238 
TAPBP Tapasin  63.4 0.002787 0.0042883 
LMF2 Lipase maturation factor 2  84.2 0.0028134 0.0043168 
AKR1C3 Aldo-keto reductase family 1 member C3  23.1 0.0028829 0.0044111 
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform  22.4 0.002969 0.0045112 
EMC2 ER membrane protein complex subunit 2  14.9 0.0029744 0.0045131 
NFKB2 Nuclear factor NF-kappa-B p100 subunit  10.4 0.0029925 0.0045343 
GOLPH3 Golgi phosphoprotein 3  58.2 0.0030331 0.0045896 
MYO1E Unconventional myosin-Ie  6.2 0.0030482 0.004606 
SSR1 Translocon-associated protein subunit alpha  24.7 0.0031407 0.0047327 
PRDX5 Peroxiredoxin-5, mitochondrial  22.9 0.0034586 0.0051269 
ACSL4 Long-chain-fatty-acid--CoA ligase 4  10.1 0.0035111 0.0051837 
DYNC1LI1 Cytoplasmic dynein 1 light intermediate chain 1  56.6 0.003676 0.0053907 
MAN2A1 Alpha-mannosidase 2  23.9 0.0036824 0.0053907 
VPS35 Vacuolar protein sorting-associated protein 35  92.0 0.0036916 0.005392 
CARS Cysteine--tRNA ligase, cytoplasmic  37.9 0.0037891 0.0055196 
ANXA11 Annexin A11  29.6 0.0042039 0.0060754 
YES1 Tyrosine-protein kinase Yes  15.3 0.0043549 0.0062689 
BID BH3-interacting domain death agonist  50.4 0.0045425 0.0064876 
ALPP Alkaline phosphatase, placental type  19.8 0.0045737 0.0065236 
IDH2 Isocitrate dehydrogenase [NADP], mitochondrial  54.3 0.0045974 0.0065489 
METTL7A Methyltransferase-like protein 7A  10.5 0.0047632 0.0067259 
ZW10 Centromere/kinetochore protein zw10 homolog  18.7 0.0049653 0.0069553 
HAT1 Histone acetyltransferase type B catalytic subunit  53.4 0.0050693 0.0070681 
BCAP31 B-cell receptor-associated protein 31  50.5 0.0051163 0.0071212 
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PIGT GPI transamidase component PIG-T  7.8 0.0051463 0.0071538 
CLPTM1 Cleft lip and palate transmembrane protein 1  140.7 0.0052642 0.0072808 
ATM Serine-protein kinase ATM  14.3 0.0052966 0.0073163 
ROCK2 Rho-associated protein kinase 2  39.2 0.0054535 0.0074858 
NUP35 Nucleoporin NUP53  11.8 0.0058779 0.0079684 
PEX16 Peroxisomal membrane protein PEX16  12.8 0.0064354 0.0086172 
ACADM Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  
10.4 0.0065049 0.0086891 
LDLR Low-density lipoprotein receptor  5.7 0.0069318 0.009192 
MAP2K2 Dual specificity mitogen-activated protein kinase 
2  
9.2 0.0071417 0.0094361 
TM9SF4 Transmembrane 9 superfamily member 4  1627.4 0.0074196 0.0097673 
RNF114 E3 ubiquitin-protein ligase RNF114  19.4 0.0076873 0.0100718 
LRRC47 Leucine-rich repeat-containing protein 47  5.4 0.0077208 0.0101036 
CYB5R3 NADH-cytochrome b5 reductase 3  39.6 0.0077599 0.0101304 
TM9SF2 Transmembrane 9 superfamily member 2  10.1 0.0084791 0.0109131 
SLC38A2 Sodium-coupled neutral amino acid transporter 2  12.7 0.0089263 0.0114348 
NBAS Neuroblastoma-amplified sequence  7.9 0.0092029 0.0117479 
AGPS Alkyldihydroxyacetonephosphate synthase, 
peroxisomal  
12.2 0.0096248 0.0122153 
GCLM Glutamate--cysteine ligase regulatory subunit  52.8 0.0100256 0.0126651 
STX5 Syntaxin-5  10.0 0.0107782 0.0134912 
PCYT1A Choline-phosphate cytidylyltransferase A  127.1 0.0114963 0.014292 
STIM1 Stromal interaction molecule 1  550.6 0.0120895 0.0149277 
ARFGAP1 ADP-ribosylation factor GTPase-activating 
protein 1  
66.9 0.0132804 0.0162697 
FNDC3A Fibronectin type-III domain-containing protein 
3A  
13.8 0.0137959 0.0168446 
RAB5B Ras-related protein Rab-5B  20.5 0.0140001 0.0170369 
RINT1 RAD50-interacting protein 1  47.4 0.0140272 0.0170508 
ABCB6 ATP-binding cassette sub-family B member 6, 
mitochondrial  
18.8 0.0155045 0.0187012 
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Abstract
The impressive selectivity and efﬁcacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent
hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The
recent description of S63845 as the ﬁrst speciﬁc and potent MCL-1 inhibitor represents an important therapeutic advance,
since MCL-1 is not targeted by the currently available BH3 mimetics, Navitoclax or Venetoclax, and is commonly
associated with chemoresistance. In this study, we conﬁrm a high binding afﬁnity and selectivity of S63845 to induce
apoptosis in MCL-1-dependent cancer cell lines. Furthermore, S63845 synergizes with other BH3 mimetics to induce
apoptosis in cell lines derived from both hematological and solid tumors. Although the anti-apoptotic BCL-2 family
members in these cell lines interact with a spectrum of pro-apoptotic BH3-only proteins to regulate apoptosis, these
interactions alone do not explain the relative sensitivities of these cell lines to BH3 mimetic-induced apoptosis. These
ﬁndings necessitated further investigation into the requirement of BH3-only proteins in BH3 mimetic-mediated apoptosis.
Concurrent inhibition of BCL-XL and MCL-1 by BH3 mimetics in colorectal HCT116 cells induced apoptosis in a BAX- but
not BAK-dependent manner. Remarkably this apoptosis was independent of all known BH3-only proteins. Although BH3-
only proteins were required for apoptosis induced as a result of BCL-XL inhibition, this requirement was overcome when
both BCL-XL and MCL-1 were inhibited, implicating distinct mechanisms by which different anti-apoptotic BCL-2 family
members may regulate apoptosis in cancer.
Introduction
Abnormal cell survival through resistance to apoptosis is a
cardinal feature of most malignancies and plays a key role
in chemoresistance. [1, 2] As the major regulators of the
intrinsic mitochondrial pathway of apoptosis, the pro-
survival BCL-2 family proteins (BCL-2, BCL-XL, MCL-
1, and BCL2A1) are attractive targets for novel cancer
therapeutics. [3, 4] These proteins are proposed to function
by binding and sequestering the pro-apoptotic BH3-only
proteins, which in turn prevents the effector proteins, BAX
and BAK, from forming pores in the mitochondrial mem-
brane. The development of inhibitors of the pro-survival
BCL-2 family proteins has proven particularly difﬁcult
because their inhibition requires disruption of these protein-
protein interactions. However, after many years of research,
small molecule inhibitors known as BH3 mimetics, which
target the anti-apoptotic BCL-2 family have now been
developed. The ﬁrst clinically approved BH3 mimetic was
ABT-263 (Navitoclax), an orally available form of
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ABT-737, which inhibits BCL-2, BCL-XL, and BCL-w [3,
5–7] and potently induces apoptosis in several solid and
hematological cancers. This was followed by the introduc-
tion of a BCL-2-speciﬁc inhibitor, ABT-199 (Venetoclax),
which has received approval for treating refractory chronic
lymphocytic leukemia (CLL), where BCL-2 addiction is a
key feature in the pathogenesis of the disease. [8–10]
Recently, BH3 mimetics speciﬁcally targeting BCL-XL (A-
1331852) [11–15] and MCL-1 (A-1210477 and S63845) [1,
12, 16] have also been developed.
In this study, we demonstrate that S63845 is a highly
potent and selective MCL-1 inhibitor, which can synergize
with other BH3 mimetics, including ABT-199 and A-
1331852, to induce apoptosis in a wide range of cell lines
derived from different hematological malignancies and
solid tumors. Furthermore, we demonstrate that BH3-only
proteins are required for apoptosis induced following BCL-
XL inhibition, whereas dual inhibition of BCL-XL
and MCL-1 resulted in a BH3-only protein-independent
cell death.
Materials and methods
Cell culture
Cell lines derived from mantle cell lymphoma (MAVER-1),
diffuse large B cell lymphoma (U-2946), chronic myeloid
leukemia (K562), acute myeloid leukemia (MOLM-13,
OCI-AML-3, HL-60, MV-4-11, THP-1 and U-937), Jurkat-
T-lymphocyte cell lines, wild-type and deﬁcient in caspase-
9 (from Prof. J. Borst, The Netherlands Cancer Institute-
Antoni van Leeuwenhoek, Amsterdam), caspase-8 and
FADD (from Prof. J. Blenis, Weill Cornell Medicine,
USA), non-small cell lung carcinoma (H1299), prostate
cancer (PC-3, from Prof. Y. Ke, University of Liverpool,
UK) and triple negative breast cancer (MDA-MB-231 from
P. Meier, Institute of Cancer Research, London, UK) were
cultured in RPMI 1640 medium. H929, a multiple myeloma
cell line, was cultured in the same medium supplemented
with 0.02% 2-mercaptoethanol. The non-small cell lung
carcinoma cell line A549 was cultured in DMEM/
F12 supplemented with 1% non-essential amino acids. The
pancreatic cancer cell line, SUIT-2 (from A. Mielgo, Uni-
versity of Liverpool, UK) was cultured in DMEM. Colon
cancer cell lines HT-29 (from J. Parsons, University of
Liverpool, UK) and HCT116 (wild-type, DKO and 8KO)
[3, 17–22] as well as HCT116 cells deﬁcient in BAX or
BAK (from R. J. Youle, National Institute of Health, USA),
were cultured in McCoys 5 A Modiﬁed media. All cell
lines, unless otherwise speciﬁed, were either from DMSZ
(Braunshweig, Germany) or ATCC (Middlesex, UK) and
were validated using short tandem repeat proﬁling. Per-
ipheral blood samples from CLL patients were obtained
with patient consent and local ethics committee approval
and cultured as described. [23] All media were supple-
mented with 10% fetal calf serum (Life Technologies Inc.,
Paisley, UK).
Reagents
A-1331852 and A-1210477 from AbbVie Inc. (North
Chicago, IL, USA), S63845 from ActiveBiochem (New
Jersey, USA), and ABT-199 and Z-VAD.FMK from
Selleck Chemicals Co. (Houston, TX, USA) were used.
Antibodies against BCL-XL, BIM and BAD from Cell
Signalling Technology (MA, USA), NOXA from Millipore
(Watford, UK), BID and tubulin from Abcam (Cambridge,
UK), MCL-1, BCL-2 and PUMA from Santa Cruz Bio-
technology (Santa Cruz, CA, USA) and BAX and cyto-
chrome c (BD BioSciences, California) were used for
immunoblotting. Antibodies used for immunoprecipitation
were MCL-1 (Y-37) and BCL-XL from Abcam, BCL-2 from
BD Biosciences and BAX (NT) from Merck-Millipore
(Burlington, MA, USA). siRNAs speciﬁc to BCL-XL
(SI03025141), MCL-1 (SI02781205) and a non-targeting
control (1027310) from Qiagen (Cambridge, UK) were
incubated with Interferin siRNA transfection reagent (Poly-
plus transfection Inc., NY, USA) and added to cells at a
concentration of 10 nM for 72 h.
Differential scanning ﬂuorimetry assay
Thermal shift assays were performed using a StepOnePlus
Real-Time PCR machine (Life Technologies, Paisley, UK)
with Spyro-Orange dye (Invitrogen, Paisley, UK) and pur-
iﬁed recombinant BCL-2 (Abcam) and MCL-1 protein, as
previously described. [3]
Cytochrome c release, BAX translocation and
apoptosis measurements
To quantitate cytochrome c release and BAX translocation,
cells were grown on coverslips and treated with the speci-
ﬁed inhibitors following a 0.5 h pre-treatment with the pan-
caspase inhibitor Z-VAD.FMK (30 μM), and then ﬁxed
with 4% (v/v) paraformaldehyde and permeabilized with
0.5% (v/v) Triton X-100 in PBS, followed by incubation
with primary and ﬂuorophore-conjugated secondary anti-
bodies prior to visualization under a ﬂuorescent microscope.
The extent of cytochrome c released from the mitochondria
or BAX translocation to the mitochondria was quantiﬁed by
counting at least 300 cells from three independent experi-
ments. The extent of apoptosis in cells following different
G. Greaves et al.
treatments was quantiﬁed using an Attune NxT ﬂow cyt-
ometer (Thermo Fisher Scientiﬁc, Paisley, UK), as pre-
viously described. [24]
Gel ﬁltration, immunoprecipitation and Western
blotting
Recombinant MCL-1 puriﬁcation, size exclusion chroma-
tography and immunoprecipitation experiments were car-
ried out as previously described. [3, 25] Western blotting
was carried out according to standard protocols. Brieﬂy,
50 μg of total protein lysate was subjected to SDS-PAGE
electrophoresis. Subsequently proteins were transferred to
nitrocellulose membranes and protein bands visualized with
ECL reagents (GE Healthcare).
Clonogenic studies
Cells were seeded in 6 well plates at a density of 2000 cells/
well and exposed to the speciﬁed inhibitors (100 nM) 24 h
post-seeding. Cells were ﬁxed on day 7 using methanol and
acetic acid and then stained with crystal violet and colonies
counted using the GelCount tumor colony counter (Oxford
Optronix, Abbingdon, UK).
Statistics
For time-course studies, a two-way ANOVA was performed
using Dunnet’s multiple comparisons analysis and other
studies were analyzed for statistical signiﬁcance with one-
way ANOVA using Sidak’s multiple comparisons analysis.
The asterisks depicted correspond to the following p values:
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
Results
S63845 is a potent MCL-1 inhibitor and weak
inducer of apoptosis in BCL-2- but not
BCL-XL-dependent cells
Consistent with previous ﬁndings, [1] we demonstrated that
S63845 is a potent MCL-1 inhibitor when compared with A-
1210477, as assessed by a concentration-dependent thermal
stabilization of MCL-1 in our in vitro thermal shift assay [3]
(Fig. 1a). S63845 also induced rapid apoptosis in two MCL-
1-dependent cell lines (H929 and U-2946), [3, 6] with an
IC50~100 nM, demonstrating ~100-fold higher potency than
A-1210477 (Fig. 1b). To assess the speciﬁcity of S63845 to
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Fig. 1 S63845 binds MCL-1 and induces apoptosis in several cancer
cell lines. a S63845 exhibits a concentration-dependent shift in MCL-1
stabilization in a thermal stability assay. b S63845 and A-1210477
exhibit concentration-dependent apoptosis, as assessed by PS exter-
nalization using ﬂow cytometry, in MCL-1-dependent cell lines, H929
and U-2946 after 4 h of exposure. c S63845 and A-1210477 fail to
induce apoptosis in a BCL-XL-dependent cell line, K562, at 4 h, unlike
A-1331852 (positive control). d MAVER-1, a BCL-2 dependent cell
line, when exposed to the indicated BH3 mimetics for 4 h resulted in
enhanced apoptosis. e Jurkat cells (wild type and deﬁcient in the
speciﬁed proteins), exposed to increasing concentrations of S63845 for
24 h exhibited caspase-9-dependent apoptosis. f Primary cells isolated
from CLL patients, exposed to the indicated BH3 mimetics for 8 h,
exhibited varying extents of apoptosis. g ABT-199 but not S63845
exhibits a concentration-dependent shift in BCL-2 stabilization in a
thermal stability assay. Error bars=Mean ± SEM (standard error of
the mean); *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
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induce apoptosis in a MCL-1 dependent manner, we
exposed K562 cells (a BCL-XL-dependent cell line) and
MAVER-1 cells (a BCL-2-dependent cell line) to increasing
concentrations of S63845 (Fig. 1c, d). As expected, S63845
(as well as A-1210477) failed to induce apoptosis in K562
cells, whereas extensive apoptosis was observed following
exposure to A-1331852 (Fig. 1c). However, S63845 (as well
as A-1210477) induced a concentration dependent increase
in apoptosis in MAVER-1 cells, albeit at higher concentra-
tions than ABT-199 (Fig. 1d), suggesting that S63845 could
either induce death in a non-speciﬁc manner or that it could
also be a weak inhibitor of BCL-2. To test this, we exposed
Jurkat cells (wild type as well as deﬁcient in FADD,
caspase-8 and caspase-9) to increasing concentrations of
S63845. While S63845 induced similar levels of apoptosis
in wild type as well as FADD/ caspase-8 deﬁcient Jurkat
cells, cells deﬁcient in caspase-9 were completely resistant to
S63845-mediated apoptosis (Fig. 1e), thus demonstrating
that S63845 both speciﬁcally induced the intrinsic pathway
of apoptosis and also did not induce non-speciﬁc cell death.
To identify whether S63845, in addition to binding and
inhibiting MCL-1, can also potentially bind and inhibit
BCL-2, we exposed primary CLL cells that exclusively
depend on BCL-2 for survival, [8] to increasing concentra-
tions of S63845 and A-1210477. While ABT-199 (positive
control) induced apoptosis in these cells at low nanomolar
concentrations, both S63845 and A-1210477 also induced
signiﬁcant apoptosis at concentrations similar to their IC50
values in MCL-1 dependent cells (Fig. 1f). However, we did
not detect any concentration-dependent thermal stabilization
of BCL-2 following S63845 in an in vitro thermal shift
assay, which was in marked contrast to the thermal stabili-
zation of BCL-2 following ABT-199 in this assay (Fig. 1g).
Taken together, our data demonstrates that under these
experimental conditions, S63845 does not bind BCL-2 and
induces apoptosis in a MCL-1-speciﬁc manner.
S63845 is more potent than ABT-199 in inducing
apoptosis in AML cell lines
Recent reports indicate that cells derived from acute mye-
loid leukemia (AML) patients can be effectively targeted
with a BCL-2 and/or MCL-1 inhibitor, [11, 13–15]
although other studies suggest that these cells depend pri-
marily on BCL-2 for survival. [16] Indeed, MCL-1 inhibi-
tors are currently entering clinical trials to treat AML and
multiple myeloma patients (Clinical trials—NCT02979366;
NCT02675452; NCT02992483). Therefore, we investigated
whether S63845 alone or in combination with ABT-199
could induce apoptosis in a panel of AML cell lines. Of the
six cell lines tested, MV-4-11 cells exhibited high sensi-
tivity to both S63845 (IC50~20 nM) and ABT-199 (IC50 ~
50-100 nM) individually. THP-1 was much more resistant
to ABT-199 but sensitive to S63845 (IC50~50 nM). OCI-
AML-3, U937 and MOLM-13 were completely resistant to
ABT-199 but somewhat sensitive to S63845 at higher
concentrations. In contrast, HL-60 cells were largely resis-
tant to both BH3 mimetics individually (Fig. 2a). In the
resistant cell lines, particularly U-937 and HL-60, BCL-2
and BCL-XL appeared to perform redundant functions
in cell survival, whereas MOLM-13 cells appeared to
depend on BCL-XL for survival, as exposure to A-1331852
alone resulted in signiﬁcant apoptosis (Supplemental Fig.
S1). Nevertheless, all AML cells examined were more
sensitive to the combination of S63845 and ABT-199
(Fig. 2a).
Interactions between the pro and anti-apoptotic
BCL-2 family members do not reﬂect the relative
sensitivities of AML cell lines to undergo BH3
mimetic-mediated apoptosis
BH3 mimetic-induced apoptosis is usually attributed to
displacement of BH3-only proteins from their anti-apoptotic
partners, leading to apoptosis. Since the different AML cell
lines exhibited varied responses to BH3 mimetic-mediated
apoptosis, we wished to assess if this could be attributed to
altered binding and/or displacement of the different BH3-
only proteins to their known survival counterparts. There-
fore, we immunoprecipitated the anti-apoptotic proteins
required for survival and probed for each of the BH3-only
proteins (Fig. 2b–d). In MV-4-11 cells, which are sensitive
to both ABT-199 and S63845, BIM and PUMA bound to
BCL-2 and were slightly displaced following exposure to
ABT-199 (Fig. 2b). In contrast, the traces of BIM and
NOXA bound to MCL-1 in these cells were readily dis-
placed after S63845 exposure, in-line with the extent of
apoptosis observed with S63845 (IC50~20 nM). Neither
BID nor BAD interacted with MCL-1 or BCL-2 in these
cells (Fig. 2b). In OCI-AML-3, exposure to ABT-199 also
resulted in a partial displacement of BIM and PUMA from
BCL-2, despite the cells being largely resistant to ABT-199
(Fig. 2c). Similar to MV-4-11, BIM and NOXA bound to
MCL-1 were readily displaced with S63845, and BID and
BAD failed to interact with either MCL-1 or BCL-2
(Fig. 2c). In the resistant HL-60 cell line, BIM and PUMA
bound to BCL-2 was not displaced following ABT-199,
compatible with the cells being largely resistant to ABT-199
(Fig. 2d). BID and BAD were not bound to either MCL-1 or
BCL-2. Moreover, of all the BH3-only members, only tra-
ces of NOXA appeared to interact with MCL-1 and was
displaced following S63845 (Fig. 2d). Taken together, these
results suggest that interactions between the pro- and anti-
apoptotic BCL-2 family members may not necessarily
reﬂect the relative sensitivities of different AML cell lines to
undergo BH3 mimetic-mediated apoptosis.
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Interactions of BCL-XL and MCL-1 with different
BH3-only members differ in solid tumor cell lines
Unlike several hematological malignancies, cancer cells
derived from most solid tumors depend on both BCL-XL
and MCL-1 for survival. [3, 17, 19–22] Exposure of cells
derived from a panel of solid tumors, including non-small
cell lung carcinoma (H1299 and A549), pancreas (SUIT-
2), colon (HCT116 and HT-29) and prostate cancer (PC-
3) to a combination of S63845 or A-1331852 resulted in a
marked induction of apoptosis, conﬁrming that these cell
lines depend on both BCL-XL and MCL-1 for survival
(Fig. 3a). To corroborate earlier ﬁndings in AML cell
lines (Fig. 2) in non-hematological cells, we repeated
immunoprecipitation studies and assessed interactions
between the different BH3-only proteins with their key
pro-survival counterparts, namely BCL-XL and MCL-1.
In H1299 cells, BIM and PUMA were preferentially
bound to MCL-1 and BCL-XL, respectively, and were
readily displaced following exposure to the relevant BH3
mimetics (Fig. 3b). This was particularly evident fol-
lowing exposure to S63845, in which the newly released
BIM from the MCL-1 complex exhibited enhanced
binding to BCL-XL. Similarly, exposure to A-1331852
displaced BIM from BCL-XL, which in turn facilitated its
binding to MCL-1 (Fig. 3b). Other BH3-only proteins
like NOXA and BAD exhibited selectivity in binding to
MCL-1 and BCL-XL, respectively and were also dis-
placed after exposure to the relevant BH3 mimetics. No
detectable binding of BID to either BCL-XL or MCL-1
was observed (Fig. 3b). In SUIT-2 cells, BIM was bound
to both MCL-1 and BCL-XL and was displaced to dif-
fering extents with the speciﬁc BH3 mimetics (Fig. 3c).
In contrast to H1299, PUMA was not bound to either
MCL-1 or BCL-XL (Fig. 3c). However, there were some
similarities, especially with NOXA being bound to
MCL-1 and displaced with S63845, and BAD bound to
BCL-XL, which could be disrupted following A-1331852
(Fig. 3c). Therefore, H1299 and SUIT-2 cells exhibit
signiﬁcant differences in their BCL-2 family interaction
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Fig. 2 S63845 can synergize with ABT-199 to induce apoptosis in
AML cell lines. a AML cell lines were exposed to a concentration
range of S63845 with ABT-199 at a constant concentration of 100 nM
for 24 h and assessed for PS externalization. Immunoprecipitation of
MCL-1 and BCL-2 was carried out in b MV-4-11, c OCI-AML-3, and
d HL-60 cells, following exposure to S63845 (30 nM for MV-4-11 and
100 nM for the other 2 cell lines) or ABT-199 (50 nM for MV-4-11
and 100 nM for the other 2 cell lines) for 6 h (MV-4-11) or 8 h (OCI-
AML-3 and HL60). The eluted complexes were immunoblotted for the
indicated proteins. The input represents the cell lysates and BC, beads
control. Error bars=Mean ± SEM; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
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proﬁle, despite similar expression levels of the different
proteins and cell death responsiveness to the combination
of A-1331852 and S63845. This was even more evident
in HCT116 cells, in which most of the BH3-only pro-
teins, with the exception of NOXA, interacted exclu-
sively with BCL-XL, and could be readily displaced from
their binding partners with A-1331852 (Fig. 3d). Col-
lectively, these results suggest that the preferential
sequestration of different BH3-only proteins to distinct
anti-apoptotic counterparts does not solely dictate
dependency of a cell line on an individual anti-apoptotic
protein.
BH3-only proteins are dispensable for BH3
mimetic-induced apoptosis in HCT116 cells
Since BH3-only proteins have recently been demon-
strated to be dispensable for cell death, [18, 26] we
evaluated whether selective inhibitors of BCL-XL and
MCL-1 could induce apoptosis in the absence of all
known BH3-only proteins. Remarkably, in HCT116 8KO
cells, which lack the 8 key BH3-only proteins, BIM, BID,
PUMA, NOXA, HRK, BMF, BIK and BAD, [18] a
combination of S63845 and A-1331852 induced apop-
tosis to the same extent as that of wild-type (WT)
HCT116 cells (Fig. 4a). Furthermore, this combination of
BH3 mimetics resulted in a BAX-dependent but BAK-
independent apoptosis in these cells (Fig. 4b), empha-
sizing a crucial role for BAX in BH3 mimetic-mediated
apoptosis. This raised the possibility of BAX directly
interacting with BCL-XL and/or MCL-1 to antagonize
apoptosis. To test this hypothesis, we immunoprecipi-
tated MCL-1 and BCL-XL complexes from both HCT116
WT and 8KO cells but failed to detect BAX interaction
with either anti-apoptotic protein (Fig. 4c). As a positive
control, we immunoprecipitated active-BAX in these
lysates, which pulled down BAX only following treat-
ment with a combination of S63845 and A-1331852,
indicative of BAX activation during apoptosis (Fig. 4c).
These ﬁndings suggested that the BH3 mimetics could
a
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Fig. 3 BH3-only proteins have different binding preferences in various
solid tumor cell lines despite similar sensitivities to BH3 mimetics. a
Solid tumor cell lines were treated with a concentration range of
S63845 and a constant concentration of 100 nM of A-1331852 for 4 h
and assessed for PS externalization. Immunoprecipitation of MCL-1
and BCL-XL was carried out in H1299 b, SUIT-2 c, and HCT116
d cells exposed to S63845 (100 nM) or A-1331852 (100 nM) for 2 h,
and the eluted complexes were immunoblotted for the indicated pro-
teins. * in the blots denotes non-speciﬁc bands. Error bars=Mean ±
SEM (standard error of the mean); *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
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have displaced other protein(s) distinct from the 8 BH3-
only proteins from BCL-XL and/or MCL-1, which in turn
activated BAX to facilitate mitochondrial outer mem-
brane permeabilization (MOMP) and apoptosis. Apop-
tosis induction in the 8KO cells was accompanied by
translocation of BAX from the cytosol to the mitochon-
drial membrane (Fig. 4d), BAX oligomerization into high
molecular mass complexes as assessed by gel ﬁltration
(Fig. 4e), and MOMP, measured by the release of mito-
chondrial cytochrome c (Fig. 4f). Together, this negates a
role for BH3-only proteins in several critical steps of the
intrinsic apoptotic pathway induced by BH3 mimetics.
Inhibition of BCL-XL and MCL-1 results in
BH3-independent apoptosis
Although many cell lines derived from solid tumors depend
on both BCL-XL and MCL-1 for survival, our studies
revealed that inhibition of BCL-XL following exposure to
A-1331852 was sufﬁcient to induce signiﬁcant apoptosis in
a panel of cell lines (Fig. 5a). To assess whether A-
1331852-mediated apoptosis also occurred in the absence of
all known BH3-only proteins, we employed HCT116 WT
and 8KO cells to assess several hallmarks of apoptosis
following BCL-XL inhibition. Strikingly, exposure to A-
1331852, but not S63845, resulted in enhanced apoptosis,
as assessed by phosphatidylserine (PS) externalization,
MOMP and mitochondrial translocation of BAX in
HCT116 WT but not 8KO cells (Fig. 5b–d) suggesting that
A-1331852-mediated apoptosis requires the presence of
BH3-only proteins. Support for this suggestion was also
provided by the enhanced apoptosis observed in WT, but
not 8KO, cells following siRNA knockdown of BCL-XL
(Fig. 5e). However, this protective effect in 8KO cells was
abolished when both BCL-XL and MCL-1 were down-
regulated, suggesting a requirement of BH3-only proteins in
BCL-XL but not when both BCL-XL and MCL-1 were
downregulated. Similarly, exposure to A-1331852 sig-
niﬁcantly reduced the surviving fraction of WT, but not
8KO, cell populations (Fig. 5f). As expected, S63845 had
no effect on clonogenic survival in either of the cell types,
while a combination of the two BH3 mimetics obliterated
clonogenicity in both cell types (Fig. 5f). Taken together,
our data convincingly argue against the requirement of
a
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Fig. 4 BH3 mimetics induce apoptosis even in the absence of BH3-
only proteins in HCT116 cells. a HCT116 cells, wild-type (WT) and
deﬁcient in 8 different pro-apoptotic BH3-only proteins (8KO), were
exposed to A-1331852 (100 nM) in combination with increasing
concentrations of S63845 for 4 h and assessed for PS externalization. b
Same as (a) but the experiments were carried out with HCT116
WT cells or cells deﬁcient in BAX, BAK or both (DKO). c Immu-
noprecipitation of MCL-1, BCL-XL and active-BAX in the indicated
cells exposed to a combination of S63845 (100 nM) and A-1331852
(100 nM), following a 0.5 h pre-treatment with z-VAD.FMK (30 μM),
were performed to assess BAX interaction. d The level of
mitochondrial BAX in WT and 8KO cells following S63845 and A-
1331852 treatment (both 100 nM) for 4 h was assessed by immuno-
cytochemistry using an anti-BAX antibody. e Western blots of dif-
ferent molecular weight fractions from FPLC showing BAX
oligomerization in HCT116 WT and 8KO cells upon exposure to
S63845 (100 nM) and A-1331852 (100 nM) for 2 h. f Quantiﬁcation
and representative images of cytochrome c release in the indicated cell
lines, from three independent experiments, following exposure to
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cells. Error bars=Mean ± SEM (standard error of the mean); *p ≤
0.05; **p ≤ 0.01; ***p ≤ 0.001
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BH3-only proteins in apoptosis regulated by a combination
of both BCL-XL and MCL-1 (Fig. 6).
Discussion
Prior to the discovery of S63845, putative MCL-1 inhi-
bitors were poorly suited for clinical evaluation because
they either lacked potency (high micromolar concentra-
tions were required to inhibit MCL-1) or speciﬁcity
resulting in undesirable toxicity. [3, 24, 27, 28] How-
ever, the development of S63845 potentially strengthens
the use of a wide variety of BH3 mimetics in cancer
therapy. In our hands, S63845 bound MCL-1 more
extensively than A-1210477 and resulted in marked
apoptosis in MCL-1-dependent cell lines (Fig. 1), and
synergized with ABT-199 and A-1331852 to induce
apoptosis in various cancer cell lines (Figs. 2 and 3),
supporting the concept that a potent MCL-1 inhibitor,
such as S63845, could be a valuable addition to the BH3
mimetic armamentarium.
Our ﬁnding that BH3-only proteins are dispensable for
BH3 mimetic-mediated apoptosis in HCT116 cells is
striking, particularly when the proposed mechanism of
action of BH3 mimetics is taken into consideration
(Fig. 4). Since apoptosis induction in these cells still
required BAX and not BAK, [29] it is possible that BH3
mimetics could indirectly activate BAX by disrupting the
interaction of BAX with BCL-XL and/or MCL-1. How-
ever, we could not detect any BAX interaction with either
of these anti-apoptotic proteins, despite efﬁcient mito-
chondrial translocation and oligomerization of BAX,
which resulted in MOMP and PS externalization (Fig. 4).
Failure to detect BAX in complex with anti-apoptotic
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proteins could possibly be due to the dynamic nature of
this interaction. Although BAX is generally considered to
translocate from the cytosol to the outer mitochondrial
membrane following apoptotic stimuli, several reports
suggest a role for the anti-apoptotic BCL-2 family mem-
bers in the constitutive retrotranslocation of BAX from the
mitochondrial outer membrane to the cytosol even under
non-apoptotic conditions. [30–35] Neutralization of the
anti-apoptotic BCL-2 family members with BH3 mimetics
could markedly reduce BAX retrotranslocation to the
cytosol, [33, 36] thus retaining it in the outer mitochon-
drial membrane, which may facilitate direct activation of
BAX (Fig. 6). [18] This could explain the apoptosis
observed following BH3 mimetics in HCT116 cells, even
in the absence of all known BH3-only proteins (Fig. 4).
Our data reveal that the requirement for BH3-only pro-
teins in BCL-XL-regulated apoptosis can clearly be over-
come when both MCL-1 and BCL-XL are inhibited
simultaneously (Figs. 4 and 5). Recent reports have
demonstrated novel interacting partners of MCL-1, such as
the BH3 domain-containing SUFU [37] and VLCAD, [38]
which regulate distinct cellular functions. Therefore, other
BH3-domain containing proteins distinct from the 8 key
BH3-only members could interact with MCL-1 and/or BCL-
XL and play a role in these events (Fig. 6). In summary, our
results demonstrate that BH3 mimetics induce apoptosis
even in the absence of the eight best characterized BH3-only
proteins, while also identifying differences in the regulation
of cell survival by the different anti-apoptotic BCL-2 family
members.. This highlights the need to understand the
Fig. 6 BCL-2 family members differ in their dependence on pro-
apoptotic BH3-only members to exert their anti-apoptotic functions. In
HCT116 cells, multiple BH3-only proteins, such as BIM, BID, BAD
and PUMA are sequestered by BCL-XL, whereas NOXA is the only
BH3-only protein bound to MCL-1. While the displacement of BH3-
only proteins from BCL-XL following A-1331852 is sufﬁcient to
induce apoptosis in these cells, displacement of NOXA from MCL-1
following S63845 failed to induce apoptosis. However, the combina-
tion of A-1331852 and S63845 released all the BH3-only proteins
from the anti-apoptotic counterparts and resulted in pronounced
apoptosis (bold arrow). In the absence of all eight BH3-only proteins,
neither A-1331852 nor S63845 alone resulted in apoptosis. However,
a combination of A-1331852 and S63845 still resulted in pronounced
apoptosis, even in the absence of all BH3-only proteins. This could be
due to the release of another pro-apoptotic BH3 domain-containing
‘protein x’ from MCL-1 and/or BCL-XL, which in turn could activate
BAX in the 8KO cells. Alternatively, BH3 mimetics could indirectly
result in the accumulation of BAX (either by inhibition of retro-
translocation or by passive diffusion, following the neutralization of
the anti-apoptotic members) in the outer mitochondrial membrane,
which in turn could result in BAX activation and apoptosis in the 8KO
cells
BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and. . .
fundamental mechanisms of apoptosis in order to improve
therapeutic approaches using BH3 mimetics.
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